US6465188B1
(en)
*
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Nucleic acid ligand complexes
|
US20040033977A1
(en)
*
|
1990-08-14 |
2004-02-19 |
Bennett C. Frank |
Oligonucleotide modulation of cell adhesion
|
US6605712B1
(en)
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
JPH08500481A
(en)
*
|
1992-05-11 |
1996-01-23 |
リボザイム・ファーマシューティカルズ・インコーポレーテッド |
Methods and agents for inhibiting viral replication
|
US20030206887A1
(en)
*
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
US5639647A
(en)
*
|
1994-03-29 |
1997-06-17 |
Ribozyme Pharmaceuticals, Inc. |
2'-deoxy-2'alkylnucleotide containing nucleic acid
|
US6156535A
(en)
*
|
1995-08-04 |
2000-12-05 |
University Of Ottawa |
Mammalian IAP gene family, primers, probes, and detection methods
|
US20040142895A1
(en)
*
|
1995-10-26 |
2004-07-22 |
Sirna Therapeutics, Inc. |
Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
|
US6274369B1
(en)
*
|
1996-02-02 |
2001-08-14 |
Invitrogen Corporation |
Method capable of increasing competency of bacterial cell transformation
|
US6133437A
(en)
*
|
1997-02-13 |
2000-10-17 |
Apoptogen, Inc. |
Modulation of IAPs for the treatment of proliferative diseases
|
US9096636B2
(en)
*
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20030044941A1
(en)
*
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US7812149B2
(en)
*
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
US20040171031A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
WO2005121371A2
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
US20060008448A1
(en)
*
|
1996-06-11 |
2006-01-12 |
Minzhen Xu |
Inhibition of li expression in mammalian cells
|
US20040072345A1
(en)
*
|
1997-06-20 |
2004-04-15 |
Altaba Ariel Ruiz I. |
Method and compositions for inhibiting tumorigenesis
|
US7709454B2
(en)
*
|
1997-06-20 |
2010-05-04 |
New York University |
Methods and compositions for inhibiting tumorigenesis
|
US6238876B1
(en)
*
|
1997-06-20 |
2001-05-29 |
New York University |
Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
|
US7351578B2
(en)
|
1999-12-10 |
2008-04-01 |
Invitrogen Corp. |
Use of multiple recombination sites with unique specificity in recombinational cloning
|
CA2307016A1
(en)
*
|
1997-10-24 |
1999-05-06 |
Life Technologies, Inc. |
Recombinational cloning using nucleic acids having recombination sites
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
FR2782325B1
(en)
|
1998-08-12 |
2002-05-24 |
Proteus |
METHOD OF IDENTIFYING POLYNUCLEOTIDE SEQUENCES AND / OR CORRESPONDING PROTEINS FROM A SAMPLE OF NUCLEIC ACIDS
|
US20040045056A1
(en)
*
|
1998-02-26 |
2004-03-04 |
Zhizheng Chen |
Transformation of Brassica
|
US20060260005A1
(en)
*
|
1998-02-26 |
2006-11-16 |
Zhizhen Chen |
Transformation of Brassica
|
US8598332B1
(en)
*
|
1998-04-08 |
2013-12-03 |
Bayer Cropscience N.V. |
Methods and means for obtaining modified phenotypes
|
US20040214330A1
(en)
*
|
1999-04-07 |
2004-10-28 |
Waterhouse Peter Michael |
Methods and means for obtaining modified phenotypes
|
EP3214177A3
(en)
*
|
1998-04-08 |
2017-11-22 |
Commonwealth Scientific and Industrial Research Organisation |
Methods and means for obtaining modified phenotypes
|
US20030228597A1
(en)
*
|
1998-04-13 |
2003-12-11 |
Cowsert Lex M. |
Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
|
EP1071753A2
(en)
*
|
1998-04-20 |
2001-01-31 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
US7078224B1
(en)
*
|
1999-05-14 |
2006-07-18 |
Promega Corporation |
Cell concentration and lysate clearance using paramagnetic particles
|
US7019195B1
(en)
*
|
1998-05-26 |
2006-03-28 |
Syngenta Participations Ag |
Method for conferring resistance or tolerance aganist furovirus, potyvirus, tospovirus, and cucomovirus to plant cells
|
AR020078A1
(en)
*
|
1998-05-26 |
2002-04-10 |
Syngenta Participations Ag |
METHOD FOR CHANGING THE EXPRESSION OF AN OBJECTIVE GENE IN A PLANT CELL
|
GB9827152D0
(en)
*
|
1998-07-03 |
1999-02-03 |
Devgen Nv |
Characterisation of gene function using double stranded rna inhibition
|
US7005423B1
(en)
*
|
1999-07-02 |
2006-02-28 |
Devgen Nv |
Characterization of gene function using double stranded RNA inhibition
|
US20040242521A1
(en)
*
|
1999-10-25 |
2004-12-02 |
Board Of Regents, The University Of Texas System |
Thio-siRNA aptamers
|
US20060172925A1
(en)
*
|
1998-10-26 |
2006-08-03 |
Board Of Regents, The University Of Texas System |
Thio-siRNA aptamers
|
US6759574B1
(en)
|
1998-11-05 |
2004-07-06 |
The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University |
Plants having enhanced gall resistance and methods and compositions for producing same
|
US6939712B1
(en)
*
|
1998-12-29 |
2005-09-06 |
Impedagen, Llc |
Muting gene activity using a transgenic nucleic acid
|
WO2000044914A1
(en)
*
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
DE19956568A1
(en)
*
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Method and medicament for inhibiting the expression of a given gene
|
AU2008202208C1
(en)
*
|
1999-01-30 |
2014-04-24 |
Alnylam Pharmaceuticals, Inc. |
Method and medicament for inhibiting the expression of a defined gene
|
US6987025B1
(en)
|
1999-02-11 |
2006-01-17 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Dwf4 polynucleotides, polypeptides and uses thereof
|
US7601494B2
(en)
|
1999-03-17 |
2009-10-13 |
The University Of North Carolina At Chapel Hill |
Method of screening candidate compounds for susceptibility to biliary excretion
|
EP1169480A4
(en)
*
|
1999-04-14 |
2005-02-02 |
Musc Found For Res Dev |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
KR20010112944A
(en)
*
|
1999-04-21 |
2001-12-22 |
이곤 이 버그 |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
US20040138168A1
(en)
*
|
1999-04-21 |
2004-07-15 |
Wyeth |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
EA200101186A1
(en)
*
|
1999-05-10 |
2002-04-25 |
Зингента Партисипейшнс Аг |
REGULATION OF VIRAL GENES EXPRESSION
|
EP1180165A2
(en)
*
|
1999-05-27 |
2002-02-20 |
PHARMACIA & UPJOHN COMPANY |
A nematode drug screen for modulators of mammalian disorders
|
US7485715B2
(en)
|
1999-06-18 |
2009-02-03 |
Ceres, Inc. |
Sequence-determined DNA encoding AP2 domain polypeptides
|
US7479555B2
(en)
|
1999-07-21 |
2009-01-20 |
Ceres, Inc. |
Polynucleotides having a nucleotide sequence that encodes a polypeptide having MOV34 family activity
|
US20040002153A1
(en)
*
|
1999-07-21 |
2004-01-01 |
Monia Brett P. |
Modulation of PTEN expression via oligomeric compounds
|
CA2379819A1
(en)
|
1999-07-29 |
2001-02-08 |
Dana-Farber Cancer Institute, Inc. |
Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
|
US6924109B2
(en)
*
|
1999-07-30 |
2005-08-02 |
Agy Therapeutics, Inc. |
High-throughput transcriptome and functional validation analysis
|
US6822086B1
(en)
*
|
1999-08-09 |
2004-11-23 |
The General Hospital Corporation |
Drug-carrier complexes and methods of use thereof
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US7067722B2
(en)
|
1999-08-26 |
2006-06-27 |
Monsanto Technology Llc |
Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
|
BR0013607A
(en)
|
1999-08-26 |
2002-04-30 |
Calgene Llc |
Nucleic acid sequences and processes of use for the production of plants with modified polyunsaturated fatty acids
|
US7531718B2
(en)
|
1999-08-26 |
2009-05-12 |
Monsanto Technology, L.L.C. |
Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
|
US20040106567A1
(en)
*
|
1999-09-07 |
2004-06-03 |
Hagstrom James E. |
Intravascular delivery of non-viral nucleic acid
|
US20020006664A1
(en)
*
|
1999-09-17 |
2002-01-17 |
Sabatini David M. |
Arrayed transfection method and uses related thereto
|
CA2386270A1
(en)
|
1999-10-15 |
2001-04-26 |
University Of Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
US20040157327A1
(en)
*
|
1999-10-22 |
2004-08-12 |
Wyeth |
Pablo, a polypeptide that interacts with BCL-XL, and uses related thereto
|
GB9925459D0
(en)
*
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
GB9927444D0
(en)
*
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
DE10100586C1
(en)
*
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
|
DE10160151A1
(en)
*
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang
|
US7829693B2
(en)
*
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
AU2625501A
(en)
*
|
1999-12-30 |
2001-07-16 |
Rutgers, The State University Of New Jersey |
Compositions and methods for gene silencing
|
AU3366901A
(en)
*
|
1999-12-30 |
2001-07-16 |
Novartis Ag |
Novel colloid synthetic vectors for gene therapy
|
US6531644B1
(en)
|
2000-01-14 |
2003-03-11 |
Exelixis, Inc. |
Methods for identifying anti-cancer drug targets
|
US7179796B2
(en)
|
2000-01-18 |
2007-02-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
*
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US8202979B2
(en)
*
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
US8273866B2
(en)
*
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
WO2003070918A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Rna interference by modified short interfering nucleic acid
|
US20080039414A1
(en)
*
|
2002-02-20 |
2008-02-14 |
Sima Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
US20050233329A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
Inhibition of gene expression using duplex forming oligonucleotides
|
JP2003525037A
(en)
*
|
2000-02-11 |
2003-08-26 |
リボザイム・ファーマシューティカルズ・インコーポレーテッド |
Methods and reagents for regulation and diagnosis of CD20 and NOGO gene expression
|
US20070026394A1
(en)
*
|
2000-02-11 |
2007-02-01 |
Lawrence Blatt |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
|
US7491805B2
(en)
*
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US7833992B2
(en)
*
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
US20030084471A1
(en)
*
|
2000-03-16 |
2003-05-01 |
David Beach |
Methods and compositions for RNA interference
|
EP1728862A1
(en)
*
|
2000-03-16 |
2006-12-06 |
Genetica, Inc. |
Methods and compositions for RNA interference
|
EP1272630A2
(en)
*
|
2000-03-16 |
2003-01-08 |
Genetica, Inc. |
Methods and compositions for rna interference
|
US8202846B2
(en)
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
GB2377221B
(en)
*
|
2000-03-17 |
2004-08-18 |
Benitec Australia Ltd |
Genetic silencing
|
PT2345742E
(en)
†
|
2000-03-30 |
2014-09-03 |
Max Planck Ges Zur Förderung Der Wissenschaften E V Berlin |
Rna sequence-specific mediators of rna interference
|
NZ522045A
(en)
|
2000-03-30 |
2007-05-31 |
Whitehead Biomedical Inst |
RNA sequence-specific mediators of RNA interference
|
US7691991B2
(en)
|
2000-04-17 |
2010-04-06 |
Ceres, Inc. |
Sequence-determined DNA fragments encoding cytochrome P450 proteins
|
GB0012233D0
(en)
|
2000-05-19 |
2000-07-12 |
Devgen Nv |
Vector constructs
|
ATE513910T1
(en)
*
|
2000-05-30 |
2011-07-15 |
Johnson & Johnson Res Pty Ltd |
METHODS OF GENE SUPPRESSION USING RNAI ENHANCEMENT FACTORS
|
JP2002306183A
(en)
*
|
2000-06-02 |
2002-10-22 |
Mitsubishi Chemicals Corp |
Method for identifying gene function
|
WO2001096584A2
(en)
*
|
2000-06-12 |
2001-12-20 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
EP1297163B1
(en)
|
2000-06-23 |
2011-04-27 |
E.I. Du Pont De Nemours And Company |
Recombinant constructs and their use in reducing gene expression
|
US7662791B2
(en)
*
|
2000-08-02 |
2010-02-16 |
University Of Southern California |
Gene silencing using mRNA-cDNA hybrids
|
US8044259B2
(en)
*
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
CA2456008A1
(en)
*
|
2000-08-19 |
2002-02-28 |
Axordia Limited |
Stem cell differentiation
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US20080032942A1
(en)
|
2000-08-30 |
2008-02-07 |
Mcswiggen James |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US20060247194A1
(en)
*
|
2000-08-30 |
2006-11-02 |
Sirna Therapeutics , Inc. |
Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
|
US20050209179A1
(en)
*
|
2000-08-30 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
EP1326996A4
(en)
*
|
2000-09-14 |
2005-08-24 |
Univ California |
Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
|
EP1318841A2
(en)
*
|
2000-09-19 |
2003-06-18 |
University Of South Florida |
Control of nk cell function and survival by modulation of ship activity
|
US20020165192A1
(en)
*
|
2000-09-19 |
2002-11-07 |
Kerr William G. |
Control of NK cell function and survival by modulation of ship activity
|
US7691821B2
(en)
*
|
2001-09-19 |
2010-04-06 |
University Of South Florida |
Inhibition of SHIP to enhance stem cell harvest and transplantation
|
AU3237902A
(en)
*
|
2000-10-12 |
2002-04-29 |
New York Health Res Inst |
Oligonucleotide - facilitated coalescence
|
WO2002059257A2
(en)
|
2000-10-31 |
2002-08-01 |
Commonwealth Scientific And Industrial Research Organisation |
Method and means for producing barley yellow dwarf virus resistant cereal plants
|
US20020173478A1
(en)
*
|
2000-11-14 |
2002-11-21 |
The Trustees Of The University Of Pennsylvania |
Post-transcriptional gene silencing by RNAi in mammalian cells
|
CH695778A5
(en)
*
|
2000-11-29 |
2006-08-31 |
Hoffmann La Roche |
Inhibition of transcription of a target gene in a cell or in tissues.
|
EP1873259B1
(en)
|
2000-12-01 |
2012-01-25 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
RNA interference mediated by 21 and 22nt RNAs
|
US20020160393A1
(en)
*
|
2000-12-28 |
2002-10-31 |
Symonds Geoffrey P. |
Double-stranded RNA-mediated gene suppression
|
US7385046B2
(en)
|
2001-01-03 |
2008-06-10 |
Ceres, Inc. |
Sequence-determined DNA fragments encoding ethylene responsive element binding proteins
|
US7423142B2
(en)
*
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7767802B2
(en)
*
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
JP2002208294A
(en)
*
|
2001-01-12 |
2002-07-26 |
Toshiba Corp |
Semiconductor memory having redundancy system
|
EP1860199B1
(en)
|
2001-01-12 |
2014-03-05 |
Exelixis, Inc. |
Modulating insulin receptor signaling
|
AU2002224668B2
(en)
|
2001-01-26 |
2007-09-20 |
Commonwealth Scientific And Industrial Research Organisation |
Methods and means for producing efficient silencing construct using recombinational cloning
|
CA2369944A1
(en)
*
|
2001-01-31 |
2002-07-31 |
Nucleonics Inc. |
Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
|
AU2002250034A1
(en)
*
|
2001-02-08 |
2002-08-19 |
Sequitur, Inc. |
Methods of light activated release 0f ligands from endosomes
|
GB0104948D0
(en)
*
|
2001-02-28 |
2001-04-18 |
Novartis Res Foundation |
Novel methods
|
US7563618B2
(en)
*
|
2001-03-23 |
2009-07-21 |
Geron Corporation |
Oligonucleotide conjugates
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
US20050137155A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
|
US20030175950A1
(en)
*
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20050119212A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
|
WO2003072590A1
(en)
*
|
2002-02-20 |
2003-09-04 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US20050164966A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050187174A1
(en)
*
|
2001-05-18 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050182006A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
|
US20050164967A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US20050209180A1
(en)
*
|
2001-05-18 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US20050159380A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
US20050159376A1
(en)
*
|
2002-02-20 |
2005-07-21 |
Slrna Therapeutics, Inc. |
RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
|
US20050014172A1
(en)
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
US20060142225A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
|
WO2003070972A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050164968A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
|
US20050164224A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20070270579A1
(en)
*
|
2001-05-18 |
2007-11-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050176666A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050153914A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
|
US20050130181A1
(en)
*
|
2001-05-18 |
2005-06-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
|
US20050176664A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
|
US20060019913A1
(en)
*
|
2001-05-18 |
2006-01-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
US20050233996A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050287128A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
|
US20040006035A1
(en)
*
|
2001-05-29 |
2004-01-08 |
Dennis Macejak |
Nucleic acid mediated disruption of HIV fusogenic peptide interactions
|
US20040219671A1
(en)
*
|
2002-02-20 |
2004-11-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
|
US20060142226A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
|
US20050176665A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050182009A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
|
US7517864B2
(en)
*
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050148530A1
(en)
*
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050054596A1
(en)
*
|
2001-11-30 |
2005-03-10 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050191618A1
(en)
*
|
2001-05-18 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
US20050080031A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US20050159378A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
US20050256068A1
(en)
*
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US20050191638A1
(en)
*
|
2002-02-20 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050222066A1
(en)
*
|
2001-05-18 |
2005-10-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20080188430A1
(en)
*
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
JP4358521B2
(en)
|
2001-05-18 |
2009-11-04 |
サーナ・セラピューティクス・インコーポレイテッド |
Conjugates and compositions for cellular delivery
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20040209831A1
(en)
*
|
2002-02-20 |
2004-10-21 |
Mcswiggen James |
RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
US20090299045A1
(en)
*
|
2001-05-18 |
2009-12-03 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition Of Interleukin and Interleukin Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20060241075A1
(en)
*
|
2001-05-18 |
2006-10-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20050136436A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
|
US20050227935A1
(en)
*
|
2001-05-18 |
2005-10-13 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
|
US20070049543A1
(en)
*
|
2001-05-18 |
2007-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
|
US20030124513A1
(en)
*
|
2001-05-29 |
2003-07-03 |
Mcswiggen James |
Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV
|
US20060211642A1
(en)
*
|
2001-05-18 |
2006-09-21 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US20050159379A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
|
US20040019001A1
(en)
*
|
2002-02-20 |
2004-01-29 |
Mcswiggen James A. |
RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
|
US20050054598A1
(en)
*
|
2002-02-20 |
2005-03-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050153915A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
|
US20050170371A1
(en)
*
|
2001-05-18 |
2005-08-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
|
US20050267058A1
(en)
*
|
2001-05-18 |
2005-12-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
|
US20070093437A1
(en)
*
|
2001-05-18 |
2007-04-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina)
|
US20050282188A1
(en)
*
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050124568A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
|
WO2003070197A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20070042983A1
(en)
*
|
2001-05-18 |
2007-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050124567A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
|
US7109165B2
(en)
*
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050233344A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
|
US20080161256A1
(en)
*
|
2001-05-18 |
2008-07-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20050079610A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US8008472B2
(en)
|
2001-05-29 |
2011-08-30 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
JP2005501528A
(en)
|
2001-06-05 |
2005-01-20 |
エクセリクシス・インコーポレイテッド |
GFATs as p53 pathway modifiers and methods of use
|
CA2451247A1
(en)
*
|
2001-06-22 |
2003-01-03 |
The Regents Of The University Of California |
Eukaryotic genes involved in adult lifespan regulation
|
ES2192945B1
(en)
*
|
2001-07-06 |
2005-03-01 |
Consejo Superior De Investigaciones Cientificas |
A METHOD TO INTERFER WITH VIRUS INFECTION IN PLANTS.
|
US20040126867A1
(en)
*
|
2001-07-06 |
2004-07-01 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
AUPR621501A0
(en)
|
2001-07-06 |
2001-08-02 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of ds rna
|
CN1553963A
(en)
*
|
2001-07-10 |
2004-12-08 |
ǿ����ǿ���о�����˾ |
Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
|
CA2921821A1
(en)
*
|
2001-07-12 |
2003-01-23 |
University Of Massachusetts |
In vivo production of small interfering rnas that mediate gene silencing
|
WO2003006991A1
(en)
|
2001-07-12 |
2003-01-23 |
Exelixis, Inc. |
HADHs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
|
US8022272B2
(en)
|
2001-07-13 |
2011-09-20 |
Sungene Gmbh & Co. Kgaa |
Expression cassettes for transgenic expression of nucleic acids
|
DK2280070T3
(en)
*
|
2001-07-23 |
2015-08-24 |
Univ Leland Stanford Junior |
Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals
|
US10590418B2
(en)
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
US7612194B2
(en)
*
|
2001-07-24 |
2009-11-03 |
Monsanto Technology Llc |
Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
|
GB0118223D0
(en)
*
|
2001-07-26 |
2001-09-19 |
Univ Sheffield |
Stem loop RNA
|
US20050037989A1
(en)
*
|
2001-08-27 |
2005-02-17 |
Lewis David L. |
Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
|
US20030198627A1
(en)
*
|
2001-09-01 |
2003-10-23 |
Gert-Jan Arts |
siRNA knockout assay method and constructs
|
US7456335B2
(en)
|
2001-09-03 |
2008-11-25 |
Basf Plant Science Gmbh |
Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
|
US7919309B2
(en)
|
2001-09-13 |
2011-04-05 |
California Institute Of Technology |
Method for expression of small antiviral RNA molecules within a cell
|
US7737124B2
(en)
*
|
2001-09-13 |
2010-06-15 |
California Institute Of Technology |
Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
|
US7195916B2
(en)
*
|
2001-09-13 |
2007-03-27 |
California Institute Of Technology |
Method for expression of small antiviral RNA molecules within a cell
|
US7112405B2
(en)
|
2001-09-27 |
2006-09-26 |
University Of Delaware |
Compositions and methods for enhancing oligonucleotide-mediated gene alteration
|
EP2224003B1
(en)
|
2001-09-28 |
2018-04-18 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
MicroRNA molecules
|
GB0123401D0
(en)
*
|
2001-09-28 |
2001-11-21 |
Novartis Forschungsstiftung |
Methods of inducing gene expression
|
DE10163098B4
(en)
*
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Method for inhibiting the replication of viruses
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
WO2003034985A2
(en)
*
|
2001-10-22 |
2003-05-01 |
University Of Rochester |
Telomerase interference
|
DE10230996A1
(en)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Method for inhibiting viral replication, useful particularly for treating hepatitis C infection, by altering the 3'-untranslated region of the virus
|
DE10230997A1
(en)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Drug to increase the effectiveness of a receptor-mediates apoptosis in drug that triggers tumor cells
|
WO2003035868A1
(en)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Medicament that increases the effectiveness of a drug that induces receptor-mediated apoptosis in tumor cells
|
JP2005506087A
(en)
*
|
2001-10-26 |
2005-03-03 |
リボファーマ アーゲー |
Use of double-stranded ribonucleic acid to treat infections caused by plus-strand RNA viruses
|
IL161733A0
(en)
*
|
2001-11-02 |
2005-11-20 |
Insert Therapeutics Inc |
Methods and compositions for therapeutic use of rna interference
|
US20040063654A1
(en)
*
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
NZ531803A
(en)
*
|
2001-11-05 |
2006-09-29 |
Janssen Pharmaceutica Nv |
Method for the in vitro synthesis of short double stranded RNAs
|
US20030150017A1
(en)
*
|
2001-11-07 |
2003-08-07 |
Mesa Jose Ramon Botella |
Method for facilitating pathogen resistance
|
US20030148519A1
(en)
*
|
2001-11-14 |
2003-08-07 |
Engelke David R. |
Intracellular expression and delivery of siRNAs in mammalian cells
|
IL162062A0
(en)
*
|
2001-11-19 |
2005-11-20 |
Proteologics Inc |
Methods for identifying and validating potential drug targets
|
ES2401326T3
(en)
*
|
2001-11-21 |
2013-04-18 |
Astellas Pharma Inc. |
Procedure to inhibit gene expression
|
WO2003046173A1
(en)
*
|
2001-11-28 |
2003-06-05 |
Center For Advanced Science And Technology Incubation, Ltd. |
siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
|
US20040138163A1
(en)
*
|
2002-05-29 |
2004-07-15 |
Mcswiggen James |
RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20070203333A1
(en)
*
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050075304A1
(en)
*
|
2001-11-30 |
2005-04-07 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
GB0130199D0
(en)
*
|
2001-12-17 |
2002-02-06 |
Syngenta Mogen Bv |
New nematode feeding assay
|
US7294504B1
(en)
*
|
2001-12-27 |
2007-11-13 |
Allele Biotechnology & Pharmaceuticals, Inc. |
Methods and compositions for DNA mediated gene silencing
|
DE10202419A1
(en)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Method of inhibiting expression of a target gene resulting from chromosome aberration
|
AU2008246266B2
(en)
*
|
2002-01-22 |
2012-09-06 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
AU2012261651B2
(en)
*
|
2002-01-22 |
2015-09-24 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
EP1470148B1
(en)
|
2002-02-01 |
2012-07-18 |
Life Technologies Corporation |
Double-stranded oligonucleotides
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20030166282A1
(en)
*
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
US20030203868A1
(en)
*
|
2002-02-06 |
2003-10-30 |
Bushman Frederic D. |
Inhibition of pathogen replication by RNA interference
|
US20050096289A1
(en)
*
|
2002-02-07 |
2005-05-05 |
Hans Prydz |
Methods and compositions for modulating tissue factor
|
WO2003068961A2
(en)
*
|
2002-02-13 |
2003-08-21 |
Axordia Limited |
Method to modify differentiation of pluripotential stem cells
|
WO2003068797A1
(en)
*
|
2002-02-14 |
2003-08-21 |
City Of Hope |
Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules
|
ATE519774T1
(en)
|
2002-02-20 |
2011-08-15 |
Sirna Therapeutics Inc |
RNA DISRUPTION-MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION WITH SHORT INTERFERING NUCLEIC ACID (SINA)
|
US7910724B2
(en)
|
2002-02-20 |
2011-03-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US7678897B2
(en)
|
2002-02-20 |
2010-03-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US7897757B2
(en)
|
2002-02-20 |
2011-03-01 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
US7897752B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
|
US7667030B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US7662952B2
(en)
*
|
2002-02-20 |
2010-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7928220B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
|
US8013143B2
(en)
|
2002-02-20 |
2011-09-06 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
US7928219B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
|
US8258288B2
(en)
|
2002-02-20 |
2012-09-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
|
US7897753B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
|
US7928218B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20090253773A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7935812B2
(en)
|
2002-02-20 |
2011-05-03 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US7700760B2
(en)
|
2002-02-20 |
2010-04-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
EP1432724A4
(en)
|
2002-02-20 |
2006-02-01 |
Sirna Therapeutics Inc |
Rna interference mediated inhibition of map kinase genes
|
JP2005517450A
(en)
*
|
2002-02-20 |
2005-06-16 |
サーナ・セラピューティクス・インコーポレイテッド |
RNA interference-mediated target discovery and target evaluation using short interfering nucleic acids (siNA)
|
US20050137153A1
(en)
*
|
2002-02-20 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
|
US20090137513A1
(en)
*
|
2002-02-20 |
2009-05-28 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20050222064A1
(en)
*
|
2002-02-20 |
2005-10-06 |
Sirna Therapeutics, Inc. |
Polycationic compositions for cellular delivery of polynucleotides
|
EP1448590A4
(en)
*
|
2002-02-20 |
2004-12-15 |
Sirna Therapeutics Inc |
Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
|
AU2003215161A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Ribozyme Pharmaceuticals, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20090137510A1
(en)
*
|
2002-02-20 |
2009-05-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/ REL-A GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7683165B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US7683166B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US8067575B2
(en)
|
2002-02-20 |
2011-11-29 |
Merck, Sharp & Dohme Corp. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US7691999B2
(en)
|
2002-02-20 |
2010-04-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
|
US20090099117A1
(en)
|
2002-02-20 |
2009-04-16 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20090192105A1
(en)
|
2002-02-20 |
2009-07-30 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
|
US20050096284A1
(en)
*
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US7893248B2
(en)
*
|
2002-02-20 |
2011-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
WO2003106476A1
(en)
*
|
2002-02-20 |
2003-12-24 |
Sirna Therapeutics, Inc |
Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
|
US7667029B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
CA2477014A1
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of tnf and tnf receptor superfamily gene expression using short interfering nucleic acid (sina)
|
US20090253774A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7795422B2
(en)
|
2002-02-20 |
2010-09-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
AU2003207099A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Otsuka Pharmaceutical Co., Ltd. |
Polynucleotide for target gene
|
US20050176008A1
(en)
*
|
2002-02-22 |
2005-08-11 |
Mikio Suzuki |
Polynucleotide for target gene
|
AUPS078002A0
(en)
*
|
2002-02-27 |
2002-03-21 |
Unisearch Limited |
Dnazyme therapeutics
|
CA2476410C
(en)
|
2002-03-01 |
2013-09-24 |
Celltech R & D, Inc. |
Methods to increase or decrease bone density
|
US7274703B2
(en)
*
|
2002-03-11 |
2007-09-25 |
3Com Corporation |
Stackable network units with resiliency facility
|
EP2258712A3
(en)
*
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
|
US20070037769A1
(en)
*
|
2003-03-14 |
2007-02-15 |
Multicell Immunotherapeutics, Inc. |
Compositions and methods to treat and control tumors by loading antigen presenting cells
|
EP1485403A4
(en)
*
|
2002-03-15 |
2007-08-08 |
Multicell Immunotherapeutics I |
Compositions and methods to initiate or enhance antibody and major-histocompatibility class i or class ii-restricted t cell responses by using immunomodulatory, non-coding rna motifs
|
AU2003221506A1
(en)
|
2002-03-19 |
2003-09-29 |
Novartis Ag |
Methods for the identification of compounds useful for the suppression of chronic neuropathic pain and compositions thereof
|
DE10212893A1
(en)
*
|
2002-03-20 |
2003-10-16 |
Basf Plant Science Gmbh |
Process for increasing the oil content in plants
|
DE10212892A1
(en)
|
2002-03-20 |
2003-10-09 |
Basf Plant Science Gmbh |
Constructs and methods for regulating gene expression
|
US7566813B2
(en)
|
2002-03-21 |
2009-07-28 |
Monsanto Technology, L.L.C. |
Nucleic acid constructs and methods for producing altered seed oil compositions
|
US7601888B2
(en)
*
|
2002-03-21 |
2009-10-13 |
Monsanto Technology L.L.C. |
Nucleic acid constructs and methods for producing altered seed oil compositions
|
US7166771B2
(en)
*
|
2002-06-21 |
2007-01-23 |
Monsanto Technology Llc |
Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
|
EP1490490B1
(en)
|
2002-03-27 |
2009-05-13 |
Aegera Therapeutics Inc. |
Antisense iap nucleobase oligomers and uses thereof
|
US7357928B2
(en)
|
2002-04-08 |
2008-04-15 |
University Of Louisville Research Foundation, Inc. |
Method for the diagnosis and prognosis of malignant diseases
|
US7541150B2
(en)
*
|
2002-04-08 |
2009-06-02 |
University Of Louisville Research Foundation, Inc |
Method for the diagnosis and prognosis of malignant diseases
|
EP1352960A1
(en)
*
|
2002-04-12 |
2003-10-15 |
Viruvation B.V. |
Antiviral therapy on the basis of RNA interference
|
WO2003087367A2
(en)
*
|
2002-04-18 |
2003-10-23 |
Lynkeus Biotech Gmbh |
Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
|
CN1659276A
(en)
|
2002-04-19 |
2005-08-24 |
戴弗萨公司 |
Phospholipases, nucleic acids encoding them and methods for making and using them
|
US7226771B2
(en)
|
2002-04-19 |
2007-06-05 |
Diversa Corporation |
Phospholipases, nucleic acids encoding them and methods for making and using them
|
US20040180438A1
(en)
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
EP2339010B1
(en)
|
2002-05-01 |
2017-04-12 |
Miltenyi Biotec Technology, Inc. |
Lentiviral vector particles resistant to complement inactivation
|
WO2003093441A2
(en)
|
2002-05-03 |
2003-11-13 |
Duke University |
A method of regulating gene expression
|
JP4868739B2
(en)
|
2002-05-06 |
2012-02-01 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Nucleic acid delivery methods
|
US20030228691A1
(en)
*
|
2002-05-17 |
2003-12-11 |
Lewis David L. |
Processes for inhibiting gene expression using polynucleotides
|
US7351542B2
(en)
|
2002-05-20 |
2008-04-01 |
The Regents Of The University Of California |
Methods of modulating tubulin deacetylase activity
|
US20040121353A1
(en)
*
|
2002-05-23 |
2004-06-24 |
Ceptyr, Inc. |
Modulation of TCPTP signal transduction by RNA interference
|
GB0212302D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Method of selecting targets for gene silencing by RNA interference
|
US20040019008A1
(en)
*
|
2002-05-28 |
2004-01-29 |
Lewis David L. |
Compositions and processes using siRNA, amphipathic compounds and polycations
|
GB0212303D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Molecular targetting of IGF-1 receptor
|
FR2840217B1
(en)
*
|
2002-06-03 |
2005-06-24 |
Oreal |
COSMETIC COMPOSITIONS COMPRISING AT LEAST ONE DOUBLE-STRANDED RNA OLIGONUCLEOTIDE (DSRNA) AND USES THEREOF
|
AUPS282602A0
(en)
|
2002-06-07 |
2002-06-27 |
Garvan Institute Of Medical Research |
Method of inhibiting cell proliferation
|
CA2388441A1
(en)
*
|
2002-06-10 |
2003-12-10 |
Wei-Ping Min |
Immunomodulation using rna interference
|
US20100075423A1
(en)
*
|
2002-06-12 |
2010-03-25 |
Life Technologies Corporation |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
EP1532271A4
(en)
*
|
2002-06-12 |
2006-10-18 |
Ambion Inc |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
WO2003106654A2
(en)
|
2002-06-14 |
2003-12-24 |
Diversa Corporation |
Xylanases, nucleic adics encoding them and methods for making and using them
|
AU2003251579B2
(en)
*
|
2002-06-21 |
2008-04-03 |
Monsanto Technology Llc |
Intron double stranded RNA constructs and uses thereof
|
AU2003256325A1
(en)
*
|
2002-06-26 |
2004-01-19 |
The Penn State Research Foundation |
Methods and materials for treating human papillomavirus infections
|
DE60331310D1
(en)
*
|
2002-06-26 |
2010-04-01 |
Univ Louisville Res Found |
PROCEDURE FOR APOPTOSE DETECTION
|
BR0312580A
(en)
*
|
2002-07-10 |
2006-10-10 |
Univ Kansas State |
compositions and methods for controlling parasitic nematodes
|
US7655790B2
(en)
|
2002-07-12 |
2010-02-02 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
WO2004009768A2
(en)
*
|
2002-07-18 |
2004-01-29 |
Invitrogen Corporation |
Viral vectors containing recombination sites
|
DE10233327A1
(en)
*
|
2002-07-22 |
2004-02-05 |
Basf Ag |
Process for achieving pathogen resistance in plants
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
US7399851B2
(en)
|
2002-07-25 |
2008-07-15 |
Dana Farber Cancer Institute, Inc. |
Composition and method for imaging cells
|
ATE546539T1
(en)
|
2002-07-26 |
2012-03-15 |
Basf Plant Science Gmbh |
REVERSING THE NEGATIVE-SELECTIVE EFFECT OF NEGATIVE MARKER PROTEINS AS A SELECTION METHOD
|
CA2493949C
(en)
|
2002-07-26 |
2015-06-02 |
Chiron Corporation |
Modified small interfering rna molecules and methods of use
|
WO2004011624A2
(en)
*
|
2002-07-31 |
2004-02-05 |
Nucleonics, Inc. |
Double stranded rna structures and constructs, and methods for generating and using the same
|
JP2006515158A
(en)
|
2002-08-01 |
2006-05-25 |
シティ・オブ・ホープ |
Methods and kits for synthesizing siRNA expression cassettes
|
EP2258847B2
(en)
|
2002-08-05 |
2020-07-01 |
Silence Therapeutics GmbH |
Futher novel forms of interfering RNA molecules
|
US20040023390A1
(en)
*
|
2002-08-05 |
2004-02-05 |
Davidson Beverly L. |
SiRNA-mediated gene silencing with viral vectors
|
US20050106731A1
(en)
*
|
2002-08-05 |
2005-05-19 |
Davidson Beverly L. |
siRNA-mediated gene silencing with viral vectors
|
US20080176812A1
(en)
*
|
2002-08-05 |
2008-07-24 |
Davidson Beverly L |
Allele-specific silencing of disease genes
|
US20080274989A1
(en)
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
US20040241854A1
(en)
|
2002-08-05 |
2004-12-02 |
Davidson Beverly L. |
siRNA-mediated gene silencing
|
US20050255086A1
(en)
*
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
US20050042646A1
(en)
*
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
AU2003258100A1
(en)
*
|
2002-08-06 |
2004-02-23 |
Intradigm Corporation |
Methods of down regulating target gene expression in vivo by introduction of interfering rna
|
US20060064784A1
(en)
|
2002-08-07 |
2006-03-23 |
Basf Plant Science Gmbh |
Nucleic acid sequences encoding proteins associated with abiotic stress response
|
US8729036B2
(en)
*
|
2002-08-07 |
2014-05-20 |
University Of Massachusetts |
Compositions for RNA interference and methods of use thereof
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
ATE435303T1
(en)
*
|
2002-08-12 |
2009-07-15 |
New England Biolabs Inc |
METHODS AND COMPOSITIONS RELATED TO GENE SILENCING
|
US20040198967A1
(en)
*
|
2002-09-04 |
2004-10-07 |
Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth |
Compositions and methods for tissue specific or inducible inhibition of gene expression
|
US7956176B2
(en)
|
2002-09-05 |
2011-06-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20050272650A1
(en)
*
|
2004-02-17 |
2005-12-08 |
Mohapatra Shyam S |
Materials and methods for treatment of inflammatory and cell proliferation disorders
|
US7655772B2
(en)
|
2002-09-06 |
2010-02-02 |
University Of South Florida |
Materials and methods for treatment of allergic diseases
|
US20080214437A1
(en)
*
|
2002-09-06 |
2008-09-04 |
Mohapatra Shyam S |
Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
|
US20080260744A1
(en)
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
CN1694959B
(en)
*
|
2002-09-13 |
2013-09-18 |
雷普利瑟公司 |
Non-sequence complementary antiviral oligonucleotides
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
US8609831B2
(en)
*
|
2002-09-16 |
2013-12-17 |
University Of Southern California |
RNA-mediated gene modulation
|
US7476777B2
(en)
|
2002-09-17 |
2009-01-13 |
Ceres, Inc. |
Biological containment system
|
WO2004027030A2
(en)
*
|
2002-09-18 |
2004-04-01 |
Isis Pharmaceuticals, Inc. |
Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds
|
WO2004029212A2
(en)
|
2002-09-25 |
2004-04-08 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable sirna
|
AU2003277005A1
(en)
*
|
2002-09-26 |
2004-04-19 |
The Regents Of The University Of California |
Conditional gene expression using rnai
|
US20040242518A1
(en)
*
|
2002-09-28 |
2004-12-02 |
Massachusetts Institute Of Technology |
Influenza therapeutic
|
US20060160759A1
(en)
*
|
2002-09-28 |
2006-07-20 |
Jianzhu Chen |
Influenza therapeutic
|
US20070224124A1
(en)
*
|
2002-09-30 |
2007-09-27 |
University Of South Florida |
Novel SH2containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein
|
AU2003275449A1
(en)
*
|
2002-10-07 |
2004-05-04 |
Wei Liu |
Compositions, organisms and methodologies employing a novel human kinase
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
AU2003304238A1
(en)
*
|
2002-10-08 |
2005-01-13 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
WO2004032870A2
(en)
*
|
2002-10-08 |
2004-04-22 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
|
US7122361B2
(en)
*
|
2002-10-10 |
2006-10-17 |
Wyeth |
Compositions employing a novel human kinase
|
US20040096890A1
(en)
*
|
2002-10-10 |
2004-05-20 |
Wyeth |
Compositions, organisms and methodologies employing a novel human kinase
|
AU2003301348A1
(en)
*
|
2002-10-18 |
2004-05-04 |
Wyeth |
Compositions and methods for diagnosing and treating autoimmune disease
|
US7208306B2
(en)
*
|
2002-10-24 |
2007-04-24 |
Wyeth |
Compositions employing a novel human protein phosphatase
|
US7521431B2
(en)
|
2002-11-01 |
2009-04-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for siRNA inhibition of HIF-1 alpha
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
GB0225799D0
(en)
*
|
2002-11-05 |
2002-12-11 |
Novartis Forschungsstiftung |
Tel/etv6-mediated inhibition of cell proliferation
|
AU2003287505A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
AU2003290598A1
(en)
*
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
US7696345B2
(en)
|
2002-11-05 |
2010-04-13 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
EP2284266B1
(en)
*
|
2002-11-14 |
2013-11-06 |
Thermo Fisher Scientific Biosciences Inc. |
siRNA targeting tp53
|
WO2006006948A2
(en)
*
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
US7592442B2
(en)
*
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
US7619081B2
(en)
*
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
US8198427B1
(en)
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7635770B2
(en)
*
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7781575B2
(en)
|
2002-11-14 |
2010-08-24 |
Dharmacon, Inc. |
siRNA targeting tumor protein 53 (p53)
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7612196B2
(en)
*
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
US20080268457A1
(en)
*
|
2002-11-14 |
2008-10-30 |
Dharmacon, Inc. |
siRNA targeting forkhead box P3 (FOXP3)
|
US20090227780A1
(en)
*
|
2002-11-14 |
2009-09-10 |
Dharmacon, Inc. |
siRNA targeting connexin 43
|
US7691998B2
(en)
*
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
US7977471B2
(en)
*
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
US20100113307A1
(en)
*
|
2002-11-14 |
2010-05-06 |
Dharmacon, Inc. |
siRNA targeting vascular endothelial growth factor (VEGF)
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
AU2003295539A1
(en)
*
|
2002-11-15 |
2004-06-15 |
University Of Massachusetts |
Allele-targeted rna interference
|
CA2505416A1
(en)
*
|
2002-11-21 |
2004-06-10 |
Wyeth |
Methods for diagnosing rcc and other solid tumors
|
US7365186B2
(en)
*
|
2002-11-22 |
2008-04-29 |
Arborgen, Llc |
Vascular-preferred promoter sequences and uses thereof
|
US20040191905A1
(en)
*
|
2002-11-22 |
2004-09-30 |
University Of Massachusetts |
Modulation of HIV replication by RNA interference
|
US7297779B2
(en)
*
|
2002-11-24 |
2007-11-20 |
Daiichi Pharmaceutical Co., Ltd. |
Colon cancer metastasis inhibitor
|
EP2112229A3
(en)
|
2002-11-25 |
2009-12-02 |
Sequenom, Inc. |
Methods for identifying risk of breast cancer and treatments thereof
|
US7790867B2
(en)
*
|
2002-12-05 |
2010-09-07 |
Rosetta Genomics Inc. |
Vaccinia virus-related nucleic acids and microRNA
|
US7605249B2
(en)
*
|
2002-11-26 |
2009-10-20 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
US20050048641A1
(en)
*
|
2002-11-26 |
2005-03-03 |
Medtronic, Inc. |
System and method for delivering polynucleotides to the central nervous system
|
KR20090046973A
(en)
|
2002-11-27 |
2009-05-11 |
아이알엠 엘엘씨 |
Methods and compositions for inducing apoptosis in cancer cells
|
WO2004050831A2
(en)
*
|
2002-11-27 |
2004-06-17 |
Wyeth |
Compositions, organisms and methodologies employing a novel human kinase
|
US20040110698A1
(en)
*
|
2002-12-10 |
2004-06-10 |
Kimron Veterinary Institute |
Oligonucleotides and methods using same for treating cox-ll associated diseases
|
EP1583836A4
(en)
*
|
2002-12-11 |
2006-12-27 |
Univ Massachusetts |
METHOD OF INTRODUCING siRNA INTO ADIPOCYTES
|
EP2218779A1
(en)
|
2002-12-16 |
2010-08-18 |
Halozyme, Inc. |
Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
|
US7078234B2
(en)
|
2002-12-18 |
2006-07-18 |
Monsanto Technology Llc |
Maize embryo-specific promoter compositions and methods for use thereof
|
CN1301263C
(en)
*
|
2002-12-18 |
2007-02-21 |
北京昭衍新药研究中心 |
Nucleotide sequence for anti HIV infection and preventing AIDS and use thereof
|
WO2004058307A1
(en)
*
|
2002-12-18 |
2004-07-15 |
Wyeth |
Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
ES2382918T3
(en)
|
2002-12-24 |
2012-06-14 |
Rinat Neuroscience Corp. |
Anti-NGF antibodies and procedures using them
|
EP1576178A4
(en)
|
2002-12-26 |
2008-03-05 |
Syngenta Participations Ag |
Cell proliferation-related polypeptides and uses therefor
|
US20040248299A1
(en)
*
|
2002-12-27 |
2004-12-09 |
Sumedha Jayasena |
RNA interference
|
WO2004061423A2
(en)
*
|
2003-01-06 |
2004-07-22 |
Wyeth |
Compositions and methods for diagnosing and treating colon cancers
|
ATE477337T1
(en)
*
|
2003-01-16 |
2010-08-15 |
Univ Pennsylvania |
COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ICAM-1
|
DE602004030315D1
(en)
|
2003-01-17 |
2011-01-13 |
Max Planck Gesellschaft |
INDUCIBLE SIRNA EXPRESSION CONSTRUCTS FOR TARGET GENERAL SWITCHING
|
JP3792655B2
(en)
*
|
2003-01-20 |
2006-07-05 |
日本電気株式会社 |
Novel oncogene, recombinant protein derived from the oncogene, and uses thereof
|
US20040147027A1
(en)
*
|
2003-01-28 |
2004-07-29 |
Troy Carol M. |
Complex for facilitating delivery of dsRNA into a cell and uses thereof
|
US20050266409A1
(en)
*
|
2003-02-04 |
2005-12-01 |
Wyeth |
Compositions and methods for diagnosing, preventing, and treating cancers
|
AU2004211949A1
(en)
*
|
2003-02-05 |
2004-08-26 |
University Of Massachusetts |
RNAi targeting of viruses
|
US7326768B2
(en)
*
|
2003-02-05 |
2008-02-05 |
Juan Saus |
Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
|
US20040171118A1
(en)
*
|
2003-02-13 |
2004-09-02 |
City Of Hope |
Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs
|
US20070104688A1
(en)
|
2003-02-13 |
2007-05-10 |
City Of Hope |
Small interfering RNA mediated transcriptional gene silencing in mammalian cells
|
US20070149449A1
(en)
|
2003-02-14 |
2007-06-28 |
Morris David W |
Therapeutic targets in cancer
|
EP1594441B1
(en)
|
2003-02-19 |
2010-12-15 |
Rinat Neuroscience Corp. |
Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
|
JP2006523103A
(en)
*
|
2003-02-21 |
2006-10-12 |
ザ ペン ステイト リサーチ ファウンデーション |
RNA interference compositions and methods
|
US20040261149A1
(en)
*
|
2003-02-24 |
2004-12-23 |
Fauquet Claude M. |
siRNA-mediated inhibition of gene expression in plant cells
|
WO2004076639A2
(en)
*
|
2003-02-26 |
2004-09-10 |
Wyeth |
Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
|
ATE504648T1
(en)
|
2003-02-28 |
2011-04-15 |
Oncotherapy Science Inc |
RNA INTERFERENCE FOR THE ZNFN3A1 GENE AS A METHOD OF INHIBITING CANCER CELL GROWTH
|
WO2004078995A2
(en)
|
2003-03-04 |
2004-09-16 |
Neurogenetics, Inc. |
Methods of modulating and of identifying agents that modulate intracellular calcium
|
WO2004078940A2
(en)
*
|
2003-03-05 |
2004-09-16 |
Senesco Technologies, Inc. |
USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF eIF-5A1
|
KR20130135986A
(en)
|
2003-03-05 |
2013-12-11 |
할로자임, 아이엔씨 |
Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
JP4778418B2
(en)
*
|
2003-03-06 |
2011-09-21 |
ヴェレニウム コーポレイション |
Amylase, nucleic acid encoding the same, and production and use thereof
|
US20050164212A1
(en)
*
|
2003-03-06 |
2005-07-28 |
Todd Hauser |
Modulation of gene expression using DNA-RNA hybrids
|
DK2194133T3
(en)
|
2003-03-06 |
2016-02-29 |
Basf Enzymes Llc |
Amylases, nucleic acids encoding them, and methods of making and using the same
|
CA2515583C
(en)
|
2003-03-07 |
2015-07-14 |
Diversa Corporation |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
EP1601382A4
(en)
*
|
2003-03-13 |
2006-11-22 |
Univ Utah Res Found |
Phospholipid scramblase 3
|
CA2519860C
(en)
|
2003-03-21 |
2018-01-16 |
Santaris Pharma A/S |
Short interfering rna (sirna) analogues
|
WO2004087901A2
(en)
|
2003-03-25 |
2004-10-14 |
Wyeth |
Brain-localized protein kinases homologous to homeodomain-interacting protein kinases
|
WO2004087877A2
(en)
*
|
2003-03-26 |
2004-10-14 |
Astral Inc. |
Selected rna motifs to include cell death and/or apoptosis
|
US20040265961A1
(en)
*
|
2003-03-28 |
2004-12-30 |
Wei Liu |
Novel proteins homologous to kinase suppressor of Ras
|
CN1836045B
(en)
|
2003-03-28 |
2012-05-09 |
孟山都技术有限公司 |
Novel plant promoters for use in early seed development
|
WO2004089284A2
(en)
|
2003-04-01 |
2004-10-21 |
Intradigm Corporation |
Targets for tumor growth inhibition
|
US20070197457A1
(en)
*
|
2003-04-01 |
2007-08-23 |
Dan Gazit |
Tak1-mediated inhibition of osteogenesis
|
JP4605799B2
(en)
*
|
2003-04-02 |
2011-01-05 |
ダーマコン, インコーポレイテッド |
Modified polynucleotides for use in RNA interference
|
US8158420B2
(en)
|
2003-04-04 |
2012-04-17 |
The Trustees Of Columbia University In The City Of New York |
Methods for inhibiting the differentation of proliferative telencephalic cells in vitro by addition of ATF5
|
ES2545639T3
(en)
|
2003-04-04 |
2015-09-14 |
Basf Enzymes Llc |
Pectate liases, nucleic acids that encode them and methods for their preparation and use
|
EP1615611B1
(en)
*
|
2003-04-09 |
2013-02-13 |
Alnylam Pharmaceuticals Inc. |
iRNA CONJUGATES
|
WO2004091515A2
(en)
*
|
2003-04-09 |
2004-10-28 |
Alnylam Pharmaceuticals, Inc. |
iRNA CONJUGATES
|
JP4912873B2
(en)
*
|
2003-04-09 |
2012-04-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
iRNA complex
|
EP1469070A1
(en)
*
|
2003-04-15 |
2004-10-20 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Livin-specific siRNAs for the treatment of therapy-resistant tumors
|
WO2004092383A2
(en)
*
|
2003-04-15 |
2004-10-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
MXPA05011221A
(en)
*
|
2003-04-18 |
2006-02-17 |
Univ Pennsylvania |
COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2.
|
IL155561A0
(en)
*
|
2003-04-24 |
2006-12-31 |
Yeda Res & Dev |
Oligonucleotides that block toll-like receptors
|
PL1623228T3
(en)
*
|
2003-04-29 |
2013-04-30 |
Biocrine Ab |
Apociii and the treatment and diagnosis of diabetes
|
EP1622572B1
(en)
|
2003-04-30 |
2017-12-20 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
WO2004098634A2
(en)
*
|
2003-04-30 |
2004-11-18 |
Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health |
Protein arginine n-methyltransferase 2 (prmt-2)
|
US7638482B2
(en)
*
|
2003-05-08 |
2009-12-29 |
Wyeth |
Protein kinase C zeta as a drug target for arthritis and other inflammatory diseases
|
AU2004239303A1
(en)
*
|
2003-05-09 |
2004-11-25 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Small interfering RNA libraries and methods of synthesis and use
|
WO2004100890A2
(en)
*
|
2003-05-09 |
2004-11-25 |
The Trustees Of Columbia University In The City Of New York |
Rage g82s-related methods and compositions for treating inflammatory disorders
|
EP1633784B1
(en)
|
2003-05-09 |
2011-07-13 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
AU2003241409A1
(en)
*
|
2003-05-12 |
2005-01-21 |
Potomac Pharmaceuticals, Inc. |
Gene expression suppression agents
|
US8609830B2
(en)
*
|
2003-05-16 |
2013-12-17 |
Merck Sharp & Dohme Corp. |
Methods and compositions for RNA interference
|
JP2007516230A
(en)
|
2003-05-19 |
2007-06-21 |
トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク |
Compositions and methods for treating and preventing degeneration of heart tissue and uses thereof
|
US20070027099A1
(en)
*
|
2003-05-19 |
2007-02-01 |
Lin Marie C |
Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA)
|
WO2005001092A2
(en)
*
|
2003-05-20 |
2005-01-06 |
Wyeth |
Compositions and methods for diagnosing and treating cancers
|
JP4638876B2
(en)
*
|
2003-05-23 |
2011-02-23 |
ワイス |
GITR ligand, GITR ligand-related molecule and antibody and use thereof
|
US20050042641A1
(en)
*
|
2003-05-27 |
2005-02-24 |
Cold Spring Harbor Laboratory |
In vivo high throughput selection of RNAi probes
|
DE602004024300D1
(en)
*
|
2003-05-28 |
2010-01-07 |
Takeda Pharmaceutical |
Anti-BAMBI antibody or RNA for diagnosis and treatment of colon or liver cancer
|
WO2004111192A2
(en)
*
|
2003-05-29 |
2004-12-23 |
The Scripps Research Institute |
Targeted delivery to legumain-expressing cells
|
WO2005001110A2
(en)
*
|
2003-05-29 |
2005-01-06 |
The Salk Institute For Biological Studies |
Transcriptional regulation of gene expression by small double-stranded modulatory rna
|
JP4505749B2
(en)
|
2003-05-30 |
2010-07-21 |
日本新薬株式会社 |
Oligo double-stranded RNA that suppresses expression of Bcl-2 and pharmaceutical composition containing the same
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
ES2712695T3
(en)
|
2003-06-02 |
2019-05-14 |
Univ Massachusetts |
Methods and compositions to control the efficiency of RNA silencing
|
AU2004252442B2
(en)
*
|
2003-06-02 |
2010-04-08 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of FNAi
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
US20050059044A1
(en)
*
|
2003-06-03 |
2005-03-17 |
Graham Michael Wayne |
Double-stranded nucleic acid
|
NZ583631A
(en)
*
|
2003-06-06 |
2011-04-29 |
Arborgen Inc |
MYB tanscription factor for regulating plant gene expression
|
JP2007516693A
(en)
|
2003-06-09 |
2007-06-28 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン |
Compositions and methods for the treatment and diagnosis of cancer
|
BRPI0411219A
(en)
|
2003-06-12 |
2006-07-18 |
Nucleonics Inc |
conserved hbv and hcv sequences useful for gene silencing
|
US20050039228A1
(en)
*
|
2003-06-19 |
2005-02-17 |
The Samuel Roberts Noble Foundation |
Methods and compositions for analysis of plant gene function
|
EP1636342A4
(en)
*
|
2003-06-20 |
2008-10-08 |
Isis Pharmaceuticals Inc |
Oligomeric compounds for use in gene modulation
|
US20080131874A1
(en)
*
|
2003-06-24 |
2008-06-05 |
Amitava Mitra |
Method for efficient post-transcriptional gene silencing using intrinsic direct repeat sequences and utilization thereof in functional genomics
|
EP1636385A4
(en)
*
|
2003-06-24 |
2010-06-02 |
Mirus Bio Corp |
Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
|
US20070196334A1
(en)
*
|
2003-06-25 |
2007-08-23 |
Shaharyar Khan |
Modified vectors for organelle transfection
|
EP2404931A1
(en)
|
2003-07-02 |
2012-01-11 |
Verenium Corporation |
Glucanases, nucleic acids encoding them and methods for making and using them
|
US20050019927A1
(en)
*
|
2003-07-13 |
2005-01-27 |
Markus Hildinger |
DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
|
US20050026290A1
(en)
*
|
2003-08-01 |
2005-02-03 |
Ciardi Joseph Anthony |
Inhibiting gene expression with dsRNA
|
AU2004262656A1
(en)
|
2003-08-01 |
2005-02-17 |
Basf Plant Science Gmbh |
Process for the production of fine chemicals in plants
|
US7674460B2
(en)
*
|
2003-08-01 |
2010-03-09 |
A&G Pharmaceutical, Inc. |
Compositions and methods for restoring sensitivity to treatment with HER2 antagonists
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
DK2927318T3
(en)
|
2003-08-08 |
2020-08-03 |
Sangamo Therapeutics Inc |
Method and compositions for targeted cleavage and recombination
|
CA2535526C
(en)
|
2003-08-11 |
2015-09-29 |
Diversa Corporation |
Laccases, nucleic acids encoding them and methods for making and using them
|
WO2005017119A2
(en)
|
2003-08-14 |
2005-02-24 |
Exelixis, Inc. |
Ups as modifiers of the beta catenin pathway and methods of use
|
US20050112763A1
(en)
*
|
2003-08-21 |
2005-05-26 |
Cold Spring Harbor Laboratory |
RNAI-based modification of heterochromatin
|
IL157538A0
(en)
*
|
2003-08-21 |
2004-03-28 |
Bar Ilan Res & Dev Company Ltd |
Plant resistant to cytoplasm-feeding parasites
|
EP1656453A2
(en)
*
|
2003-08-22 |
2006-05-17 |
Nucleonics, Inc. |
Eukaryotic expression systems for expression of inhibitory rna in multiple intracellular compartments
|
CA2536333C
(en)
*
|
2003-08-28 |
2013-01-08 |
Jan Weiler |
Interfering rna duplex having blunt-ends and 3'-modifications
|
US20070275376A1
(en)
*
|
2003-08-28 |
2007-11-29 |
Joerg Heyer |
Tumor-Specific Expression of Reporter Genes
|
US20050060771A1
(en)
*
|
2003-09-11 |
2005-03-17 |
Farmer Andrew Alan |
siRNA encoding constructs and methods for using the same
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
EP2821085B1
(en)
*
|
2003-09-12 |
2020-04-29 |
University of Massachusetts |
Rna interference for the treatment of gain-of-function disorders
|
US8680063B2
(en)
*
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
JP2007505825A
(en)
*
|
2003-09-15 |
2007-03-15 |
セニックス・バイオサイエンス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Use of eukaryotic genes that influence cell cycle control or cell cycle progression in the diagnosis and treatment of proliferative diseases
|
CA2539300A1
(en)
*
|
2003-09-16 |
2005-03-24 |
Pharmacia Corporation |
Inhibitors of pace4 for the treatment of arthritis
|
EP1670955A2
(en)
*
|
2003-09-22 |
2006-06-21 |
Rosetta Inpharmatics LLC. |
Synthetic lethal screen using rna interference
|
US20050282168A1
(en)
*
|
2003-09-29 |
2005-12-22 |
Wyeth |
Cell surface molecules as markers and therapeutic agents against kidney cancers
|
EP1672060A4
(en)
*
|
2003-09-30 |
2006-12-27 |
Takara Bio Inc |
Polypeptide having rnase iii activity
|
US20070218551A1
(en)
*
|
2003-10-02 |
2007-09-20 |
Chuan-Yuan Li |
Novel Sirna-Based Approach to Target the Hif-Alpha Factor for Gene Therapy
|
EP1687410A4
(en)
*
|
2003-10-07 |
2008-04-09 |
Isis Pharmaceuticals Inc |
Antisense oligonucleotides optimized for kidney targeting
|
US20060218673A9
(en)
*
|
2003-10-09 |
2006-09-28 |
E.I. Du Pont De Nemours And Company |
Gene silencing
|
CN103495153A
(en)
|
2003-10-23 |
2014-01-08 |
奇尼塔二有限责任公司 |
Method for detecting mutations in a gene associated with resistance to viral infection, OAS1
|
US8039587B2
(en)
*
|
2003-10-24 |
2011-10-18 |
Gencia Corporation |
Methods and compositions for delivering polynucleotides
|
US20090123468A1
(en)
*
|
2003-10-24 |
2009-05-14 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US8062891B2
(en)
|
2003-10-24 |
2011-11-22 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to plants
|
US20090208478A1
(en)
*
|
2003-10-24 |
2009-08-20 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
US8507277B2
(en)
*
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
CN1926551B
(en)
|
2003-10-27 |
2010-06-16 |
罗斯塔生化科技有限责任公司 |
Method of designing siRNA for gene silencing
|
US8012944B2
(en)
*
|
2003-10-30 |
2011-09-06 |
Pharmascience Inc. |
Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
|
US7553822B2
(en)
*
|
2003-10-30 |
2009-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Compositions and methods for inhibiting translation of a Mect1-MAML2 chimeric gene
|
US20080260717A1
(en)
*
|
2003-10-31 |
2008-10-23 |
Trustees Of Columbia University In The City Of New York |
Methods for Reducing Seizure-Induced Neuronal Damage
|
WO2005042722A2
(en)
*
|
2003-10-31 |
2005-05-12 |
University Of Florida Research Foundation, Inc. |
Materials and methods for improved sweet corn
|
US20050191653A1
(en)
*
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
US8227434B1
(en)
|
2003-11-04 |
2012-07-24 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Materials and methods for treating oncological disorders
|
CA2545182A1
(en)
*
|
2003-11-10 |
2005-05-26 |
University Of Utah Research Foundation |
Improved methods and compositions for rna interference
|
WO2005049832A2
(en)
*
|
2003-11-14 |
2005-06-02 |
Yale University |
FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE
|
US7763592B1
(en)
|
2003-11-20 |
2010-07-27 |
University Of South Florida |
SHIP-deficiency to increase megakaryocyte progenitor production
|
US7807646B1
(en)
|
2003-11-20 |
2010-10-05 |
University Of South Florida |
SHIP-deficiency to increase megakaryocyte progenitor production
|
WO2005081714A2
(en)
|
2003-11-21 |
2005-09-09 |
Revivicor, Inc. |
Use of interfering rna in the production of transgenic animals
|
US20050166289A1
(en)
*
|
2003-12-01 |
2005-07-28 |
North Carolina State University |
Small interfering RNA (siRNA)-mediated heritable gene manipulation in plants
|
ATE469984T1
(en)
|
2003-12-01 |
2010-06-15 |
Life Technologies Corp |
NUCLEIC ACID MOLECULES CONTAINING RECOMBINATION SITE AND METHOD FOR USE THEREOF
|
EP2311949A3
(en)
|
2003-12-03 |
2012-11-21 |
Coda Therapeutics (NZ) Ltd |
Antisense compounds targeted to connexins and methods of use thereof
|
WO2005059102A2
(en)
*
|
2003-12-10 |
2005-06-30 |
University Of Utah Research Foundation |
METHOD FOR OBTAINING AN ENRICHED POPULATION OF siRNA-EXPRESSING CELLS
|
WO2005059157A2
(en)
*
|
2003-12-11 |
2005-06-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
METHODS AND COMPOSITIONS FOR USE IN PREPARING HAIRPIN RNAs
|
JP4753130B2
(en)
*
|
2003-12-12 |
2011-08-24 |
独立行政法人産業技術総合研究所 |
Long interfering double-stranded RNA with reduced interferon response
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
US20050164970A1
(en)
*
|
2003-12-22 |
2005-07-28 |
University Of Kansas Medical Center |
Method for treating prostate cancer using siRNA duplex for androgen receptor
|
WO2005062937A2
(en)
*
|
2003-12-22 |
2005-07-14 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
|
CA2548484C
(en)
*
|
2003-12-23 |
2015-04-21 |
Bayer Cropscience Sa |
Method for modifying gene expression of a phytopathogenic fungus
|
FR2872383B1
(en)
*
|
2004-07-02 |
2015-10-16 |
Bayer Cropscience Sa |
METHOD FOR MODIFYING GENE EXPRESSION OF PHYTOPATHOGENIC FUNGI
|
EP1701611B1
(en)
|
2003-12-24 |
2011-05-18 |
G2 Inflammation Pty Ltd |
Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
|
US7700280B2
(en)
|
2003-12-31 |
2010-04-20 |
The Penn State Research Foundation |
Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer
|
EP1778858A4
(en)
*
|
2004-01-15 |
2009-08-19 |
Univ Washington |
High throughput pharmaceutical screening using drosophila
|
WO2005070044A2
(en)
*
|
2004-01-22 |
2005-08-04 |
The Cbr Institute For Biomedical Research, Inc. |
Systems and methods for short rna expression
|
JP2007520221A
(en)
|
2004-01-23 |
2007-07-26 |
ニュー・イングランド・バイオラブズ・インコーポレイティッド |
Composition and production method of short double-stranded RNA using mutant RNase
|
US20050203043A1
(en)
*
|
2004-01-23 |
2005-09-15 |
Dharmacon, Inc. |
Identification of toxic nucleotide sequences
|
US20080249039A1
(en)
*
|
2004-01-30 |
2008-10-09 |
Santaris Pharma A/S |
Modified Short Interfering Rna (Modified Sirna)
|
DE602005025347D1
(en)
*
|
2004-01-30 |
2011-01-27 |
Quark Pharmaceuticals Inc |
OLIGORIBONUCLEOTIDES AND METHODS FOR THEIR USE IN THE TREATMENT OF FIBROTIC SUDDEN AND OTHER DISEASES
|
ATE447024T1
(en)
*
|
2004-02-06 |
2009-11-15 |
Dharmacon Inc |
STABILIZED RNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS
|
US20090280567A1
(en)
*
|
2004-02-06 |
2009-11-12 |
Dharmacon, Inc. |
Stabilized sirnas as transfection controls and silencing reagents
|
AU2005213464A1
(en)
|
2004-02-06 |
2005-08-25 |
Wyeth |
Diagnosis and therapeutics for cancer
|
US20060075515A1
(en)
*
|
2004-08-11 |
2006-04-06 |
Luethy Michael H |
Enhanced zein reduction in transgenic corn seed
|
AR047598A1
(en)
|
2004-02-10 |
2006-01-25 |
Monsanto Technology Llc |
TRANSGENIZED CORN SEED WITH GREATER AMINO ACID CONTENT
|
US7855323B2
(en)
|
2004-02-10 |
2010-12-21 |
Monsanto Technology Llc |
Recombinant DNA for gene suppression
|
CA2554212A1
(en)
|
2004-02-10 |
2005-08-25 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina)
|
US7683237B2
(en)
*
|
2004-02-10 |
2010-03-23 |
Monsanto Technology Llc |
Maize seed with synergistically enhanced lysine content
|
WO2005078848A2
(en)
|
2004-02-11 |
2005-08-25 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
|
EP1766032B1
(en)
|
2004-02-13 |
2012-10-10 |
Monsanto Technology, LLC |
In vivo assembly of transcription units
|
US7622301B2
(en)
*
|
2004-02-24 |
2009-11-24 |
Basf Plant Science Gmbh |
Compositions and methods using RNA interference for control of nematodes
|
ES2368741T3
(en)
|
2004-02-25 |
2011-11-21 |
Dana-Farber Cancer Institute, Inc. |
INHIBITORS OF THE RECEPTOR 1 OF THE INSULIN TYPE GROWTH FACTOR TO INHIBIT THE GROWTH OF TUMOR CELLS.
|
US20060003956A1
(en)
*
|
2004-03-03 |
2006-01-05 |
Casadome David O |
Materials and methods for the derepression of the E-cadherin promoter
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
JP4937899B2
(en)
|
2004-03-12 |
2012-05-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
IRNA substances targeting VEGF
|
US20070265220A1
(en)
*
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
JP5243789B2
(en)
*
|
2004-03-15 |
2013-07-24 |
シティ・オブ・ホープ |
Methods and compositions for specific inhibition of gene expression by double stranded RNA
|
AU2005223649A1
(en)
*
|
2004-03-19 |
2005-09-29 |
The Penn State Research Foundation |
Combinatorial methods and compositions for treatment of melanoma
|
US7851452B2
(en)
*
|
2004-03-22 |
2010-12-14 |
The Trustees Of The University Of Pennsylvania |
Methods of use of bcl-6-derived nucleotides to induce apoptosis
|
EP2343384A3
(en)
*
|
2004-03-23 |
2012-01-04 |
Oncotherapy Science, Inc. |
Method for diagnosing non-small cell lung cancer
|
JP4658936B2
(en)
|
2004-03-24 |
2011-03-23 |
オンコセラピー・サイエンス株式会社 |
Compositions and methods for treating lung cancer
|
US20060041961A1
(en)
|
2004-03-25 |
2006-02-23 |
Abad Mark S |
Genes and uses for pant improvement
|
WO2005098049A2
(en)
*
|
2004-03-25 |
2005-10-20 |
California Institute Of Technology |
Hybridization chain reaction
|
KR101147147B1
(en)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Modified polynucleotides for reducing off-target effects in rna interference
|
CA2562038C
(en)
|
2004-04-02 |
2017-04-25 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
|
CA2562024C
(en)
*
|
2004-04-07 |
2014-05-27 |
Rinat Neuroscience Corp. |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
CN105002208A
(en)
|
2004-04-09 |
2015-10-28 |
孟山都技术有限公司 |
Compositions and methods for control of insect infestations in plants
|
WO2005117938A2
(en)
*
|
2004-04-13 |
2005-12-15 |
Regents Of The University Of Minnesota |
Methods of treating ocular conditions
|
US20070031417A2
(en)
*
|
2004-04-14 |
2007-02-08 |
University Of Massachusetts |
Dicer interacting proteins and uses therefor
|
US20050233994A1
(en)
*
|
2004-04-16 |
2005-10-20 |
Ajamete Kaykas |
Methods and vectors for expressing siRNA
|
MXPA06012076A
(en)
*
|
2004-04-20 |
2007-01-25 |
Nastech Pharm Co |
Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells.
|
US7834250B2
(en)
|
2004-04-22 |
2010-11-16 |
Commonwealth Scientific And Industrial Research Organisation |
Synthesis of long-chain polyunsaturated fatty acids by recombinant cells
|
WO2005103254A1
(en)
*
|
2004-04-22 |
2005-11-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
UNIVERSAL TARGET SEQUENCES FOR siRNA GENE SILENCING
|
EP1740607A2
(en)
|
2004-04-23 |
2007-01-10 |
Ceres, Inc. |
Methods for modifying plant characteristics
|
CA2557532A1
(en)
*
|
2004-04-23 |
2005-11-10 |
Angela M. Christiano |
Inhibition of hairless protein mrna
|
US8076304B2
(en)
*
|
2004-04-26 |
2011-12-13 |
The Regents Of The University Of Colorado |
Methods and compositions for the diagnosis and treatment of cyclin A-1 associated conditions
|
EP1747462A2
(en)
|
2004-04-27 |
2007-01-31 |
Galapagos N.V. |
Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
|
US20060182783A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems
|
US20060040882A1
(en)
*
|
2004-05-04 |
2006-02-23 |
Lishan Chen |
Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
|
US20060035815A1
(en)
*
|
2004-05-04 |
2006-02-16 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical compositions for delivery of ribonucleic acid to a cell
|
AU2005280659A1
(en)
*
|
2004-05-11 |
2006-03-09 |
Wyeth |
Novel polynucleotides related to oligonucleotide arrays to monitor gene expression
|
US7605250B2
(en)
*
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
US20080199960A1
(en)
*
|
2004-05-13 |
2008-08-21 |
Juliano Rudolph L |
Methods for the Delivery of Oligomeric Compounds
|
EP2322660A1
(en)
|
2004-05-14 |
2011-05-18 |
Rosetta Genomics Ltd |
MicroRNAs and uses thereof
|
US8563252B2
(en)
*
|
2004-05-14 |
2013-10-22 |
Rosetta Genomics Ltd. |
Methods for distinguishing between lung squamous carcinoma and other non small cell lung cancers
|
CA2566519C
(en)
|
2004-05-14 |
2020-04-21 |
Rosetta Genomics Ltd. |
Micrornas and uses thereof
|
US20050265927A1
(en)
*
|
2004-05-17 |
2005-12-01 |
Yale University |
Intranasal delivery of nucleic acid molecules
|
US7563885B1
(en)
*
|
2004-05-24 |
2009-07-21 |
Isis Pharmaceuticals, Inc. |
Modulation of Tudor-SN expression
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
CA2567741A1
(en)
*
|
2004-05-25 |
2006-03-30 |
Chimeracore, Inc. |
Self-assembling nanoparticle drug delivery system
|
EP2290076B1
(en)
|
2004-05-28 |
2015-03-25 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
US8394947B2
(en)
*
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7858323B2
(en)
|
2004-06-09 |
2010-12-28 |
The Regents Of The University Of Michigan |
Phage microarray profiling of the humoral response to disease
|
US20060040876A1
(en)
|
2004-06-10 |
2006-02-23 |
Rong-Hwa Lin |
Modulation of peroxisome proliferator-activated receptors
|
ES2461857T3
(en)
|
2004-06-16 |
2014-05-21 |
Dsm Ip Assets B.V. |
Compositions and methods for enzymatic discoloration of chlorophyll
|
US20060010505A1
(en)
*
|
2004-06-18 |
2006-01-12 |
Washington University |
High throughput cancer pharmaceutical screening using drosophila
|
US20060156421A1
(en)
*
|
2004-06-18 |
2006-07-13 |
Cagan Ross L |
High throughput screening methods for anti-metastatic compounds
|
US8367360B2
(en)
|
2004-06-21 |
2013-02-05 |
Proteome Sciences Plc |
Method of screening for inhibitors of tau protein phosphororylation by tyrosine kinase c-Abl
|
WO2006009575A1
(en)
|
2004-06-22 |
2006-01-26 |
The Board Of Trustees Of The University Of Illinois |
METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
|
WO2006069610A2
(en)
|
2004-07-02 |
2006-07-06 |
Metanomics Gmbh |
Process for the production of fine chemicals
|
US8680062B2
(en)
|
2004-07-06 |
2014-03-25 |
Deliversir Ltd. |
System for delivering therapeutic agents into living cells and cells nuclei
|
US7968762B2
(en)
*
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
WO2006014755A2
(en)
*
|
2004-07-20 |
2006-02-09 |
Wyeth |
Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer’s disease
|
EP1782321A4
(en)
|
2004-07-23 |
2009-11-04 |
Univ North Carolina |
Methods and materials for determining pain sensitivity and predicting and treating related disorders
|
US8603824B2
(en)
|
2004-07-26 |
2013-12-10 |
Pfenex, Inc. |
Process for improved protein expression by strain engineering
|
DE102004036456A1
(en)
*
|
2004-07-28 |
2006-03-23 |
Basf Plant Science Gmbh |
Method for producing transgenic plants with increased pathogen resistance by changing the content and / or the activity of actin-depolymerizing factors
|
US20060075522A1
(en)
|
2004-07-31 |
2006-04-06 |
Jaclyn Cleveland |
Genes and uses for plant improvement
|
AU2005268917B2
(en)
|
2004-08-02 |
2010-05-20 |
Basf Plant Science Gmbh |
Method for isolation of transcription termination sequences
|
CN101014245A
(en)
|
2004-08-03 |
2007-08-08 |
比奥根艾迪克Ma公司 |
Taj in neuronal function
|
US7659444B2
(en)
*
|
2004-08-13 |
2010-02-09 |
Basf Plant Science Gmbh |
Compositions and methods using RNA interference for control of nematodes
|
BRPI0514395A
(en)
*
|
2004-08-16 |
2008-06-10 |
Quark Biotech Inc |
therapeutic use of rtp801 inhibitors
|
CA2577036A1
(en)
|
2004-08-18 |
2006-02-23 |
Genesense Technologies Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
EP2270161A3
(en)
|
2004-08-23 |
2011-02-02 |
Alnylam Pharmaceuticals, Inc. |
Multiple RNA polymerase III promoter expression constructs
|
US20060046247A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Rapp Jeffrey C |
Protecting avians from pathogens
|
US20090313712A1
(en)
*
|
2004-08-25 |
2009-12-17 |
Leandro Christmann |
RNA interference and disease resistance in avians
|
US20080222743A1
(en)
*
|
2004-08-25 |
2008-09-11 |
Avigenics, Inc. |
RNA interference and disease resistance in avians
|
WO2006026238A2
(en)
*
|
2004-08-25 |
2006-03-09 |
Avigenics, Inc. |
Rna interference in avians
|
WO2006026738A2
(en)
*
|
2004-08-31 |
2006-03-09 |
Qiagen North American Holdings, Inc. |
Methods and compositions for rna amplification and detection using an rna-dependent rna-polymerase
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US20060059585A1
(en)
|
2004-09-14 |
2006-03-16 |
Boris Jankowski |
Modulating plant sugar levels
|
US7595433B2
(en)
|
2004-09-14 |
2009-09-29 |
Ceres, Inc. |
Modulations of amino acid and sugar content in plants
|
FI20041204A0
(en)
|
2004-09-16 |
2004-09-16 |
Riikka Lund |
Methods for the utilization of new target genes associated with immune-mediated diseases
|
DE602005024704D1
(en)
|
2004-09-18 |
2010-12-23 |
Univ Maryland |
THERAPEUTIC AGENTS FOR TARGETING THE NC CA ATP CHANNEL AND USE METHOD THEREFOR
|
WO2006036278A2
(en)
|
2004-09-18 |
2006-04-06 |
University Of Maryland, Baltimore |
THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF
|
US7456338B2
(en)
|
2004-09-22 |
2008-11-25 |
Arborgen Llc |
Modification of plant lignin content
|
US7402428B2
(en)
|
2004-09-22 |
2008-07-22 |
Arborgen, Llc |
Modification of plant lignin content
|
US7799906B1
(en)
|
2004-09-22 |
2010-09-21 |
Arborgen, Llc |
Compositions and methods for modulating lignin of a plant
|
CA2579927A1
(en)
|
2004-09-24 |
2006-03-30 |
Basf Plant Science Gmbh |
Plant cells and plants with increased tolerance to environmental stress
|
LT1799269T
(en)
*
|
2004-09-28 |
2016-10-25 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
|
WO2006039399A2
(en)
*
|
2004-09-29 |
2006-04-13 |
University Of Rochester |
Staufen 1 (stau1) - mediated mrna decay
|
WO2006039582A2
(en)
*
|
2004-09-30 |
2006-04-13 |
The Regents Of The University Of California |
Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
|
US8765704B1
(en)
|
2008-02-28 |
2014-07-01 |
Novartis Ag |
Modified small interfering RNA molecules and methods of use
|
EP1796732B1
(en)
*
|
2004-10-01 |
2013-10-30 |
Novartis Vaccines and Diagnostics, Inc. |
Modified small interfering rna molecules and methods of use
|
US20060247197A1
(en)
|
2004-10-04 |
2006-11-02 |
Van De Craen Marc |
Method for down-regulating gene expression in fungi
|
WO2006070227A2
(en)
*
|
2004-10-04 |
2006-07-06 |
Devgen Nv |
Method for down-regulating gene expression in fungi
|
CN101056981A
(en)
*
|
2004-10-04 |
2007-10-17 |
德福根有限公司 |
Method for down-regulating gene expression in fungi
|
EP2166097B1
(en)
|
2004-10-05 |
2014-08-06 |
SunGene GmbH |
Constitutive expression cassettes for regulation of plant expression
|
EP1809748B1
(en)
*
|
2004-10-12 |
2012-12-26 |
The Rockefeller University |
Micrornas
|
US20090036355A1
(en)
*
|
2004-10-13 |
2009-02-05 |
Sanjay Bhanot |
Antisense Modulation of PTP1B Expression
|
MX2007004310A
(en)
*
|
2004-10-13 |
2007-06-18 |
Univ Georgia Res Found |
Nematode resistant transgenic plants.
|
US7429692B2
(en)
|
2004-10-14 |
2008-09-30 |
Ceres, Inc. |
Sucrose synthase 3 promoter from rice and uses thereof
|
EP1807522B1
(en)
*
|
2004-10-21 |
2013-11-20 |
Venganza Inc. |
Methods and materials for conferring resistance to pests and pathogens of plants
|
US7592322B2
(en)
*
|
2004-10-22 |
2009-09-22 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
US7790878B2
(en)
*
|
2004-10-22 |
2010-09-07 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
US8772254B2
(en)
*
|
2004-10-25 |
2014-07-08 |
Devgen N.V. |
Method and constructs for delivering double stranded RNA to pest organisms
|
AR051829A1
(en)
*
|
2004-10-27 |
2007-02-14 |
Schering Corp |
COMPOSITIONS AND METHODS FOR NAV INHIBITION 1 THROUGH SHORT ARN INTERFERENCE
|
US9492400B2
(en)
*
|
2004-11-04 |
2016-11-15 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
WO2006137941A2
(en)
|
2004-11-12 |
2006-12-28 |
Ambion, Inc. |
Methods and compositions involving mirna and mirna inhibitor molecules
|
WO2006060182A2
(en)
*
|
2004-11-17 |
2006-06-08 |
University Of Maryland, Baltimore |
HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA
|
EP1813289B1
(en)
*
|
2004-11-19 |
2010-03-03 |
Miyagi Ken |
Medicinal composition for treating cancer or diabetes
|
US7935811B2
(en)
*
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
US20060166234A1
(en)
*
|
2004-11-22 |
2006-07-27 |
Barbara Robertson |
Apparatus and system having dry control gene silencing compositions
|
EP2163631B1
(en)
|
2004-11-25 |
2013-05-22 |
SunGene GmbH |
Expression cassettes for guard cell-preferential expression in plants
|
WO2006060454A2
(en)
*
|
2004-12-02 |
2006-06-08 |
B-Bridge International, Inc. |
Methods of designing small interfering rnas, antisense polynucleotides, and other hybridizing polynucleotides
|
EP1666599A3
(en)
|
2004-12-04 |
2006-07-12 |
SunGene GmbH |
Expression cassettes for mesophyll- and/or epidermis-preferential expression in plants
|
WO2007089610A1
(en)
|
2006-01-26 |
2007-08-09 |
Ceres, Inc. |
Modulating plant oil levels
|
WO2008069878A2
(en)
|
2006-10-27 |
2008-06-12 |
Ceres, Inc. |
Modulating lignin in plants
|
US7329797B2
(en)
|
2004-12-08 |
2008-02-12 |
Ceres, Inc. |
Modulating plant carbon levels
|
US9758790B2
(en)
|
2004-12-08 |
2017-09-12 |
Ceres, Inc. |
Modulating the level of components within plants
|
EP1669455B1
(en)
|
2004-12-08 |
2009-10-28 |
SunGene GmbH |
Expression cassettes for vascular tissue-preferential expression in plants
|
EP1669456A3
(en)
|
2004-12-11 |
2006-07-12 |
SunGene GmbH |
Expression cassettes for meristem-preferential expression in plants
|
BRPI0519657A2
(en)
|
2004-12-16 |
2009-03-03 |
Ceres Inc |
modulation of nitrogen levels in plants
|
EP1974049A2
(en)
|
2004-12-17 |
2008-10-01 |
Metanomics GmbH |
Process for the control of production of fine chemicals
|
US20060200878A1
(en)
|
2004-12-21 |
2006-09-07 |
Linda Lutfiyya |
Recombinant DNA constructs and methods for controlling gene expression
|
US8404927B2
(en)
*
|
2004-12-21 |
2013-03-26 |
Monsanto Technology Llc |
Double-stranded RNA stabilized in planta
|
US7335760B2
(en)
|
2004-12-22 |
2008-02-26 |
Ceres, Inc. |
Nucleic acid sequences encoding zinc finger proteins
|
CA2592099A1
(en)
|
2004-12-22 |
2006-06-29 |
Nucleonics, Inc. |
Conserved hbv and hcv sequences useful for gene silencing
|
NZ556158A
(en)
*
|
2004-12-22 |
2010-04-30 |
Auckland Uniservices Ltd |
Trefoil factors and methods of treating proliferation disorders using same
|
TWI401316B
(en)
*
|
2004-12-23 |
2013-07-11 |
Alcon Inc |
Rnai inhibition of serum amyloid a for treatment of glaucoma
|
TWI386225B
(en)
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
Rnai inhibition of ctgf for treatment of ocular disorders
|
US20060142228A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
MX2007007948A
(en)
|
2004-12-28 |
2007-09-11 |
Pioneer Hi Bred Int |
Improved grain quality through altered expression of seed proteins.
|
US8252742B2
(en)
|
2004-12-30 |
2012-08-28 |
Hill's Pet Nutrition, Inc. |
Methods for enhancing the quality of life of a senior animal
|
BRPI0519690A2
(en)
*
|
2004-12-30 |
2009-03-03 |
Todd M Hauser |
compositions and methods for modulating gene expression using self-protected oligonucleotides
|
US8137907B2
(en)
|
2005-01-03 |
2012-03-20 |
Cold Spring Harbor Laboratory |
Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
|
ES2343746T3
(en)
|
2005-01-07 |
2010-08-09 |
Diadexus, Inc. |
OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE.
|
US7507809B2
(en)
*
|
2005-01-07 |
2009-03-24 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV and therapeutic uses thereof
|
AU2006204997B2
(en)
|
2005-01-12 |
2011-09-01 |
Monsanto Technology, Llc |
Genes and uses for plant improvement
|
US7268226B2
(en)
|
2005-01-13 |
2007-09-11 |
Pioneer Hi-Bred International, Inc. |
Maize Cyclo1 gene and promoter
|
BRPI0606621A2
(en)
|
2005-01-14 |
2009-07-07 |
Univ Guelph |
Nitrogen-regulated sugar perception gene and protein
|
US7718625B2
(en)
*
|
2005-01-27 |
2010-05-18 |
University Of South Florida |
Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof
|
TW200639253A
(en)
*
|
2005-02-01 |
2006-11-16 |
Alcon Inc |
RNAi-mediated inhibition of ocular targets
|
US9248141B2
(en)
|
2005-02-03 |
2016-02-02 |
Coda Therapeutics, Inc. |
Methods of treatment by administering anti-connexin proteins and mimetics
|
WO2006084868A2
(en)
|
2005-02-09 |
2006-08-17 |
Basf Plant Science Gmbh |
Expression cassettes for regulation of expression in monocotyledonous plants
|
EP2302076B1
(en)
|
2005-02-14 |
2014-11-12 |
University of Iowa Research Foundation |
Methods and reagents for treatment and diagnosis of age-related macular degeneration
|
CN101160528A
(en)
*
|
2005-02-14 |
2008-04-09 |
惠氏公司 |
Use of il-17f in diagnosis and therapy of airway inflammation
|
AR052289A1
(en)
*
|
2005-02-14 |
2007-03-07 |
Wyeth Corp |
ANTIBODIES FOR INTERLEUCINE-17F AND OTHER ANTAGONISTS OF THE SIGNALING OF IL-17F AND ITS USES
|
US20060211004A1
(en)
|
2005-02-15 |
2006-09-21 |
Ilsley Diane D |
Methods and compositions for determining non-specific cytotoxicity of a transfection agent
|
US8088976B2
(en)
|
2005-02-24 |
2012-01-03 |
Monsanto Technology Llc |
Methods for genetic control of plant pest infestation and compositions thereof
|
EP1856264B1
(en)
|
2005-02-26 |
2014-07-23 |
BASF Plant Science GmbH |
Expression cassettes for seed-preferential expression in plants
|
US7727721B2
(en)
*
|
2005-03-08 |
2010-06-01 |
California Institute Of Technology |
Hybridization chain reaction amplification for in situ imaging
|
EP2169058B1
(en)
|
2005-03-08 |
2013-01-23 |
BASF Plant Science GmbH |
Expression enhancing intron sequences
|
EP1869174B1
(en)
|
2005-03-10 |
2015-02-18 |
BASF Enzymes LLC |
Lyase enzymes, nucleic acids encoding them and methods for making and using them
|
AU2006223498A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
WO2006099353A1
(en)
|
2005-03-11 |
2006-09-21 |
Alcon, Inc. |
Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
|
DE202005004135U1
(en)
*
|
2005-03-11 |
2005-05-19 |
Klocke Verpackungs-Service Gmbh |
Multi-component packaging with applicator
|
WO2006130201A1
(en)
*
|
2005-03-14 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
Antigene oligomers inhibit transcription
|
DE102005011648A1
(en)
*
|
2005-03-14 |
2006-09-21 |
IPK-Institut für Pflanzengenetik und Kulturpflanzenforschung |
A method of increasing fungal resistance in transgenic plants by host-induced suppression of gene expression in fungal pathogens
|
KR101393679B1
(en)
|
2005-03-15 |
2014-05-21 |
비피 코포레이션 노쓰 아메리카 인코포레이티드 |
Cellulases, nucleic acids encoding them and methods for making and using them
|
EP3312196B1
(en)
|
2005-03-23 |
2019-07-17 |
Genmab A/S |
Antibodies against cd38 for treatment of multiple myeloma
|
US20060223777A1
(en)
*
|
2005-03-29 |
2006-10-05 |
Dharmacon, Inc. |
Highly functional short hairpin RNA
|
JP4131271B2
(en)
*
|
2005-03-30 |
2008-08-13 |
ソニー株式会社 |
Information processing apparatus and method, and program
|
MX2007012056A
(en)
|
2005-03-31 |
2008-03-10 |
Ronen Kahana |
Creating poultry and other animals resistant to viral disease.
|
JP2008537551A
(en)
|
2005-03-31 |
2008-09-18 |
カランド ファーマシューティカルズ, インコーポレイテッド |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
JP2008535857A
(en)
|
2005-04-07 |
2008-09-04 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド |
CACNA1E in cancer diagnosis, detection and treatment
|
US20090220495A1
(en)
|
2005-04-07 |
2009-09-03 |
Abdallah Fanidi |
Cancer Related Genes (PRLR)
|
US20060234973A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Kevin Fitzgerald |
Transcription factor RNA interference reagents and methods of use thereof
|
JP4982757B2
(en)
|
2005-04-15 |
2012-07-25 |
国立大学法人鳥取大学 |
hTERT expression regulatory gene
|
JP2008536874A
(en)
*
|
2005-04-15 |
2008-09-11 |
ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム |
Delivery of siRNA by neutral lipid composition
|
WO2006112879A2
(en)
*
|
2005-04-15 |
2006-10-26 |
The Trustees Of The University Of Pennsylvania |
Hunk, a snf1-related kinase essential for mammary tumor metastasis
|
US20090203055A1
(en)
*
|
2005-04-18 |
2009-08-13 |
Massachusetts Institute Of Technology |
Compositions and methods for RNA interference with sialidase expression and uses thereof
|
US20060269556A1
(en)
*
|
2005-04-18 |
2006-11-30 |
Karl Nocka |
Mast cell activation using siglec 6 antibodies
|
ATE552343T1
(en)
|
2005-04-19 |
2012-04-15 |
Basf Plant Science Gmbh |
ENDOSPERM-SPECIFIC EXPRESSION AND/OR EXPRESSION IN GERMINATING EMBRYOS OF MONOCOTYLEDONE PLANTS
|
CA2604807C
(en)
|
2005-04-19 |
2018-06-12 |
Basf Plant Science Gmbh |
Improved methods controlling gene expression
|
WO2006120197A2
(en)
|
2005-05-10 |
2006-11-16 |
Basf Plant Science Gmbh |
Expression cassettes for seed-preferential expression in plants
|
CA2605508A1
(en)
|
2005-05-12 |
2006-11-23 |
Wisconsin Alumni Research Foundation |
Blockade of pin1 prevents cytokine production by activated immune cells
|
US8669236B2
(en)
*
|
2005-05-12 |
2014-03-11 |
The General Hospital Corporation |
Biotinylated compositions
|
FR2885808B1
(en)
|
2005-05-19 |
2007-07-06 |
Oreal |
VECTORIZATION OF DSRNA BY CATIONIC PARTICLES AND TOPICAL USE.
|
US20090081119A1
(en)
*
|
2005-05-19 |
2009-03-26 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Inhibiting dna polymerase beta to enhance efficacy of anticancer agents
|
WO2006129204A2
(en)
|
2005-05-31 |
2006-12-07 |
Devgen Nv |
Rnai for control of insects and arachnids
|
WO2007053184A2
(en)
|
2005-05-31 |
2007-05-10 |
Cold Spring Harbor Laboratory |
Methods for producing micrornas
|
US8802640B2
(en)
*
|
2005-06-01 |
2014-08-12 |
Polyplus-Transfection Sa |
Oligonucleotides for RNA interference and biological applications thereof
|
AU2006254971A1
(en)
*
|
2005-06-06 |
2006-12-14 |
Wyeth |
Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
|
US20070299029A1
(en)
*
|
2005-06-09 |
2007-12-27 |
Agency For Science, Technology And Research |
Hepatic stellate cell specific promoter and uses thereof
|
JP2008543281A
(en)
*
|
2005-06-09 |
2008-12-04 |
エイジェンシー フォー サイエンス, テクノロジー アンド リサーチ |
Liver astrocyte-specific promoter and use thereof
|
US20070014776A1
(en)
*
|
2005-06-09 |
2007-01-18 |
Gimeno Ruth E |
Identification of adiponutrin-related proteins as esterases and methods of use for the same
|
WO2006135862A2
(en)
*
|
2005-06-10 |
2006-12-21 |
Children's Hospital And Research Center At Oakland |
Immunomodulation by altering sphingosine 1-phosphate lyase (spl) activity
|
WO2006131925A2
(en)
*
|
2005-06-10 |
2006-12-14 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
|
US20070105133A1
(en)
*
|
2005-06-13 |
2007-05-10 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
ES2267390B1
(en)
*
|
2005-06-16 |
2008-03-16 |
Universidad Politecnica De Valencia |
INSULATION AND CHARACTERIZATION OF MUTANT CSB3-1 OF THALIAN ARABIDOPSIS, AND ITS USE AS A REGULATOR OF THE RESISTANCE IN PLANTS TO DISEASES PRODUCED BY BIOTROPHIC PATHOGENS.
|
US7994399B2
(en)
|
2005-06-23 |
2011-08-09 |
Basf Plant Science Gmbh |
Methods for the production of stably transformed, fertile Zea mays plants
|
US20080280843A1
(en)
|
2006-05-24 |
2008-11-13 |
Van Bilsen Paul |
Methods and kits for linking polymorphic sequences to expanded repeat mutations
|
JP2009500019A
(en)
*
|
2005-07-01 |
2009-01-08 |
プロメガ・コーポレーション |
Suspended particle network for the purification of biomolecules, and the use of buoyant particles or buoyant particle networks for the purification of biomolecules
|
CA2614531C
(en)
*
|
2005-07-07 |
2015-06-16 |
Avraham Hochberg |
Nucleic acid agents for downregulating h19, and methods of using same
|
US8703769B2
(en)
|
2005-07-15 |
2014-04-22 |
The University Of North Carolina At Chapel Hill |
Use of EGFR inhibitors to prevent or treat obesity
|
KR20080033455A
(en)
*
|
2005-07-26 |
2008-04-16 |
상가모 바이오사이언스 인코포레이티드 |
Targeted integration and expression of exogenous nucleic acid sequences
|
WO2007013575A2
(en)
*
|
2005-07-28 |
2007-02-01 |
Oncotherapy Science, Inc. |
Method for diagnosing and treating renal cell carcinoma
|
US20090176725A1
(en)
*
|
2005-08-17 |
2009-07-09 |
Sirna Therapeutics Inc. |
Chemically modified short interfering nucleic acid molecules that mediate rna interference
|
CA2619534A1
(en)
|
2005-08-18 |
2007-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating neurological disease
|
WO2007022427A2
(en)
|
2005-08-18 |
2007-02-22 |
Accelalox, Inc. |
Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
|
US20070111231A1
(en)
*
|
2005-08-23 |
2007-05-17 |
Illumigen Biosciences, Inc. |
Detection of mutations in a gene associated with resistance to viral infection, OAS2 and OAS3
|
WO2007025231A2
(en)
*
|
2005-08-26 |
2007-03-01 |
The Trustees Of The University Of Pennsylvania |
Methods using snail transcriptional repressor
|
WO2007026958A1
(en)
|
2005-09-01 |
2007-03-08 |
Suntory Limited |
Tryptophan transporter gene and use thereof
|
US7666584B2
(en)
*
|
2005-09-01 |
2010-02-23 |
Philadelphia Health & Education Coporation |
Identification of a pin specific gene and protein (PIN-1) useful as a diagnostic treatment for prostate cancer
|
US20090018097A1
(en)
*
|
2005-09-02 |
2009-01-15 |
Mdrna, Inc |
Modification of double-stranded ribonucleic acid molecules
|
CA2621874C
(en)
|
2005-09-08 |
2014-12-16 |
Chromatin Inc. |
Plants modified with mini-chromosomes
|
CA2622295C
(en)
|
2005-09-12 |
2019-01-15 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in prostate cancer
|
CA2889540A1
(en)
|
2005-09-15 |
2007-03-22 |
Marina Biotech, Inc. |
Improvements in or relating to amphoteric liposomes
|
ATE548459T1
(en)
|
2005-09-16 |
2012-03-15 |
Monsanto Technology Llc |
METHOD FOR THE GENETIC CONTROL OF INSECT INFESTATION IN PLANTS AND COMPOSITIONS
|
CN104357446A
(en)
|
2005-09-16 |
2015-02-18 |
德福根有限公司 |
Transgenic plant-based methods for plant pests using RNAI
|
EP1931789B1
(en)
|
2005-09-20 |
2016-05-04 |
BASF Plant Science GmbH |
Methods for controlling gene expression using ta-siran
|
DK1926996T3
(en)
|
2005-09-20 |
2012-01-23 |
Osi Pharmaceuticals Llc |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US8221740B2
(en)
|
2005-09-26 |
2012-07-17 |
The Trustees Of Columbia University In The City Of New York |
Side population cells in cardiac repair
|
AU2006297173A1
(en)
*
|
2005-09-29 |
2007-04-12 |
Viral Logic Systems Technology Corp. |
Immunomodulatory compositions and uses therefor
|
ATE542912T1
(en)
*
|
2005-10-03 |
2012-02-15 |
Monsanto Technology Llc |
TRANSGENIC PLANT SEEDS WITH INCREASED LYSINE
|
WO2007044727A2
(en)
|
2005-10-07 |
2007-04-19 |
California Institute Of Technology |
Pkr activation via hybridization chain reaction
|
US8093369B2
(en)
*
|
2005-10-11 |
2012-01-10 |
Ben Gurion University Of The Negev Research And Development Authority Ltd. |
Compositions for silencing the expression of VDAC1 and uses thereof
|
WO2007047706A2
(en)
|
2005-10-17 |
2007-04-26 |
Children's Hospital |
Methods and compositions for regulating gene expression
|
US7794951B2
(en)
*
|
2005-10-18 |
2010-09-14 |
University Of Massachusetts Medical School |
SREBP2gc transcription factors and uses thereof
|
EP1947925B1
(en)
|
2005-10-20 |
2013-12-25 |
Commonwealth Scientific And Industrial Research Organisation |
Cereals with altered dormancy
|
EP1948827B1
(en)
|
2005-10-21 |
2016-03-23 |
The Regents of The University of California |
C-kit oncogene mutations in melanoma
|
WO2007048122A2
(en)
*
|
2005-10-21 |
2007-04-26 |
Genzyme Corporation |
Antibody-based therapeutics with enhanced adcc activity
|
US7723314B1
(en)
|
2005-10-28 |
2010-05-25 |
Transderm, Inc. |
Methods and compositions for treating pachyonychia congenita
|
EP2325315B1
(en)
|
2005-10-28 |
2014-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
PL1978993T3
(en)
|
2005-10-31 |
2017-07-31 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for treating cancer based on human fzd receptors
|
EP1945754B1
(en)
|
2005-10-31 |
2014-07-23 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
US7582745B2
(en)
|
2005-11-04 |
2009-09-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Nav1.8 gene
|
WO2007054441A2
(en)
|
2005-11-08 |
2007-05-18 |
Basf Plant Science Gmbh |
Use of armadillo repeat (arm1) polynucleotides for obtaining pathogen resistance in plants
|
WO2007056331A2
(en)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
CN100447243C
(en)
*
|
2005-11-15 |
2008-12-31 |
中国人民解放军第四军医大学 |
HBV specificity interference target point gene and its siRNA and application in anti HBV infecting thereof
|
EP2641970B1
(en)
|
2005-11-17 |
2014-12-24 |
Board of Regents, The University of Texas System |
Modulation of gene expression by oligomers targeted to chromosomal DNA
|
US8603991B2
(en)
*
|
2005-11-18 |
2013-12-10 |
Gradalis, Inc. |
Individualized cancer therapy
|
US8916530B2
(en)
*
|
2005-11-18 |
2014-12-23 |
Gradalis, Inc. |
Individualized cancer therapy
|
US20090175871A1
(en)
*
|
2005-11-25 |
2009-07-09 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for demonstrating presence or absence of markers associated with the presence and/or the chemosensitivity of tumors
|
WO2007064759A2
(en)
*
|
2005-11-29 |
2007-06-07 |
The Scripps Research Institute |
Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain
|
JP4737531B2
(en)
|
2005-12-05 |
2011-08-03 |
サントリーホールディングス株式会社 |
Method for producing ceramide using transformed yeast
|
CA2632405A1
(en)
|
2005-12-09 |
2007-06-14 |
Basf Plant Science Gmbh |
Nucleic acid molecules encoding polypeptides involved in regulation of sugar and lipid metabolism and methods of use viii
|
EP1963526A4
(en)
|
2005-12-09 |
2009-11-18 |
Promega Corp |
Nucleic acid purification with a binding matrix
|
US20090317802A1
(en)
*
|
2005-12-09 |
2009-12-24 |
Bhatia Sangeeta N |
Compositions and Methods to Monitor RNA Delivery to Cells
|
WO2007070682A2
(en)
*
|
2005-12-15 |
2007-06-21 |
Massachusetts Institute Of Technology |
System for screening particles
|
US20090012029A1
(en)
*
|
2006-01-06 |
2009-01-08 |
Hussey Richard S |
Cyst Nematode Resistant Transgenic Plants
|
US8906876B2
(en)
|
2006-01-12 |
2014-12-09 |
Devgen Nv |
Methods for controlling pests using RNAi
|
CA2632872A1
(en)
*
|
2006-01-12 |
2007-07-19 |
Basf Plant Science Gmbh |
Use of stomatin (stm1) polynucleotides for achieving a pathogen resistance in plants
|
EP2374462A3
(en)
|
2006-01-12 |
2011-12-14 |
deVGen N.V. |
Methods for controlling pests using RNAi
|
JP5474355B2
(en)
|
2006-01-12 |
2014-04-16 |
デブジェン エヌブイ |
Genetically modified plant system method for plant pests using RNAi
|
US20090060921A1
(en)
*
|
2006-01-17 |
2009-03-05 |
Biolex Therapeutics, Inc. |
Glycan-optimized anti-cd20 antibodies
|
CN100562342C
(en)
*
|
2006-01-17 |
2009-11-25 |
奥林格斯技术有限公司 |
The oligonucleotide drug of control influenza infection
|
EP1974040B1
(en)
*
|
2006-01-17 |
2012-10-03 |
Biolex Therapeutics, Inc. |
Compositions and methods for humanization and optimization of N-glycans in plants
|
US7825099B2
(en)
*
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
UY30097A1
(en)
*
|
2006-01-20 |
2007-08-31 |
Atugen Ag |
THERAPEUTIC USES OF RTP801 INHIBITORS
|
EP1984382B1
(en)
*
|
2006-01-27 |
2012-08-15 |
Santaris Pharma A/S |
Lna modified phosphorothiolated oligonucleotides
|
EP1981902B1
(en)
|
2006-01-27 |
2015-07-29 |
Biogen MA Inc. |
Nogo receptor antagonists
|
EP1987142A4
(en)
|
2006-02-02 |
2009-07-15 |
Verenium Corp |
Esterases and related nucleic acids and methods
|
US20080022423A1
(en)
*
|
2006-02-03 |
2008-01-24 |
Monsanto Technology Llc |
IN PLANTA RNAi CONTROL OF FUNGI
|
BRPI0707626A2
(en)
|
2006-02-10 |
2011-05-10 |
Monsanto Technology Llc |
identification and use of target genes for the control of plant parasitic nematodes
|
EP2415864B1
(en)
|
2006-02-10 |
2014-02-12 |
Verenium Corporation |
Oligomerase-2 (or beta-xylosidase) enzymes, nucleic acids encoding them and methods for making and using them
|
CN101421406B
(en)
|
2006-02-13 |
2016-08-31 |
孟山都技术有限公司 |
For producing nucleic acid construct and the method that the seed oil of change forms
|
CN101384721A
(en)
*
|
2006-02-13 |
2009-03-11 |
孟山都技术有限公司 |
Selecting and stabilizing dsrna constructs
|
TR201809912T4
(en)
|
2006-02-14 |
2018-07-23 |
Bp Corp North America Inc |
Xylanases, nucleic acids encoding them, and methods for making and using them.
|
US20070293657A1
(en)
*
|
2006-02-17 |
2007-12-20 |
Nastech Pharmaceutical Company Inc. |
Complexes and methods of forming complexes of ribonucleic acids and peptides
|
WO2007120989A2
(en)
|
2006-02-24 |
2007-10-25 |
Ceres, Inc. |
Shade regulatory regions
|
US20090074913A1
(en)
|
2006-02-24 |
2009-03-19 |
Suntory Limited |
Gene Encoding Protein Responsible for Flocculation Property of Yeast and Use Thereof
|
JP2009165352A
(en)
*
|
2006-02-24 |
2009-07-30 |
Suntory Liquors Ltd |
ACYL-CoA:ETHANOL O-ACYLTRANSFERASE/ESTERASE GENE AND USE THEREOF
|
CA2638762A1
(en)
|
2006-02-24 |
2007-08-30 |
Suntory Limited |
Ammonia transporter gene and use thereof
|
US20090061427A1
(en)
|
2006-02-24 |
2009-03-05 |
Yoshihiro Nakao |
Gene Encoding Protein Responsible for Flocculation Property of Yeast and Use Thereof
|
WO2007097093A1
(en)
*
|
2006-02-27 |
2007-08-30 |
Suntory Limited |
Branched amino acid transporter gene and use thereof
|
WO2007097095A1
(en)
*
|
2006-02-27 |
2007-08-30 |
Suntory Limited |
Aromatic amino acid transporter gene and use thereof
|
JP2009528845A
(en)
*
|
2006-03-08 |
2009-08-13 |
プロメガ・コーポレーション |
Purification method of low molecular weight RNA
|
US7910566B2
(en)
*
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
US20100068172A1
(en)
*
|
2006-03-16 |
2010-03-18 |
Devgen N.V. |
Nematode Control
|
WO2007109441A2
(en)
|
2006-03-20 |
2007-09-27 |
Novozymes, Inc. |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
US8329888B2
(en)
*
|
2006-03-23 |
2012-12-11 |
Santaris Pharma A/S |
Small internally segmented interfering RNA
|
FR2898908A1
(en)
|
2006-03-24 |
2007-09-28 |
Agronomique Inst Nat Rech |
Process, useful to prepare differentiated avian cells from avian stem cells grown in culture medium, comprises induction of stem cells differentiation by inhibiting expression/activity of gene expressed in the stem cells e.g. Nanog gene
|
WO2007123777A2
(en)
|
2006-03-30 |
2007-11-01 |
Duke University |
Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
|
EP2374877A3
(en)
|
2006-03-30 |
2012-11-07 |
Novozymes A/S |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
ES2776100T3
(en)
|
2006-03-31 |
2020-07-29 |
Massachusetts Inst Technology |
System for targeted delivery of therapeutic agents
|
CA2873833A1
(en)
|
2006-03-31 |
2007-10-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
WO2008034648A1
(en)
|
2006-04-05 |
2008-03-27 |
Metanomics Gmbh |
Process for the production of a fine chemical
|
WO2007117657A2
(en)
|
2006-04-07 |
2007-10-18 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
US9044461B2
(en)
|
2006-04-07 |
2015-06-02 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
AU2007348315A1
(en)
*
|
2006-04-07 |
2008-09-12 |
Chimeros, Inc. |
Compositions and methods for treating B- cell malignancies
|
US7625874B2
(en)
*
|
2006-04-11 |
2009-12-01 |
The Regents Of The University Of California |
Compositions and methods for treating diseases associated with T-box and N-Myc
|
CN101460634A
(en)
*
|
2006-04-13 |
2009-06-17 |
康乃尔研究基金会有限公司 |
Methods and compositions for targeting C-REL
|
TW200813231A
(en)
|
2006-04-13 |
2008-03-16 |
Novartis Vaccines & Diagnostic |
Methods of treating, diagnosing or detecting cancer
|
CN101484578A
(en)
*
|
2006-04-19 |
2009-07-15 |
惠氏公司 |
Short interfering rna duplexes targeting an ires sequence and uses therefor
|
BRPI0710637A2
(en)
*
|
2006-04-21 |
2012-03-13 |
Wyeth |
analysis of differential expression profile of cell culture phenotypes and their uses
|
CA2656990A1
(en)
*
|
2006-04-28 |
2007-11-08 |
University Of South Florida |
Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
US20070281900A1
(en)
*
|
2006-05-05 |
2007-12-06 |
Nastech Pharmaceutical Company Inc. |
COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
|
US8716327B2
(en)
|
2006-05-09 |
2014-05-06 |
Genzyme Corporation |
Methods of treating fatty liver disease
|
CN103614375A
(en)
|
2006-05-11 |
2014-03-05 |
阿尔尼拉姆医药品有限公司 |
Composition and method for inhibiting expression of PCSK9 gene
|
GB0609498D0
(en)
*
|
2006-05-12 |
2006-06-21 |
Oncomethylome Sciences S A |
Novel methylation marker
|
JP5630998B2
(en)
|
2006-05-15 |
2014-11-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
Polymers for functional particles
|
WO2007132867A1
(en)
|
2006-05-15 |
2007-11-22 |
Takeda Pharmaceutical Company Limited |
Prophylactic and therapeutic agent for cancer
|
JP2009537150A
(en)
|
2006-05-16 |
2009-10-29 |
モンサント テクノロジー エルエルシー |
Use of non-Agrobacterium species for plant transformation
|
US20070286863A1
(en)
*
|
2006-05-17 |
2007-12-13 |
Christopher Sinal |
CMKLR regulation of adipogenesis and adipocyte metabolic function
|
WO2007137117A2
(en)
*
|
2006-05-17 |
2007-11-29 |
Massachusetts Institute Of Technology |
Aptamer-directed drug delivery
|
US20070269892A1
(en)
*
|
2006-05-18 |
2007-11-22 |
Nastech Pharmaceutical Company Inc. |
FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
|
US7812150B2
(en)
|
2006-05-19 |
2010-10-12 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of Aha and therapeutic uses thereof
|
WO2007137129A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Alcon Research, Ltd. |
RNAI-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR α-RELATED CONDITIONS
|
US7888498B2
(en)
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
US9273356B2
(en)
|
2006-05-24 |
2016-03-01 |
Medtronic, Inc. |
Methods and kits for linking polymorphic sequences to expanded repeat mutations
|
US20070274987A1
(en)
*
|
2006-05-25 |
2007-11-29 |
Valerie Clerin |
Expression of the cysteine protease legumain in vascular and inflammatory diseases
|
US20070275923A1
(en)
*
|
2006-05-25 |
2007-11-29 |
Nastech Pharmaceutical Company Inc. |
CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
|
EP2035439A4
(en)
|
2006-06-05 |
2010-01-13 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
WO2007141790A2
(en)
|
2006-06-07 |
2007-12-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Plant expression constructs and methods of utilizing same
|
EP2026843A4
(en)
*
|
2006-06-09 |
2011-06-22 |
Quark Pharmaceuticals Inc |
Therapeutic uses of inhibitors of rtp801l
|
JP2009540011A
(en)
*
|
2006-06-12 |
2009-11-19 |
エクセジェニックス、インク.ディー/ビー/エー オプコ ヘルス、インク. |
Compositions and methods for siRNA inhibition of angiogenesis
|
JP5554564B2
(en)
|
2006-06-13 |
2014-07-23 |
ザ ロックフェラー ユニヴァーシティ |
Novel therapeutic and diagnostic products and methods
|
WO2007147067A2
(en)
*
|
2006-06-14 |
2007-12-21 |
Rosetta Inpharmatics Llc |
Methods and compositions for regulating cell cycle progression
|
US8227437B2
(en)
*
|
2006-06-22 |
2012-07-24 |
Tai June Yoo |
Restoration of hearing loss
|
WO2007150030A2
(en)
|
2006-06-23 |
2007-12-27 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
AU2007293187A1
(en)
|
2006-06-30 |
2008-03-13 |
Rosetta Genomics Ltd |
A method for detecting nucleic acids
|
US8097596B2
(en)
*
|
2006-06-30 |
2012-01-17 |
Lakewood-Amedex, Inc. |
Compositions and methods for the treatment of muscle wasting
|
US20130191941A1
(en)
|
2006-07-05 |
2013-07-25 |
Shing Kwok |
Modulating light response pathways in plants, increasing light-related tolerances in plants, and increasing biomass in plants
|
WO2008005631A2
(en)
|
2006-07-07 |
2008-01-10 |
Washington State University |
Genes encoding chavicol/eugenol synthase from the creosote bush larrea tridentata
|
WO2008054561A2
(en)
|
2006-07-11 |
2008-05-08 |
University Of Medicine And Dentistry Of New Jersey |
Proteins, nucleic acids encoding the same and associated methods of use
|
WO2008006169A1
(en)
|
2006-07-12 |
2008-01-17 |
Commonwealth Scientific And Industrial Research Organisation |
Polynucleotides and methods for enhancing salinity tolerance in plants
|
WO2008008986A2
(en)
|
2006-07-13 |
2008-01-17 |
University Of Iowa Research Foundation |
Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
|
US20100105610A1
(en)
|
2006-07-28 |
2010-04-29 |
Children's Memorial Hospital |
Methods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells
|
PL380335A1
(en)
*
|
2006-07-31 |
2008-02-04 |
Instytut Chemii Bioorganicznej Pan W Poznaniu |
Sequence of double-stranded ATN-RNA, intervention using interference RNA (iRnAi) as well as application of sequence of double-stranded ATN-RNA in brain tumour treatment
|
EP2069389B1
(en)
|
2006-08-04 |
2014-10-08 |
BP Corporation North America Inc. |
Glucanases, nucleic acids encoding them and methods for making and using them
|
WO2008021207A2
(en)
|
2006-08-11 |
2008-02-21 |
Dow Agrosciences Llc |
Zinc finger nuclease-mediated homologous recombination
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
US9580515B2
(en)
|
2006-08-21 |
2017-02-28 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Neukinase, a downstream protein of neuregulin
|
RU2428480C9
(en)
*
|
2006-08-30 |
2012-03-20 |
Басф Плант Сайенс Гмбх |
Method for providing higher transgenic plant resistance to pathogenic exposure
|
WO2008028121A1
(en)
|
2006-08-31 |
2008-03-06 |
Monsanto Technology Llc |
Plant transformation without selection
|
US7872118B2
(en)
*
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
WO2008030605A2
(en)
*
|
2006-09-08 |
2008-03-13 |
The Regents Of The University Of Michigan |
Herv group ii viruses in lymphoma and cancer
|
WO2008032876A1
(en)
|
2006-09-15 |
2008-03-20 |
Tokai University |
Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same
|
US7737266B2
(en)
|
2006-09-18 |
2010-06-15 |
Board Of Regents, The University Of Texas System |
RNAi modulation of SCAP and therapeutics uses thereof
|
EP2145001A2
(en)
*
|
2006-09-19 |
2010-01-20 |
Asuragen, Inc. |
Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
AU2007299804A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
MiR-200 regulated genes and pathways as targets for therapeutic intervention
|
CA2663001A1
(en)
|
2006-09-21 |
2008-03-27 |
Verenium Corporation |
Phospholipases, nucleic acids encoding them and methods for making and using them
|
US20090209478A1
(en)
|
2006-09-21 |
2009-08-20 |
Tomoko Nakayama |
Compositions and methods for inhibiting expression of the hamp gene
|
CA2663819C
(en)
|
2006-09-21 |
2019-04-30 |
Verenium Corporation |
Phytases, nucleic acids encoding them and methods for making and using them
|
WO2008036825A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by rna interference
|
EP3066934A1
(en)
|
2006-10-06 |
2016-09-14 |
BASF Plant Science GmbH |
Method for producing polyunsatured fatty acids in transgenic organisms
|
CN101802215A
(en)
|
2006-10-12 |
2010-08-11 |
孟山都技术有限公司 |
Plant micrornas and using method thereof
|
JP5424885B2
(en)
|
2006-10-13 |
2014-02-26 |
マリーナ バイオテック,インコーポレイテッド |
Improvements in or on amphoteric liposomes, methods of formulating amphoteric liposomes and methods of filling amphoteric liposomes
|
WO2008049078A1
(en)
|
2006-10-18 |
2008-04-24 |
Nastech Pharmaceutical Company Inc. |
Nicked or gapped nucleic acid molecules and uses thereof
|
EP2077838B1
(en)
|
2006-10-25 |
2013-04-03 |
The Rockefeller University |
Methods for the treatment of amyloid-beta related disorders and compositions therefor
|
JP2010507387A
(en)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
Novel siRNA and method of using the same
|
US9279127B2
(en)
*
|
2006-11-01 |
2016-03-08 |
The Medical Research Fund At The Tel-Aviv Sourasky Medical Center |
Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
|
EP2094086B1
(en)
*
|
2006-11-08 |
2013-08-28 |
Veritas Bio, LLC |
In vivo delivery of double stranded rna to a target cell
|
US8906874B2
(en)
|
2006-11-09 |
2014-12-09 |
Gradalis, Inc. |
Bi-functional shRNA targeting Stathmin 1 and uses thereof
|
US8252526B2
(en)
|
2006-11-09 |
2012-08-28 |
Gradalis, Inc. |
ShRNA molecules and methods of use thereof
|
US8758998B2
(en)
|
2006-11-09 |
2014-06-24 |
Gradalis, Inc. |
Construction of bifunctional short hairpin RNA
|
EP2433635A1
(en)
|
2006-11-10 |
2012-03-28 |
Massachusetts Institute Of Technology |
PAK Modulators
|
EP2091557A2
(en)
|
2006-11-15 |
2009-08-26 |
Coda Therapeutics, INC. |
Improved methods and compositions for wound healing
|
WO2008147456A2
(en)
*
|
2006-11-20 |
2008-12-04 |
Massachusetts Institute Of Technology |
Drug delivery systems using fc fragments
|
US8222388B2
(en)
|
2006-11-22 |
2012-07-17 |
Ceres, Inc. |
Broadly expressing regulatory regions
|
EP2104513B1
(en)
|
2006-11-27 |
2015-05-20 |
diaDexus, Inc. |
Ovr110 antibody compositions and methods of use
|
JP2010510772A
(en)
|
2006-11-27 |
2010-04-08 |
パトリス リミテッド |
Novel glycosylated peptide targets in neoplastic cells
|
WO2008067423A2
(en)
|
2006-11-29 |
2008-06-05 |
Novozymes, Inc. |
Methods of improving the introduction of dna into bacterial cells
|
WO2008066931A2
(en)
|
2006-11-29 |
2008-06-05 |
Novozymes, Inc. |
Bacillus licheniformis chromosome
|
CN101195821A
(en)
*
|
2006-12-04 |
2008-06-11 |
中国科学院上海生命科学研究院 |
Method for improving insect resistance of plant by using RNAi technique
|
WO2009024834A2
(en)
*
|
2006-12-05 |
2009-02-26 |
Rosetta Genomics Ltd |
Nucleic acids involved in viral infection
|
WO2008073856A2
(en)
*
|
2006-12-08 |
2008-06-19 |
Massachusetts Institute Of Technology |
Delivery of nanoparticles and/or agents to cells
|
CA2671299A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Functions and targets of let-7 micro rnas
|
CA2671294A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Mir-21 regulated genes and pathways as targets for therapeutic intervention
|
WO2008067840A1
(en)
|
2006-12-08 |
2008-06-12 |
Swetree Technologies Ab |
Plants having improved growth characteristics and method for making the same
|
CN101622349A
(en)
*
|
2006-12-08 |
2010-01-06 |
奥斯瑞根公司 |
miR-20 regulated genes and pathways as targets for therapeutic intervention
|
KR101613624B1
(en)
|
2006-12-14 |
2016-04-29 |
다우 아그로사이언시즈 엘엘씨 |
Optimized non-canonical zinc finger proteins
|
ES2620288T3
(en)
|
2006-12-21 |
2017-06-28 |
Basf Enzymes Llc |
Amylases and glucoamylases, nucleic acids that encode them and methods to form and use them
|
EP2913341A1
(en)
|
2006-12-22 |
2015-09-02 |
University of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
EP2097445A1
(en)
*
|
2006-12-22 |
2009-09-09 |
F. Hoffmann-Roche AG |
Shrna-mediated inhibition of expression of alpha-1. 6-fucosyltransferase
|
CA2674949A1
(en)
|
2007-01-12 |
2008-07-24 |
J. Marc Simard |
Targeting ncca-atp channel for organ protection following ischemic episode
|
EP2202314B1
(en)
|
2007-01-15 |
2014-03-12 |
BASF Plant Science GmbH |
Use of subtilisin (RNR9) polynucleotides for achieving a pathogen resistance in plants
|
WO2008087641A2
(en)
*
|
2007-01-16 |
2008-07-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
H19 silencing nucleic acid agents for treating rheumatoid arthritis
|
WO2008089265A2
(en)
*
|
2007-01-17 |
2008-07-24 |
University Of Georgia Research Foundation, Inc. |
Anti-viral methods and compositions
|
WO2008092002A2
(en)
|
2007-01-24 |
2008-07-31 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
WO2008092099A2
(en)
*
|
2007-01-26 |
2008-07-31 |
Rosetta Genomics, Ltd. |
Compositions and methods for treating hematopoietic malignancies
|
AU2008207735B2
(en)
|
2007-01-26 |
2013-10-03 |
University Of Louisville Research Foundation, Inc. |
Modification of exosomal components for use as a vaccine
|
WO2008094937A2
(en)
*
|
2007-01-29 |
2008-08-07 |
Joslin Diabetes Center, Inc. |
Methods of modulating angiogenesis
|
CA2674721C
(en)
|
2007-01-30 |
2018-04-03 |
Verenium Corporation |
Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
|
ATE533353T1
(en)
|
2007-02-05 |
2011-12-15 |
Univ Singapore |
PUTATIVE CYTOKININ RECEPTOR AND METHOD FOR USE THEREOF
|
WO2008095886A1
(en)
|
2007-02-06 |
2008-08-14 |
Basf Plant Science Gmbh |
Compositions and methods using rna interference for control of nematodes
|
ATE553195T1
(en)
|
2007-02-08 |
2012-04-15 |
Basf Plant Science Gmbh |
COMPOSITIONS AND METHODS WITH RNA INTERFERENCE OPR3-LIKE GENE FOR CONTROL OF NEMATODES
|
WO2008095970A1
(en)
|
2007-02-09 |
2008-08-14 |
Basf Plant Science Gmbh |
Compositions and methods using rna interference of cdpk-like for control of nematodes
|
EP2134830A2
(en)
*
|
2007-02-09 |
2009-12-23 |
Massachusetts Institute of Technology |
Oscillating cell culture bioreactor
|
DE102007008596B4
(en)
|
2007-02-15 |
2010-09-02 |
Friedrich-Schiller-Universität Jena |
Biologically active molecules based on PNA and siRNA, methods for their cell-specific activation and application kit for administration
|
CN101631868B
(en)
|
2007-02-16 |
2016-02-10 |
巴斯福植物科学有限公司 |
For regulating the nucleotide sequence of embryo-specific expression in monocotyledons
|
WO2008103643A1
(en)
|
2007-02-20 |
2008-08-28 |
Monsanto Technology, Llc |
Invertebrate micrornas
|
CA2714335A1
(en)
|
2007-02-20 |
2008-08-28 |
Merrimack Pharmaceuticals, Inc. |
Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
|
JP2010518880A
(en)
*
|
2007-02-26 |
2010-06-03 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
Inhibitors of RTP801 and their use in the treatment of diseases
|
US9006206B2
(en)
|
2007-02-27 |
2015-04-14 |
Rosetta Genomics Ltd. |
Composition and methods for modulating cell proliferation and cell death
|
ATE553196T1
(en)
*
|
2007-02-27 |
2012-04-15 |
Rosetta Genomics Ltd |
COMPOSITION AND METHOD FOR MODULATING CELL PROLIFERATION AND CELL DEATH
|
WO2008104978A2
(en)
*
|
2007-02-28 |
2008-09-04 |
Quark Pharmaceuticals, Inc. |
Novel sirna structures
|
US9340601B2
(en)
*
|
2007-03-01 |
2016-05-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Splice variants of the EGF receptor
|
US8318921B2
(en)
*
|
2007-03-01 |
2012-11-27 |
California Institute Of Technology |
Triggered RNAi
|
WO2008109432A2
(en)
*
|
2007-03-02 |
2008-09-12 |
The Board Of Regents Of The University Of Texas System |
Therapeutic targeting of interleukins using sirna in neutral liposomes
|
US20110189663A1
(en)
|
2007-03-05 |
2011-08-04 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
US8080648B1
(en)
|
2007-03-09 |
2011-12-20 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Pesticidal double stranded RNA composition and method of use thereof
|
JP2010521460A
(en)
*
|
2007-03-12 |
2010-06-24 |
アンティジェン・エクスプレス・インコーポレーテッド |
Ii-RNAi involvement Ii suppression in cancer immunotherapy
|
EP2125898B1
(en)
|
2007-03-14 |
2013-05-15 |
Novartis AG |
Apcdd1 inhibitors for treating, diagnosing or detecting cancer
|
JP5759673B2
(en)
*
|
2007-03-21 |
2015-08-05 |
ブルックヘブン サイエンス アソシエイツ,エルエルシー |
Combined hairpin-antisense composition and method for modulating expression
|
US7812002B2
(en)
*
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
PE20090064A1
(en)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
|
US20100105043A1
(en)
*
|
2007-03-26 |
2010-04-29 |
Ko Minoru S H |
Methods for modulating embryonic stem cell differentiation
|
US20100273172A1
(en)
|
2007-03-27 |
2010-10-28 |
Rosetta Genomics Ltd. |
Micrornas expression signature for determination of tumors origin
|
CL2008000883A1
(en)
*
|
2007-03-28 |
2008-10-03 |
Wyeth6 3 |
METHOD OF DETECTION OF CAPABLE COMPOUNDS TO ANTAGONIZE THE SIGNALING OF IL-17F / IL-17A; COMPOUND IDENTIFIED BY SUCH METHOD; USE OF A QUANTITY OF AN IL-17F / IL-17A SENALIZATION ANTAGONIST, PHARMACEUTICAL COMPOSITION UNDERSTANDING
|
AP3018A
(en)
|
2007-03-29 |
2014-10-31 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expressionof a gene from the ebola
|
EP1985295A1
(en)
*
|
2007-04-04 |
2008-10-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
|
WO2008124634A1
(en)
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Polymer-encapsulated reverse micelles
|
JP2010523595A
(en)
|
2007-04-04 |
2010-07-15 |
マサチューセッツ インスティテュート オブ テクノロジー |
Poly (amino acid) targeting part
|
CA2683063A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Chimeros, Inc. |
Self-assembling nanoparticle drug delivery system
|
EP2147013A4
(en)
*
|
2007-04-16 |
2012-03-07 |
Modgene Llc |
Methods and compositions for diagnosis and treatment of depression and anxiety
|
CA2584934A1
(en)
|
2007-04-17 |
2008-10-17 |
University Of Guelph |
Nitrogen-regulated sugar sensing gene and protein and modulation thereof
|
CN101686939B
(en)
*
|
2007-04-17 |
2013-03-27 |
巴克斯特国际公司 |
Nucleic acid microparticles for pulmonary delivery
|
US9556210B2
(en)
|
2007-04-23 |
2017-01-31 |
Sabag-Rfa Ltd. |
System for delivering therapeutic agents into living cells and cells nuclei
|
EP2144633B1
(en)
|
2007-04-23 |
2014-07-16 |
Deliversir Ltd |
A system for delivering therapeutic agents into living cells and cells nuclei
|
US9156865B2
(en)
|
2007-04-23 |
2015-10-13 |
Deliversir Ltd |
System for delivering therapeutic agents into living cells and cells nuclei
|
EP2377952A1
(en)
|
2007-04-26 |
2011-10-19 |
Ludwig Institute For Cancer Research |
Methods for diagnosing and treating astrocytomas
|
BRPI0810120A2
(en)
|
2007-04-27 |
2014-11-11 |
Dow Global Technologies Inc |
PROCESS TO QUICKLY SELECT MICROBIAN HOST FOR THE IDENTIFICATION OF CERTAIN BETTER YIELDS AND / OR QUALITY IN EXPRESSION OF HETEROLOGICAL PROTEINS
|
EP2147100B1
(en)
|
2007-04-27 |
2017-06-07 |
The Regents of The University of California |
Plant co2 sensors, nucleic acids encoding them, and methods for making and using them
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
EP2152877A2
(en)
*
|
2007-05-02 |
2010-02-17 |
Sirna Therapeutics Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CYCLIC NUCLEOTIDE TYPE 4 PHOSPHODIESTERASE ( PDE4B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2607477B1
(en)
|
2007-05-03 |
2020-09-23 |
The Brigham and Women's Hospital, Inc. |
Multipotent stem cells and uses thereof
|
US20100251392A1
(en)
*
|
2007-05-04 |
2010-09-30 |
Abbott Laboratories |
Methods for assessing the delivery of exogenous agents
|
US20100115635A1
(en)
*
|
2007-05-04 |
2010-05-06 |
Abbott Laboratories |
Methods for Assessing the Delivery of Exogenous Agents
|
SI2494993T1
(en)
|
2007-05-04 |
2019-01-31 |
Marina Biotech, Inc. |
Amino acid lipids and uses thereof
|
BRPI0811531A2
(en)
|
2007-05-04 |
2014-10-07 |
Basf Plant Science Gmbh |
POLYNUCLEOTIDE, VECTOR, METHOD FOR MANUFACTURING A PIRUVATO KINASE POLYPEPTIDE, MOUNTED PIRUVATO KINASE POLYPEPTIDE, ANTIBODY, TRANSGENIC ORGANISM FOR A HUMAN FEMAIN WITHOUT A HUMAN FEMALE, A HYDROAUS WITHOUT A HUMAN FEMALE PLANT, USE OF TRANSGENIC NON-HUMAN ORGANISM OR SEED, AND NUCLEIC ACID MOLECULA.
|
US8298781B2
(en)
*
|
2007-05-08 |
2012-10-30 |
Duke University |
Compositions and methods for characterizing and regulating olfactory sensation
|
KR101461659B1
(en)
|
2007-05-11 |
2014-11-17 |
토마스 제퍼슨 유니버시티 |
Methods of treatment and prevention of neurodegenerative diseases and disorders
|
AU2008251467B2
(en)
|
2007-05-11 |
2014-07-31 |
The Trustees Of The University Of Pennsylvania |
Methods of treatment of skin ulcers
|
WO2008143786A1
(en)
*
|
2007-05-14 |
2008-11-27 |
The Rockefeller University |
Production of artificial micrornas using synthetic microrna precursors
|
EP1992699A1
(en)
*
|
2007-05-15 |
2008-11-19 |
Genoplante-Valor |
Method for increasing the resistance of a plant to endoparasitic nematodes
|
EP2155770B1
(en)
|
2007-05-16 |
2013-10-16 |
California Institute of Technology |
A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
|
AR066642A1
(en)
|
2007-05-22 |
2009-09-02 |
Basf Plant Gmbh |
VEGETABLE CELLS AND PLANTS WITH HIGHER TOLERANCE AND / OR RESISTANCE TO ENVIRONMENTAL STRESS AND HIGHER PRODUCTION OF BIOMASS PRODUCED BY SILENCING OF GENES
|
US20090131354A1
(en)
*
|
2007-05-22 |
2009-05-21 |
Bader Andreas G |
miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
US20090232893A1
(en)
*
|
2007-05-22 |
2009-09-17 |
Bader Andreas G |
miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
KR101750640B1
(en)
|
2007-05-22 |
2017-06-23 |
아크투루스 쎄라퓨틱스, 인크. |
Oligomer for therapeutics
|
WO2008142167A2
(en)
|
2007-05-23 |
2008-11-27 |
Syngenta Participations Ag |
Polynucleotide markers
|
DK2157979T3
(en)
|
2007-05-24 |
2018-08-27 |
Calcimedica Inc |
CALCIUM CHANNEL PROTEINS AND APPLICATIONS THEREOF
|
IN2009KN04568A
(en)
|
2007-06-01 |
2015-08-28 |
Univ Princeton |
|
CA2689974A1
(en)
*
|
2007-06-08 |
2008-12-18 |
Asuragen, Inc. |
Mir-34 regulated genes and pathways as targets for therapeutic intervention
|
US20090017460A1
(en)
*
|
2007-06-15 |
2009-01-15 |
Wyeth |
Differential expression profiling analysis of cell culture phenotypes and uses thereof
|
US20100273854A1
(en)
*
|
2007-06-15 |
2010-10-28 |
Hagar Kalinski |
Compositions and methods for inhibiting nadph oxidase expression
|
US20100240597A1
(en)
|
2007-06-15 |
2010-09-23 |
Arkansas State University |
Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
|
DE102007029471A1
(en)
|
2007-06-20 |
2008-12-24 |
Novosom Ag |
New optional cationic sterols
|
US8097422B2
(en)
|
2007-06-20 |
2012-01-17 |
Salk Institute For Biological Studies |
Kir channel modulators
|
EP2167107B1
(en)
|
2007-06-22 |
2016-12-14 |
University of Maryland, Baltimore |
Inhibitors of ncca-atp channels for therapy
|
SI2170403T1
(en)
*
|
2007-06-27 |
2014-07-31 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of pro-apoptotic genes
|
US20090324596A1
(en)
|
2008-06-30 |
2009-12-31 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
US10745701B2
(en)
|
2007-06-28 |
2020-08-18 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
CN102149826A
(en)
*
|
2007-06-29 |
2011-08-10 |
波士顿生物医药公司 |
Bacteria-mediated gene modulation via microRNA machinery
|
JP2010532360A
(en)
*
|
2007-07-02 |
2010-10-07 |
ワイス・エルエルシー |
Modulator of AXL for use in the treatment of bone disorders
|
AU2008272051A1
(en)
|
2007-07-03 |
2009-01-08 |
Cytopathfinder, Inc. |
Treatment of influenza
|
US20100184823A1
(en)
|
2007-07-05 |
2010-07-22 |
Mark Aron Labow |
dsRNA For Treating Viral Infection
|
EP2170351A4
(en)
*
|
2007-07-06 |
2011-07-06 |
Intradigm Corp |
Methods and compositions for treatment of cancer and other angiogenesis - related diseases
|
WO2009009432A2
(en)
|
2007-07-06 |
2009-01-15 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in prostate cancer
|
BRPI0814685A2
(en)
*
|
2007-07-10 |
2019-09-24 |
Neurin Pharmaceuticals 1991 Ltd |
splicing variants of cd44 in neurodegenerative diseases
|
US9689031B2
(en)
|
2007-07-14 |
2017-06-27 |
Ionian Technologies, Inc. |
Nicking and extension amplification reaction for the exponential amplification of nucleic acids
|
WO2009012263A2
(en)
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
PT2185719E
(en)
|
2007-08-02 |
2014-02-20 |
Novimmune Sa |
Anti-rantes antibodies and methods of use thereof
|
US20090044296A1
(en)
*
|
2007-08-07 |
2009-02-12 |
Cornell Research Foundation, Inc. |
Hrpn interactors and uses thereof
|
RU2518241C2
(en)
|
2007-08-13 |
2014-06-10 |
Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн |
Barley with low hordein content
|
AU2008286701B2
(en)
|
2007-08-14 |
2015-02-12 |
Commonwealth Scientific And Industrial Research Organisation |
Improved gene silencing methods
|
JP5406187B2
(en)
|
2007-08-16 |
2014-02-05 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Metabolic profiling of prostate cancer
|
JP2010536852A
(en)
|
2007-08-23 |
2010-12-02 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ |
Regulation of synapse formation
|
CN101970491A
(en)
|
2007-08-30 |
2011-02-09 |
沃尔特及伊莱萨霍尔医学研究院 |
Dendritic cell marker and uses thereof
|
US8183221B2
(en)
*
|
2007-09-05 |
2012-05-22 |
Medtronic, Inc. |
Suppression of SCN9A gene expression and/or function for the treatment of pain
|
US8361714B2
(en)
*
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
WO2009039300A2
(en)
*
|
2007-09-18 |
2009-03-26 |
Intradigm Corporation |
Compositions comprising hif-1 alpha sirna and methods of use thereof
|
CA2704737A1
(en)
*
|
2007-09-18 |
2009-09-03 |
Intradigm Corporation |
Compositions comprising k-ras sirna and methods of use
|
JP5723154B2
(en)
|
2007-09-19 |
2015-05-27 |
アプライド バイオシステムズ リミテッド ライアビリティー カンパニー |
SiRNA sequence-independent modification format for reducing the influence of off-target phenotype in RNAi and its stabilized form
|
CA2699769C
(en)
|
2007-09-27 |
2020-08-18 |
Manju Gupta |
Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
|
USRE46733E1
(en)
|
2007-10-03 |
2018-02-27 |
Bp Corporation North America Inc. |
Xylanases, nucleic acids encoding them and methods for making and using them
|
CN103898110A
(en)
*
|
2007-10-03 |
2014-07-02 |
夸克制药公司 |
Novel sirna structures
|
WO2009046397A2
(en)
*
|
2007-10-04 |
2009-04-09 |
Board Of Regents, The University Of Texas System |
Modulating gene expression with agrna and gapmers targeting antisense transcripts
|
WO2009045536A2
(en)
*
|
2007-10-05 |
2009-04-09 |
The University Of North Carolina At Chapel Hill |
Receptor targeted oligonucleotides
|
WO2009051837A2
(en)
|
2007-10-12 |
2009-04-23 |
Massachusetts Institute Of Technology |
Vaccine nanotechnology
|
EP2200649A4
(en)
|
2007-10-19 |
2012-09-26 |
Univ California |
Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
|
PE20091163A1
(en)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
ANTIBODIES FOR GDF8
|
AU2008321253B2
(en)
|
2007-11-12 |
2014-01-16 |
Masaryk Memorial Cancer Institute |
Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
|
EP2065037A1
(en)
|
2007-11-27 |
2009-06-03 |
DKFZ Deutsches Krebsforschungszentrum |
Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (Tlx)
|
AU2008329557B2
(en)
|
2007-11-27 |
2014-08-14 |
Commonwealth Scientific And Industrial Research Organisation |
Plants with modified starch metabolism
|
US8071562B2
(en)
*
|
2007-12-01 |
2011-12-06 |
Mirna Therapeutics, Inc. |
MiR-124 regulated genes and pathways as targets for therapeutic intervention
|
US7968525B1
(en)
|
2007-12-03 |
2011-06-28 |
University Of Florida Research Foundation, Inc. |
Use of RNA interference to validate new termiticide target sites and a method of termite control
|
CN101909461B
(en)
|
2007-12-06 |
2015-10-07 |
诺维信公司 |
There are the polypeptide of acetyl xylan esterase activity and the polynucleotide of this polypeptide of coding
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
US20100204305A1
(en)
*
|
2007-12-11 |
2010-08-12 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
US20110105584A1
(en)
*
|
2007-12-12 |
2011-05-05 |
Elena Feinstein |
Rtp80il sirna compounds and methods of use thereof
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
CA2709109A1
(en)
*
|
2007-12-13 |
2009-06-18 |
Alnylam Pharmaceuticals Inc. |
Methods and compositions for prevention or treatment of rsv infection
|
EP2225380A2
(en)
|
2007-12-17 |
2010-09-08 |
BASF Plant Science GmbH |
Lipid metabolism protein and uses thereof i (bzip transcription factor)
|
BRPI0821230A2
(en)
|
2007-12-19 |
2019-09-24 |
Novozymes As |
"nucleic acid construct, recombinant host microbial banknote, methods for producing a polypeptide having cellulolytic enhancing activity, for producing a precursor banknote mutant, for inhibiting expression of a cellulolytic enhancing activity polypeptide in a cell, for producing a protein" , to degrade or convert a cellulosic material, and to ferment a cellulosic material "
|
EP2072528A1
(en)
|
2007-12-19 |
2009-06-24 |
Labeit, Mr. Siegfried |
A host cell deficient for MuRF1 and MuRF2
|
US20100293665A1
(en)
|
2007-12-21 |
2010-11-18 |
Basf Plant Science Gmbh |
Plants With Increased Yield (KO NUE)
|
AU2008343756A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
|
JP2011507857A
(en)
|
2007-12-21 |
2011-03-10 |
コーダ セラピューティクス, インコーポレイテッド |
Use of connexin 43 inhibitors for the treatment of fibrotic conditions
|
WO2009082208A2
(en)
|
2007-12-21 |
2009-07-02 |
Keygene N.V. |
Trichome specific promoters
|
US20090186358A1
(en)
*
|
2007-12-21 |
2009-07-23 |
Wyeth |
Pathway Analysis of Cell Culture Phenotypes and Uses Thereof
|
WO2009086156A2
(en)
*
|
2007-12-21 |
2009-07-09 |
Asuragen, Inc. |
Mir-10 regulated genes and pathways as targets for therapeutic intervention
|
AU2008343754A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Use of anti-connexin polynucleotides for the treatment of surgical adhesions
|
NZ601188A
(en)
|
2007-12-28 |
2014-03-28 |
Swetree Technologies Ab |
Woody plants having improved growth characteristics and method for making the same using transcription factors
|
US20090226914A1
(en)
*
|
2007-12-31 |
2009-09-10 |
Bates Paula J |
Methods and products to target, capture and characterize stem cells
|
DK2238242T5
(en)
|
2008-01-03 |
2015-08-03 |
Basf Enzymes Llc |
-Transferases and oxidoreductases, nucleic acids encoding FOR THEM, AND PROCESSES FOR THE STILL LING AND USE THEREOF
|
WO2009088753A1
(en)
|
2008-01-03 |
2009-07-16 |
Verenium Corporation |
Isomerases, nucleic acids encoding them and methods for making and using them
|
CA2711635A1
(en)
*
|
2008-01-07 |
2009-08-06 |
Coda Therapeutics, Inc. |
Wound healing compositions and treatments
|
TW200930398A
(en)
*
|
2008-01-11 |
2009-07-16 |
Univ Chang Gung |
RNAi sequence, inhibitor, and inhibition method that specifically inhibits expression of 78-kDA glucose-regulated protein
|
WO2009090639A2
(en)
*
|
2008-01-15 |
2009-07-23 |
Quark Pharmaceuticals, Inc. |
Sirna compounds and methods of use thereof
|
BRPI0907637A8
(en)
|
2008-01-25 |
2018-01-02 |
P53 Inc |
p53 biomarkers
|
JP2011510623A
(en)
|
2008-01-27 |
2011-04-07 |
ロゼッタ ゲノミックス エルティーディー. |
Methods and compositions for diagnosing complications of pregnancy
|
US20090205078A1
(en)
|
2008-02-05 |
2009-08-13 |
Pioneer Hi-Bred International, Inc. |
Maize Leaf- and Stalk-Preferred Promoter
|
US20090263803A1
(en)
*
|
2008-02-08 |
2009-10-22 |
Sylvie Beaudenon |
Mirnas differentially expressed in lymph nodes from cancer patients
|
WO2009102427A2
(en)
|
2008-02-11 |
2009-08-20 |
Rxi Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
DE102009043743B4
(en)
|
2009-03-13 |
2016-10-13 |
Friedrich-Schiller-Universität Jena |
Cell-specific molecules based on siRNA as well as application kits for their production and use
|
US8497364B2
(en)
*
|
2008-02-27 |
2013-07-30 |
California Institute Of Technology |
Triggered RNAi
|
CN102014932B
(en)
|
2008-03-05 |
2015-11-25 |
阿尔尼拉姆医药品有限公司 |
For suppressing compositions and the method for Eg5 and VEGF gene expression
|
US20090233297A1
(en)
*
|
2008-03-06 |
2009-09-17 |
Elizabeth Mambo |
Microrna markers for recurrence of colorectal cancer
|
US20110105588A1
(en)
*
|
2008-03-12 |
2011-05-05 |
Intradigm Corporation |
Compositions comprising notch1 sirna and methods of use thereof
|
AU2009227549A1
(en)
*
|
2008-03-20 |
2009-09-24 |
Quark Pharmaceuticals, Inc. |
Novel siRNA compounds for inhibiting RTP801
|
EP2271757A2
(en)
*
|
2008-03-26 |
2011-01-12 |
Asuragen, INC. |
Compositions and methods related to mir-16 and therapy of prostate cancer
|
JP2011516065A
(en)
|
2008-04-04 |
2011-05-26 |
カランド ファーマシューティカルズ, インコーポレイテッド |
Compositions and uses of EPAS1 inhibitors
|
US20090258928A1
(en)
*
|
2008-04-08 |
2009-10-15 |
Asuragen, Inc. |
Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
|
CN107267514A
(en)
|
2008-04-10 |
2017-10-20 |
孟山都技术公司 |
Method and composition for root knot nematode control
|
WO2009125401A2
(en)
|
2008-04-10 |
2009-10-15 |
Rosetta Genomics Ltd. |
Compositions and methods for enhancing oil content in plants
|
AU2009238629C1
(en)
|
2008-04-14 |
2015-04-30 |
Sangamo Therapeutics, Inc. |
Linear donor constructs for targeted integration
|
US8278287B2
(en)
*
|
2008-04-15 |
2012-10-02 |
Quark Pharmaceuticals Inc. |
siRNA compounds for inhibiting NRF2
|
GB0807018D0
(en)
|
2008-04-17 |
2008-05-21 |
Fusion Antibodies Ltd |
Antibodies and treatment
|
US8518884B2
(en)
|
2008-04-25 |
2013-08-27 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
|
US8258111B2
(en)
*
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
US20090291073A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Ward Keith W |
Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
|
US20100021904A1
(en)
*
|
2008-05-21 |
2010-01-28 |
Pierce Niles A |
Shielded cross-linking probes
|
US8241854B2
(en)
*
|
2008-05-22 |
2012-08-14 |
California Institute Of Technology |
Triggered RNAi
|
WO2009143391A2
(en)
*
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc |
Methods for modulation expression of creb
|
US20100021901A1
(en)
*
|
2008-05-22 |
2010-01-28 |
Peng Yin |
Compositions and methods for detecting analytes
|
US8222221B2
(en)
|
2008-06-04 |
2012-07-17 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small RNA targeting of gene promoters
|
JP5524189B2
(en)
|
2008-06-06 |
2014-06-18 |
クォーク ファーマシューティカルズ インコーポレーティッド |
Compositions and methods for the treatment of otic disorders
|
EP2294184A4
(en)
|
2008-06-30 |
2013-03-06 |
Mesoblast Inc |
Treatment of eye diseases and excessive neovascularization using a combined therapy
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
US8512944B2
(en)
|
2008-08-27 |
2013-08-20 |
Oncotherapy Science, Inc. |
PRMT1 for target genes of cancer therapy and diagnosis
|
US8357503B2
(en)
|
2008-08-29 |
2013-01-22 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8198062B2
(en)
|
2008-08-29 |
2012-06-12 |
Dsm Ip Assets B.V. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8153391B2
(en)
|
2008-08-29 |
2012-04-10 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
EP2331690B1
(en)
|
2008-09-02 |
2016-01-13 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of mutant egfr gene
|
WO2010029343A2
(en)
|
2008-09-10 |
2010-03-18 |
University Of Bradford |
Compositions and methods
|
KR20150126739A
(en)
|
2008-09-15 |
2015-11-12 |
제넨테크, 인크. |
Compositions and methods for regulating cell osmolarity
|
EP2719380A3
(en)
|
2008-09-16 |
2014-07-30 |
University of Maryland, Baltimore |
SUR1 inhibitors for therapy
|
EP2165710A1
(en)
|
2008-09-19 |
2010-03-24 |
Institut Curie |
Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
|
US10138485B2
(en)
|
2008-09-22 |
2018-11-27 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
EP2334793B1
(en)
|
2008-09-25 |
2016-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of serum amyloid a gene
|
MX2011003183A
(en)
|
2008-09-26 |
2011-04-21 |
Oncomed Pharm Inc |
Frizzled-binding agents and uses thereof.
|
CN102164476A
(en)
|
2008-09-29 |
2011-08-24 |
孟山都技术公司 |
Soybean transgenic event MON87705 and methods for detection thereof
|
US8298794B2
(en)
|
2008-10-09 |
2012-10-30 |
Ceres, Inc. |
Cinnamyl-alcohol dehydrogenases
|
WO2010042933A2
(en)
|
2008-10-10 |
2010-04-15 |
Northwestern University |
Inhibition and treatment of prostate cancer metastasis
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
US8277812B2
(en)
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
US8591905B2
(en)
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
US8343498B2
(en)
*
|
2008-10-12 |
2013-01-01 |
Massachusetts Institute Of Technology |
Adjuvant incorporation in immunonanotherapeutics
|
JP2012505887A
(en)
*
|
2008-10-16 |
2012-03-08 |
サイトニックス コーポレイション |
Biomarkers and methods for detection and treatment of spinal cord and joint pain
|
WO2010045512A2
(en)
|
2008-10-16 |
2010-04-22 |
Mdrna , Inc. |
Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
|
NZ592867A
(en)
|
2008-10-20 |
2013-05-31 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of transthyretin
|
US20100168205A1
(en)
*
|
2008-10-23 |
2010-07-01 |
Alnylam Pharmaceuticals, Inc. |
Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules
|
US8691514B2
(en)
|
2008-10-31 |
2014-04-08 |
Japan Science And Technology Agency |
Method for selective control of helper T cell function
|
WO2010062240A1
(en)
|
2008-11-03 |
2010-06-03 |
Swetree Technologies Ab |
Vegetabile material, plants and a method of producing a plant having altered lignin properties
|
US9289475B2
(en)
|
2008-11-06 |
2016-03-22 |
The Johns Hopkins University |
Treatment of chronic inflammatory respiratory disorders
|
WO2010054264A1
(en)
*
|
2008-11-07 |
2010-05-14 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
CN102272157B
(en)
|
2008-11-07 |
2015-11-25 |
研究发展基金会 |
For suppressing composition and the method for the formation of CRIPTO/GRP78 mixture and signal
|
CA2742278A1
(en)
*
|
2008-11-10 |
2010-05-14 |
Wyeth Llc |
Temperature-induced polynucleotides and uses therefor
|
EP2352847B1
(en)
|
2008-11-10 |
2014-01-08 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Gene signature for predicting prognosis of patients with solid tumors
|
WO2010056737A2
(en)
*
|
2008-11-11 |
2010-05-20 |
Mirna Therapeutics, Inc. |
Methods and compositions involving mirnas in cancer stem cells
|
CA2780482A1
(en)
|
2008-11-17 |
2010-05-10 |
Anil K. Sood |
Hdl particles for delivery of nucleic acids
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
ES2667812T3
(en)
|
2008-11-20 |
2018-05-14 |
Novozymes Inc. |
Polypeptides having amylolytic enhancing activity and polynucleotides encoding them
|
CA2744093A1
(en)
|
2008-12-03 |
2010-06-10 |
Marina Biotech, Inc. |
Una oligomer structures for therapeutic agents
|
CA2745111A1
(en)
|
2008-12-03 |
2010-06-10 |
Research Development Foundation |
Modulation of olfml-3 mediated angiogenesis
|
WO2010065830A1
(en)
|
2008-12-04 |
2010-06-10 |
Novozymes, Inc. |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
AU2009322279A1
(en)
|
2008-12-04 |
2011-07-14 |
Opko Pharmaceuticals, Llc |
Compositions and methods for selective inhibition of pro-angiogenic VEGF isoforms
|
US8497075B2
(en)
|
2008-12-09 |
2013-07-30 |
Novartis Ag |
Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands
|
EP3225281A1
(en)
|
2008-12-10 |
2017-10-04 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
EP2198879A1
(en)
|
2008-12-11 |
2010-06-23 |
Institut Curie |
CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
|
US8822662B2
(en)
|
2008-12-12 |
2014-09-02 |
Basf Plant Science Company Gmbh |
Desaturases and process for the production of polyunsaturated fatty acids in transgenic organisms
|
US9493759B2
(en)
|
2008-12-12 |
2016-11-15 |
Novozymes, Inc. |
Polypeptides having aspartic endopeptidase activity and polynucleotides encoding same
|
EP2376527A1
(en)
|
2008-12-12 |
2011-10-19 |
Novozymes Inc. |
Polypeptides having lipase activity and polynucleotides encoding same
|
US20110269206A1
(en)
|
2008-12-15 |
2011-11-03 |
Novozymes, Inc |
Polypeptides Having Catalase Activity And Polynucleotides Encoding Same
|
EP2379716A1
(en)
|
2008-12-16 |
2011-10-26 |
Novozymes Inc. |
Polypeptides having alpha-mannosidase activity and polynucleotides encoding same
|
US8633030B2
(en)
|
2008-12-16 |
2014-01-21 |
Novozymes, Inc. |
Polypeptides having carboxypeptidase activity and polynucleotides encoding same
|
EP2370575B1
(en)
|
2008-12-17 |
2017-11-01 |
Dow AgroSciences LLC |
Targeted integration into the zp15 locus
|
CA3151965A1
(en)
|
2008-12-18 |
2010-07-15 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
WO2010080452A2
(en)
|
2008-12-18 |
2010-07-15 |
Quark Pharmaceuticals, Inc. |
siRNA COMPOUNDS AND METHODS OF USE THEREOF
|
EP2379076B1
(en)
|
2008-12-23 |
2014-11-12 |
The Trustees of Columbia University in the City of New York |
Phosphodiesterase inhibitors and uses thereof
|
WO2010074783A1
(en)
|
2008-12-23 |
2010-07-01 |
The Trustees Of Columbia University In The City Of New York |
Phosphodiesterase inhibitors and uses thereof
|
EP2201982A1
(en)
|
2008-12-24 |
2010-06-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Histamine H4 receptor antagonists for the treatment of vestibular disorders
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
US20100184844A1
(en)
*
|
2009-01-08 |
2010-07-22 |
Northwestern University |
Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates
|
EP2382328A2
(en)
|
2009-01-09 |
2011-11-02 |
The Regents of the University of Michigan |
Recurrent gene fusions in cancer
|
EP2391715A1
(en)
|
2009-01-28 |
2011-12-07 |
Novozymes Inc. |
Polypeptides having beta-glucosidase activity and polynucleotides encoding same
|
US8629324B2
(en)
|
2009-01-30 |
2014-01-14 |
Novozymes, Inc. |
Polypeptides having expansin activity and polynucleotides encoding same
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
US8309530B2
(en)
*
|
2009-02-04 |
2012-11-13 |
Washington State University |
Compositions and methods for modulating ghrelin-mediated conditions
|
WO2010093954A2
(en)
|
2009-02-13 |
2010-08-19 |
The Regents Of The University Of California |
Control of plant stress tolerance, water use efficiency and gene expression using novel aba receptor proteins and synthetic agonists
|
CN102341106A
(en)
|
2009-02-13 |
2012-02-01 |
印第安那大学科技研究公司 |
Compounds and methods for inhibiting mmp2 and mmp9
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
AU2010223967B2
(en)
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
JP2012520685A
(en)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
RNA interference-mediated inhibition of GATA binding protein 3 (GATA3) gene expression using small interfering nucleic acids (siNA)
|
US20120035247A1
(en)
|
2009-03-19 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
WO2010107952A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
CA2755773A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
|
US8748493B2
(en)
|
2009-03-20 |
2014-06-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Inhibitors of cathepsin S for prevention or treatment of obesity-associated disorders
|
CN102361987A
(en)
*
|
2009-03-20 |
2012-02-22 |
巴斯夫植物科学有限公司 |
Nematode-resistant transgenic plants
|
KR101764437B1
(en)
|
2009-03-20 |
2017-08-02 |
메소블라스트, 아이엔씨. |
Production of reprogrammed pluripotent cells
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
EP2411520A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010111468A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
US20120022142A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
JP2012521760A
(en)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
RNA interference-mediated inhibition of apoptosis signal-regulated kinase 1 (ASK1) gene expression using small interfering nucleic acids (siNA)
|
EA201171175A1
(en)
|
2009-03-27 |
2012-05-30 |
Мерк Шарп Энд Домэ Корп. |
PHK-MEDIATED INTERFERENCE INHIBITING EXPRESSION OF A CELL INTERCEPTIVE ADHESION MOLECULE 1 (ICAM-1) WITH USING A SHORT INTERFERATING NUCLEINIC ACID (IC) -1
|
CN103555722B
(en)
|
2009-04-03 |
2016-08-31 |
戴瑟纳制药公司 |
Asymmetric double-stranded RNA is utilized specifically to suppress the method and composition of KRAS
|
US20100257634A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Venganza Inc. |
Bioassay for gene silencing constructs
|
WO2010115874A1
(en)
|
2009-04-07 |
2010-10-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
WO2010120874A2
(en)
|
2009-04-14 |
2010-10-21 |
Chimeros, Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
US8283332B2
(en)
|
2009-04-17 |
2012-10-09 |
University Of Louisville Research Foundation, Inc. |
PFKFB4 inhibitors and methods of using the same
|
EA201101530A1
(en)
*
|
2009-04-21 |
2012-03-30 |
Селекта Байосайенсиз, Инк. |
IMMUNONANOTHERAPY, PROVIDING TH1-DISPERSED RESPONSE
|
WO2010122110A1
(en)
|
2009-04-22 |
2010-10-28 |
Basf Plant Science Company Gmbh |
Whole seed specific promoter
|
EP2421972A2
(en)
*
|
2009-04-24 |
2012-02-29 |
The Board of Regents of The University of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
EP2243828A1
(en)
|
2009-04-24 |
2010-10-27 |
DKFZ Deutsches Krebsforschungszentrum |
Use of mixed lineage like kinase polypeptides (MLKL polypeptides) in cancer therapy
|
CA2760883A1
(en)
|
2009-05-05 |
2010-11-11 |
Beeologics Inc. |
Prevention and treatment of nosema disease in bees
|
MY186558A
(en)
*
|
2009-05-13 |
2021-07-27 |
Malaysian Palm Oil Board |
A constitutive promoter from oil palm type 2
|
US20100298697A1
(en)
*
|
2009-05-19 |
2010-11-25 |
Medtronic, Inc. |
Method and devices for improved efficiency of rna delivery to cells
|
US8207138B2
(en)
|
2009-05-19 |
2012-06-26 |
Medtronic, Inc. |
Methods and devices for improved efficiency of RNA delivery to cells
|
EP2432499A2
(en)
|
2009-05-20 |
2012-03-28 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
EP2253316B1
(en)
|
2009-05-20 |
2013-08-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
|
KR101779991B1
(en)
|
2009-05-20 |
2017-09-19 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders
|
NZ596459A
(en)
|
2009-05-21 |
2013-11-29 |
Verenium Corp |
Phytases, nucleic acids encoding them and methods for making and using them
|
US9200276B2
(en)
|
2009-06-01 |
2015-12-01 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotides for multivalent RNA interference, compositions and methods of use thereof
|
WO2010141325A1
(en)
|
2009-06-02 |
2010-12-09 |
Novozymes, Inc. |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
EP2437592A4
(en)
|
2009-06-05 |
2013-02-27 |
Univ Florida |
Isolation and targeted suppression of lignin biosynthetic genes from sugarcane
|
EP2258858A1
(en)
|
2009-06-05 |
2010-12-08 |
Universitätsklinikum Freiburg |
Transgenic LSD1 animal model for cancer
|
MX336182B
(en)
|
2009-06-08 |
2016-01-11 |
Nunhems Bv |
Drought tolerant plants.
|
US8466342B2
(en)
|
2009-06-09 |
2013-06-18 |
Pioneer Hi Bred International Inc |
Early endosperm promoter and methods of use
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
EP2266550A1
(en)
|
2009-06-15 |
2010-12-29 |
Institut Curie |
Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders
|
US8273869B2
(en)
|
2009-06-15 |
2012-09-25 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated dsRNA targeting the PCSK9 gene
|
US20100323018A1
(en)
*
|
2009-06-17 |
2010-12-23 |
Massachusetts Institute Of Technology |
Branched DNA/RNA monomers and uses thereof
|
US20100324124A1
(en)
*
|
2009-06-17 |
2010-12-23 |
Massachusetts Institute Of Technology |
Compositions and methods relating to DNA-based particles
|
EP2445334A1
(en)
|
2009-06-26 |
2012-05-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Non human animal models for increased retinal vascular permeability
|
BRPI1008189A2
(en)
|
2009-06-30 |
2015-08-25 |
Du Pont |
Transgenic plant transgenic seed obtained from transgenic plant transgenic seed production method of a transgenic plant transgenic seed production method product and or by-product of transgenic seed and transgenic seed obtained by the method
|
EP2451957B1
(en)
|
2009-07-07 |
2017-11-15 |
Novozymes Inc. |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
WO2011003834A1
(en)
|
2009-07-09 |
2011-01-13 |
Marina Biotech, Inc. |
Amphoteric liposomes comprising imino lipids
|
AU2010270309A1
(en)
|
2009-07-10 |
2012-02-02 |
Basf Plant Science Company Gmbh |
Expression cassettes for endosperm-specific expression in plants
|
ES2562463T3
(en)
|
2009-07-14 |
2016-03-04 |
Mayo Foundation For Medical Education And Research |
Non-covalent, peptide-mediated administration of active agents across the blood brain barrier
|
BR112012001263B1
(en)
|
2009-07-20 |
2023-11-28 |
Ceres, Inc |
METHOD OF PRODUCING A PLANT, METHOD OF MODULATING BIOMASS LEVEL
|
US9409983B2
(en)
|
2009-07-23 |
2016-08-09 |
The Board Of Trustess Of The University Of Illinois |
Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
|
IN2012DN00303A
(en)
|
2009-07-24 |
2015-05-08 |
Univ California |
|
WO2011014458A1
(en)
|
2009-07-28 |
2011-02-03 |
Novozymes, Inc. |
Polypeptides having phytase activity and polynucleotides encoding same
|
CA2806295A1
(en)
|
2009-08-03 |
2011-02-10 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating insects
|
WO2011017315A2
(en)
*
|
2009-08-03 |
2011-02-10 |
Recombinetics, Inc. |
Methods and compositions for targeted gene modification
|
EP2464336A4
(en)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
WO2011021177A2
(en)
|
2009-08-19 |
2011-02-24 |
Rosetta Genomics Ltd. |
Compositions and methods for prognosis and treatment of prostate cancer
|
EP2467159A1
(en)
|
2009-08-20 |
2012-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
|
US20120157512A1
(en)
|
2009-08-21 |
2012-06-21 |
Monsanto Technology Llc |
Preventing and Curing Beneficial Insect Diseases Via Plant Transcribed Molecules
|
US8222397B2
(en)
*
|
2009-08-28 |
2012-07-17 |
Promega Corporation |
Methods of optimal purification of nucleic acids and kit for use in performing such methods
|
US8039613B2
(en)
|
2009-08-28 |
2011-10-18 |
Promega Corporation |
Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
|
JP5785948B2
(en)
|
2009-09-04 |
2015-09-30 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Methods for promoting genomic stability and telomere elongation in embryonic stem cells
|
EP2475388B1
(en)
|
2009-09-10 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Use of il-33 antagonists to treat fibrotic disease
|
WO2011032100A1
(en)
|
2009-09-11 |
2011-03-17 |
Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Inhibitors of kshv vil6 and human il6
|
WO2011032119A1
(en)
|
2009-09-14 |
2011-03-17 |
The Regents Of The University Of Colorado |
Modulation of yeast-based immunotherapy products and responses
|
CN102770534B
(en)
|
2009-09-17 |
2016-07-06 |
诺维信股份有限公司 |
There is the polypeptide of cellulolytic enhancing activity and encode its polynucleotide
|
EP2478095A1
(en)
|
2009-09-18 |
2012-07-25 |
Novozymes Inc. |
Polypeptides having beta-glucosidase activity and polynucleotides encoding same
|
WO2011036118A1
(en)
*
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
BR112012006978B1
(en)
|
2009-09-29 |
2018-11-06 |
Novozymes, Inc. |
transgenic microbial host cell, methods for producing a polypeptide having xylanase activity, for degrading or converting a cellulosic material or a xylan containing material, for producing a fermentation product, for fermenting a cellulosic material or a xylane containing material, nucleic acid containing construct , and, expression vector.
|
DK2483295T3
(en)
|
2009-09-29 |
2016-02-22 |
Novozymes Inc |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding them
|
WO2011041504A1
(en)
|
2009-09-30 |
2011-04-07 |
Novozymes, Inc. |
Polypeptides derived from thermoascus crustaceus having cellulolytic enhancing activity and polynucleotides encoding same
|
WO2011039319A1
(en)
|
2009-09-30 |
2011-04-07 |
Novozymes A/S |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
US20150025122A1
(en)
|
2009-10-12 |
2015-01-22 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
UA109884C2
(en)
|
2009-10-16 |
2015-10-26 |
|
A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD
|
UA111708C2
(en)
|
2009-10-16 |
2016-06-10 |
Бандж Ойлз, Інк. |
METHOD OF OIL REFINING
|
WO2011048070A1
(en)
|
2009-10-20 |
2011-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
|
IN2012DN03073A
(en)
|
2009-10-26 |
2015-07-31 |
Pioneer Hi Bred Int |
|
EP2494042A1
(en)
|
2009-10-29 |
2012-09-05 |
Novozymes Inc. |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
CN102639697B
(en)
|
2009-11-06 |
2015-03-25 |
诺维信股份有限公司 |
Polypeptides having xylanase activity and polynucleotides encoding same
|
DK2496693T3
(en)
|
2009-11-06 |
2018-01-22 |
Novozymes Inc |
Polypeptides with cellobiohydrolase activity and polynucleotides encoding them
|
US20120311728A1
(en)
|
2009-11-06 |
2012-12-06 |
Ziad Mallat |
Methods and pharmaceutical composition for the treatment of atherosclerosis
|
US9799416B2
(en)
*
|
2009-11-06 |
2017-10-24 |
Terrapower, Llc |
Methods and systems for migrating fuel assemblies in a nuclear fission reactor
|
CN102666856B
(en)
|
2009-11-08 |
2016-04-06 |
夸克制药公司 |
Be directed to the purposes of double-stranded RNA compound in the medicine manufacturing treatment neuropathic pain of RhoA target gene
|
EP2322927A1
(en)
|
2009-11-16 |
2011-05-18 |
Deutsches Krebsforschungszentrum |
Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer
|
EP2501414B1
(en)
|
2009-11-17 |
2018-01-10 |
The Trustees Of The University Of Pennsylvania |
Smndelta7 degron: novel compositions and methods of use
|
US9260517B2
(en)
|
2009-11-17 |
2016-02-16 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
EP2322619A1
(en)
|
2009-11-17 |
2011-05-18 |
Deutsches Krebsforschungszentrum |
Inhibitors of centrosomal clustering
|
CN102597239A
(en)
|
2009-11-26 |
2012-07-18 |
夸克医药公司 |
Sirna compounds comprising terminal substitutions
|
EP2505660B1
(en)
|
2009-11-27 |
2014-05-21 |
Japan Science And Technology Agency |
Method for screening of therapeutic agent for hyperlipemia
|
CA2782290A1
(en)
|
2009-12-03 |
2011-06-09 |
Basf Plant Science Company Gmbh |
Expression cassettes for embryo-specific expression in plants
|
CA2785996C
(en)
|
2009-12-07 |
2021-04-13 |
The Johns Hopkins University |
Sr-bi as a predictor of human female infertility and responsiveness to treatment
|
EP2862929B1
(en)
|
2009-12-09 |
2017-09-06 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating diseases, disorders or injury of the CNS
|
TWI543763B
(en)
|
2009-12-09 |
2016-08-01 |
日東電工股份有限公司 |
Modulation of hsp47 expression
|
EP2509594A1
(en)
|
2009-12-09 |
2012-10-17 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
|
EP2510090A1
(en)
|
2009-12-09 |
2012-10-17 |
BASF Plant Science Company GmbH |
Methods for increasing the resistance of plants to fungi by silencing the fungal smt1-gene
|
ES2764999T3
(en)
|
2009-12-10 |
2020-06-05 |
Univ Columbia |
Histone acetyltransferase activators and uses thereof
|
US10640457B2
(en)
|
2009-12-10 |
2020-05-05 |
The Trustees Of Columbia University In The City Of New York |
Histone acetyltransferase activators and uses thereof
|
US8691227B2
(en)
|
2009-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
|
CA2784783C
(en)
|
2009-12-18 |
2021-07-20 |
Novartis Ag |
Organic compositions to treat hsf1-related diseases
|
US9157084B2
(en)
|
2009-12-23 |
2015-10-13 |
Gradalis, Inc. |
Furin-knockdown bi-functional RNA
|
US9132146B2
(en)
|
2009-12-23 |
2015-09-15 |
Gradalis, Inc. |
Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine
|
EP2516010A2
(en)
|
2009-12-23 |
2012-10-31 |
Novartis AG |
Lipids, lipid compositions, and methods of using them
|
WO2011080261A1
(en)
|
2009-12-28 |
2011-07-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for improved cardiomyogenic differentiation of pluripotent cells
|
EP2493491B1
(en)
|
2009-12-29 |
2014-04-23 |
Hill's Pet Nutrition, Inc. |
COMPOSITIONS INCLUDING GINGER FOR THE AMELIORATION OR PREVENTION OF INFLAMMATORY CONDITIONS In CATS AND DOGS
|
HUE045270T2
(en)
|
2010-01-05 |
2019-12-30 |
Inst Nat Sante Rech Med |
Flt3 receptor antagonists for the treatment or the prevention of pain disorders
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
TWI535445B
(en)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt antagonists and methods of treatment and screening
|
DE102010004957A1
(en)
|
2010-01-14 |
2011-07-21 |
Universitätsklinikum Jena, 07743 |
Biologically active molecules for influencing virus, bacterial, parasite-infected cells and / or tumor cells and methods for their use
|
PL2523661T3
(en)
|
2010-01-15 |
2017-09-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nkcc inhibitors for the treatment of autism
|
CA3101636A1
(en)
|
2010-01-26 |
2011-08-04 |
National Jewish Health |
Diagnosis and prognosis of idiopathic interstitial pneumonia by rs35705950 snp in muc5b gene promoter
|
EP2660318A1
(en)
|
2010-02-09 |
2013-11-06 |
Sangamo BioSciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
AU2011214465A1
(en)
|
2010-02-10 |
2012-08-30 |
Novartis Ag |
Methods and compounds for muscle growth
|
CA2788036A1
(en)
|
2010-02-23 |
2011-09-01 |
Basf Plant Science Company Gmbh |
Nematode-resistant transgenic plants
|
CA2790836A1
(en)
|
2010-03-03 |
2011-09-09 |
E.I. Du Pont De Nemours And Company |
Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding oxidoreductase motif polypeptides
|
CA2783656A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
CA2783665A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
EP2548025A4
(en)
|
2010-03-17 |
2013-09-25 |
Univ Michigan |
Using phage epitopes to profile the immune response
|
JP6060071B2
(en)
|
2010-03-24 |
2017-01-11 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
RNA interference in skin and fibrosis applications
|
EP2550000A4
(en)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
Reduced size self-delivering rnai compounds
|
US9095504B2
(en)
|
2010-03-24 |
2015-08-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in ocular indications
|
WO2011120023A1
(en)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting survivin gene expression uses thereof
|
ES2893199T3
(en)
|
2010-03-29 |
2022-02-08 |
Alnylam Pharmaceuticals Inc |
dsRNA therapy for transthyretin (TTR)-related ocular amyloidosis
|
EP2552460A1
(en)
|
2010-03-29 |
2013-02-06 |
Universite De Strasbourg |
Polymers for delivering molecules of interest
|
NZ602700A
(en)
|
2010-04-01 |
2014-10-31 |
Oncomed Pharm Inc |
Frizzled-binding agents and uses thereof
|
CA2792561C
(en)
|
2010-04-06 |
2021-10-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of cd274/pd-l1 gene
|
WO2011133584A2
(en)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
US20130190383A1
(en)
|
2010-04-26 |
2013-07-25 |
Marina Biotech, Inc. |
Nucleic acid compounds with conformationally restricted monomers and uses thereof
|
WO2011139842A2
(en)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
|
CA2805267C
(en)
|
2010-05-04 |
2019-07-30 |
The Brigham And Women's Hospital, Inc. |
Detection and treatment of fibrosis
|
US9441233B2
(en)
|
2010-05-06 |
2016-09-13 |
Ceres, Inc. |
Transgenic plants having increased biomass
|
WO2011141456A1
(en)
|
2010-05-10 |
2011-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
|
MX342130B
(en)
|
2010-05-11 |
2016-09-14 |
Dow Agrosciences Llc * |
Spnk strains.
|
US8658780B2
(en)
|
2010-05-18 |
2014-02-25 |
California Institute Of Technology |
Triggered covalent probes for imaging and silencing genetic expression
|
KR101223660B1
(en)
|
2010-05-20 |
2013-01-17 |
광주과학기술원 |
Pharmaceutical Compositions for Preventing or Treating Arthritis Comprising HIF-2α Inhibitor as an Active Ingredient
|
CA2800065A1
(en)
|
2010-05-21 |
2011-11-24 |
Peptimed, Inc. |
Reagents and methods for treating cancer
|
KR20180099900A
(en)
|
2010-05-26 |
2018-09-05 |
셀렉타 바이오사이언시즈, 인크. |
Dose selection of adjuvanted synthetic nanocarriers
|
US20130145499A1
(en)
|
2010-05-28 |
2013-06-06 |
Willem Hendrik Vriezen |
Plants with Increased Fruit Size
|
US20130149320A1
(en)
|
2010-05-31 |
2013-06-13 |
Centre National De La Recherche Scientifique |
Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer
|
WO2011153323A2
(en)
|
2010-06-02 |
2011-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
DE102010022937A1
(en)
|
2010-06-04 |
2011-12-08 |
Universitätsklinikum Jena |
Cell-specific activatable biologically active molecules based on siRNA, methods for their activation and application kit for administration
|
GB201009601D0
(en)
|
2010-06-08 |
2010-07-21 |
Devgen Private Ltd |
Method for down-grading gene expression in fungi
|
JP6180930B2
(en)
|
2010-06-16 |
2017-08-16 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Methods and compositions for stimulating reepithelialization during wound healing processes
|
JP5912111B2
(en)
|
2010-06-21 |
2016-04-27 |
ノボザイムス,インコーポレイティド |
Polypeptide having C4-dicarboxylic acid transporter activity derived from Aspergillus acreatus and polynucleotide encoding the same
|
WO2011163466A1
(en)
|
2010-06-23 |
2011-12-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (nrg-1)
|
WO2012000904A1
(en)
|
2010-06-28 |
2012-01-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical composition for use in the treatment of glaucoma
|
CN103108951A
(en)
|
2010-06-30 |
2013-05-15 |
诺维信公司 |
Polypeptides having beta-glucosidase activity and polynucleotides encoding same
|
CN103080320A
(en)
|
2010-07-01 |
2013-05-01 |
纳幕尔杜邦公司 |
Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding PAE and PAE-like polypeptides
|
EP2593468B1
(en)
|
2010-07-12 |
2020-06-10 |
The State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center |
Isolated polynucleotides and methods and plants using same for regulating plant acidity
|
US8877438B2
(en)
|
2010-07-20 |
2014-11-04 |
California Institute Of Technology |
Self-assembled polynucleotide structure
|
US9834439B2
(en)
|
2010-07-20 |
2017-12-05 |
California Institute Of Technology |
Biomolecular self-assembly
|
US8962241B2
(en)
|
2010-07-20 |
2015-02-24 |
California Institute Of Technology |
Triggered molecular geometry based bioimaging probes
|
US9040671B2
(en)
|
2010-07-23 |
2015-05-26 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods for cancer management targeting Co-029
|
EP3330377A1
(en)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
EP2603587B1
(en)
|
2010-08-09 |
2015-10-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment and prevention of hiv-1 infections
|
EP2603591A1
(en)
|
2010-08-13 |
2013-06-19 |
Pioneer Hi-Bred International Inc. |
Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (hppd) activity
|
CN108676800B
(en)
|
2010-08-17 |
2022-11-11 |
瑟纳治疗公司 |
RNA interference-mediated suppression of Hepatitis B Virus (HBV) gene expression using short interfering nucleic acids (siNA)
|
EP3636778B1
(en)
|
2010-08-18 |
2022-01-12 |
Fred Hutchinson Cancer Research Center |
Agents for use in treating facioscapulohumeral dystrophy (fshd)
|
WO2012027206A1
(en)
|
2010-08-24 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
WO2012027467A1
(en)
|
2010-08-26 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2012030845A2
(en)
|
2010-08-30 |
2012-03-08 |
Novozymes A/S |
Polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and polynucleotides encoding same
|
EP3470514A1
(en)
|
2010-08-30 |
2019-04-17 |
Novozymes A/S |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
WO2012030858A2
(en)
|
2010-08-30 |
2012-03-08 |
Novozymes A/S |
Polypeptides having hemicellulolytic activity and polynucleotides encoding same
|
WO2012030811A1
(en)
|
2010-08-30 |
2012-03-08 |
Novozymes A/S |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
US8624082B2
(en)
|
2010-08-30 |
2014-01-07 |
Novozymes A/S |
Polypeptides having xylanase activity and polynucleotides encoding same
|
WO2012030844A1
(en)
|
2010-08-30 |
2012-03-08 |
Novozymes A/S |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
US20130224192A1
(en)
|
2010-09-02 |
2013-08-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for the prognosis of the progression of cancer
|
US20130195863A1
(en)
|
2010-09-28 |
2013-08-01 |
Philippe Clezardin |
Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases
|
EP2622095B1
(en)
|
2010-10-01 |
2016-09-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the progression and treating a chronic kidney disease in a patient
|
WO2012051055A2
(en)
|
2010-10-06 |
2012-04-19 |
Bp Corporation North America Inc. |
Variant cbh i polypeptides
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
WO2012051491A1
(en)
|
2010-10-14 |
2012-04-19 |
The United States Of America, As Represented By The Secretary National Institutes Of Health |
Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
|
BR112013009196A2
(en)
|
2010-10-15 |
2020-08-25 |
The Trustees Of Columbia University In The City Of New York |
uses of polypeptide to reduce fatty acid acquisition and food intake, as well as promoting satiety related to obesity
|
CN107828820B
(en)
|
2010-10-27 |
2022-06-07 |
学校法人自治医科大学 |
Adeno-associated virus particles for gene transfer into nervous system cells
|
US8822427B2
(en)
|
2010-10-27 |
2014-09-02 |
Harrisvaccines |
Methods and compositions to protect aquatic invertebrates from disease
|
WO2012058072A1
(en)
|
2010-10-27 |
2012-05-03 |
Harrisvaccines, Inc |
Method of rapidly producing vaccines for animals
|
US10004797B2
(en)
|
2010-10-27 |
2018-06-26 |
Harrisvaccines, Inc. |
Method of rapidly producing improved vaccines for animals
|
WO2012058223A1
(en)
|
2010-10-27 |
2012-05-03 |
Ceres, Inc. |
Transgenic plants having altered biomass composition
|
WO2012058566A1
(en)
|
2010-10-29 |
2012-05-03 |
Novozymes A/S |
Polypeptides having succinyl-coa:aceto acetate transferase activity and polynucleotides encoding same
|
ES2663009T3
(en)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibition of RNA-mediated gene expression using short interference nucleic acids (ANic)
|
CA2816584A1
(en)
|
2010-11-01 |
2012-05-10 |
Peptimed, Inc. |
Compositions of a peptide-based system for cell-specific targeting
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
SI2635299T1
(en)
|
2010-11-02 |
2020-02-28 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
RU2619636C2
(en)
|
2010-11-04 |
2017-05-17 |
Ариста Сириэл Текнолоджиз Пти Лтд |
High amylose wheat
|
EP2635594B1
(en)
|
2010-11-04 |
2017-01-11 |
Novozymes Inc. |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
SG189475A1
(en)
|
2010-11-05 |
2013-05-31 |
Transbio Ltd |
Markers of endothelial progenitor cells and uses thereof
|
CN110123830A
(en)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare
|
DK2638153T3
(en)
|
2010-11-12 |
2017-10-16 |
Novozymes Inc |
POLYPEPTIDES WITH ENDOGLUCANASE ACTIVITY AND POLYNUCLEOTIDES CODING THEM
|
EP2455456A1
(en)
|
2010-11-22 |
2012-05-23 |
Institut Curie |
Use of kinesin inhibitors in HIV infection treatment and a method for screening them
|
EP2643479B1
(en)
|
2010-11-22 |
2017-09-13 |
Rosetta Genomics Ltd |
Methods and materials for classification of tissue of origin of tumor samples
|
US20130336979A1
(en)
|
2010-12-01 |
2013-12-19 |
Fatima Smih |
Diagnostic and treatment of chronic heart failure
|
WO2012074868A2
(en)
|
2010-12-03 |
2012-06-07 |
Ms Technologies, Llc |
Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells
|
EP2646555B1
(en)
|
2010-12-03 |
2015-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of heart failure
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
WO2012078536A2
(en)
|
2010-12-06 |
2012-06-14 |
Quark Pharmaceuticals, Inc. |
Double stranded oligonucleotide compounds comprising positional modifications
|
US10202615B2
(en)
|
2010-12-10 |
2019-02-12 |
Vanderbilt University |
Mammalian genes involved in toxicity and infection
|
US9617542B2
(en)
|
2010-12-14 |
2017-04-11 |
The United States of America, as representd by The Secretary of Agriculture |
Lepidopteran moth control using double-stranded RNA constructs
|
BR112013014698A2
(en)
|
2010-12-22 |
2017-03-07 |
E I Du Point De Nemours & Company |
dna construct, vector, plant cell, plant, transgenic plant-derived seed, method for expression of a nucleotide sequence in a plant, method for expression of a nucleotide sequence in a plant cell, method for selectively expressing a nucleotide sequence in corn root, stem, grain and tassel tissues
|
BR112013014988A2
(en)
|
2010-12-22 |
2017-06-27 |
Du Pont |
isolated nucleic acid molecule, dna construct, vector, plant cell, plant, transgenic seed from plant, method for expression of a nucleotide sequence in a plant, method for expression of a nucleotide sequence in a plant cell, method for selectively express a nucleotide sequence in green corn plant tissues
|
WO2012088420A1
(en)
|
2010-12-22 |
2012-06-28 |
The Trustees Of Columbia University In The City Of New York |
Histone acetyltransferase modulators and usese thereof
|
US8883757B2
(en)
|
2011-01-03 |
2014-11-11 |
Rosetta Genomics Ltd. |
Compositions and methods for treatment of ovarian cancer
|
CN103547288B
(en)
|
2011-01-10 |
2016-03-16 |
密执安大学评议会 |
Stem cell factor inhibitor
|
DK2668269T3
(en)
|
2011-01-26 |
2018-04-09 |
Novozymes Inc |
POLYPEPTIDES WITH ENDOGLUCANASE ACTIVITY AND POLYNUCLEOTIDES CODING THEM
|
WO2012103350A1
(en)
|
2011-01-26 |
2012-08-02 |
Novozymes A/S |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
EP2487242A1
(en)
|
2011-02-09 |
2012-08-15 |
Ruprecht-Karls-Universität Heidelberg |
B-type plexin antagonists and uses thereof
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
ES2680636T3
(en)
|
2011-02-14 |
2018-09-10 |
Revivicor Inc. |
Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
|
EP2675900B1
(en)
|
2011-02-15 |
2017-09-06 |
Pioneer Hi-Bred International, Inc. |
Root-preferred promoter and methods of use
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
US9796979B2
(en)
|
2011-03-03 |
2017-10-24 |
Quark Pharmaceuticals Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
CN103562387A
(en)
|
2011-03-03 |
2014-02-05 |
夸克医药公司 |
Oligonucleotide modulators of the toll-like receptor pathway
|
JP6000287B2
(en)
|
2011-03-03 |
2016-09-28 |
クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. |
Compositions and methods for treating lung disease and injury
|
EP2684045B2
(en)
|
2011-03-09 |
2023-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods to characterize patients suffering from hemolysis
|
US9409958B2
(en)
|
2011-03-10 |
2016-08-09 |
Novozymes, Inc. |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
JP2014510526A
(en)
|
2011-03-15 |
2014-05-01 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
Diagnosis and treatment of vascular-related macular disease and its symptoms
|
US10184942B2
(en)
|
2011-03-17 |
2019-01-22 |
University Of South Florida |
Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
|
US8648230B2
(en)
|
2011-03-18 |
2014-02-11 |
Ms Technologies, Llc |
Regulatory regions preferentially expressing in non-pollen plant tissue
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
CA2832680A1
(en)
|
2011-04-13 |
2012-10-18 |
Eric Ogier-Denis |
Screening methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases
|
CN103547588B
(en)
|
2011-04-13 |
2016-06-29 |
Isis制药公司 |
The antisense that PTP1B expresses regulates
|
KR101291668B1
(en)
|
2011-04-21 |
2013-08-01 |
서울대학교산학협력단 |
Shuttle Vectors for Mycobacteria-Escherichia coli and Uses Thereof
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
US9926547B2
(en)
|
2011-04-28 |
2018-03-27 |
Novozymes, Inc. |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
US20140050710A1
(en)
|
2011-04-28 |
2014-02-20 |
Universite Montpellier I |
Methods for preparing accessory cells and uses thereof for preparing activated nk cells
|
EP2794643A1
(en)
*
|
2011-04-29 |
2014-10-29 |
Pioneer Hi-Bred International Inc. |
Down-regulation of a homeodomain-leucine zipper i-class homeobox gene for improved plant performance
|
DK2520653T3
(en)
|
2011-05-03 |
2017-07-03 |
Dow Agrosciences Llc |
INTEGRATION OF GENES IN THE CHROMOSOME OF SACCHAROPOLYSPORA SPINOSA
|
AU2012250568B2
(en)
|
2011-05-05 |
2017-06-29 |
Matinas Biopharma Nanotechnologies, Inc. |
Cochleate compositions and methods of making and using same
|
EP2527432A1
(en)
|
2011-05-23 |
2012-11-28 |
Novozymes A/S |
Bi-directional cytosine deaminase-encoding selection marker
|
EP2527448A1
(en)
|
2011-05-23 |
2012-11-28 |
Novozymes A/S |
Simultaneous site-specific integrations of multiple gene-copies in filamentous fungi
|
WO2012160551A2
(en)
|
2011-05-24 |
2012-11-29 |
Rosetta Genomics Ltd |
Methods and compositions for determining heart failure or a risk of heart failure
|
ES2597052T3
(en)
|
2011-05-25 |
2017-01-13 |
Université Paris Descartes |
ERK inhibitors for use in the treatment of spinal muscular atrophy
|
WO2012163848A1
(en)
|
2011-05-27 |
2012-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of crohn's disease
|
WO2012170304A2
(en)
|
2011-06-02 |
2012-12-13 |
The Regents Of The University Of California |
Plants with elevated levels of glucan
|
DK3011974T3
(en)
|
2011-06-02 |
2018-11-12 |
Univ Louisville Res Found Inc |
Anti-nucleolin agent-conjugated nanoparticles
|
TWI658830B
(en)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Retinoid-liposomes for enhancing modulation of hsp47 expression
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
GB201109965D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating estrogen receptor alpher(ER) positive cancer
|
MY166780A
(en)
|
2011-06-10 |
2018-07-23 |
Temasek Life Sciences Laboratory Ltd |
Genetic manipulation and expression system for pucciniomycotina and ustilaginomycotina subphyla
|
GB201109966D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating pten mutated or deficient cancer
|
CN112111492A
(en)
|
2011-06-21 |
2020-12-22 |
阿尔尼拉姆医药品有限公司 |
Compositions and methods for inhibiting expression of apolipoprotein C-III (APOC3) gene
|
CA2839896A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
WO2012177921A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc |
Compositions and methods for inhibiting hepcidin antimicrobial peptide (hamp) or hamp-related gene expression
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
WO2012175711A1
(en)
|
2011-06-24 |
2012-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for predicting the responsiveness of a patient affected with an osteosarcoma to a chemotherapy
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
RS55088B1
(en)
|
2011-07-06 |
2016-12-30 |
Sykehuset Sorlandet Hf |
Egfr targeted therapy
|
EP2734632A1
(en)
|
2011-07-21 |
2014-05-28 |
The Regents of the University of California |
Transcription factors for the production of cellulose degrading enzymes
|
EP2735613A1
(en)
|
2011-07-22 |
2014-05-28 |
Public University Corporation Yokohama City University |
TECHNIQUE FOR CLEAVING OUT PART OF poly(A) CHAIN AND/OR 3'-TERMINAL SEQUENCE OF mRNA TO INHIBIT TRANSLATION REACTION
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
WO2013014262A1
(en)
|
2011-07-27 |
2013-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating myhre syndrome
|
US9382559B2
(en)
|
2011-08-10 |
2016-07-05 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
US9487761B2
(en)
|
2011-08-10 |
2016-11-08 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
WO2013021059A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
WO2013021065A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
WO2013021060A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
WO2013021064A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
WO2013021062A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
US20140215655A1
(en)
*
|
2011-08-12 |
2014-07-31 |
Bayer Cropscience Nv |
Guard cell-specific expression of transgenes in cotton
|
US20140271680A1
(en)
|
2011-08-12 |
2014-09-18 |
Universite Paris-Est Creteil Val De Marne |
Methods and pharmaceutical compositions for treatment of pulmonary hypertension
|
WO2013028927A1
(en)
|
2011-08-24 |
2013-02-28 |
Novozymes, Inc. |
Aspergillus fumigatus cellulolytic enzyme compositions and uses thereof
|
CA2846398A1
(en)
|
2011-08-24 |
2013-02-28 |
Novozymes, Inc. |
Cellulolytic enzyme compositions and uses thereof
|
CA2845179A1
(en)
|
2011-08-31 |
2013-03-07 |
Genentech, Inc. |
Diagnostic markers
|
CN103930165B
(en)
|
2011-09-02 |
2018-05-25 |
纽约市哥伦比亚大学理事会 |
To treat CaMKII, IP3R of the metabolic disorder of obesity, calcineurin, P38 and MK2/3 inhibitor
|
EA201490553A1
(en)
|
2011-09-02 |
2014-08-29 |
Новартис Аг |
ORGANIC COMPOSITIONS FOR THE TREATMENT OF HSF1-CONNECTED DISEASES
|
KR20140067092A
(en)
|
2011-09-07 |
2014-06-03 |
마리나 바이오테크, 인크. |
Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
|
AU2012306285B2
(en)
|
2011-09-07 |
2017-05-18 |
Deutsches Krebsforschungszentrum |
Means and methods for treating and/or preventing natural AHR ligand-dependent cancer
|
EP2747774A4
(en)
|
2011-09-09 |
2015-02-11 |
Biomed Realty L P |
Methods and compositions for controlling assembly of viral proteins
|
WO2013036799A2
(en)
|
2011-09-09 |
2013-03-14 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving nkg2d inhibitors and cancer
|
UY34333A
(en)
*
|
2011-09-13 |
2013-04-30 |
Monsanto Technology Llc |
? METHODS AND COMPOSITIONS FOR WEED CONTROL, AND METHODS TO REDUCE THE EXPRESSION OF ENZYME DHPS?
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
EP2756085B1
(en)
*
|
2011-09-13 |
2019-03-20 |
Monsanto Technology LLC |
Methods and compositions for weed control
|
MX350774B
(en)
*
|
2011-09-13 |
2017-09-15 |
Monsanto Technology Llc |
Methods and compositions for weed control.
|
BR112014005795A2
(en)
*
|
2011-09-13 |
2020-12-08 |
Monsanto Technology Llc |
methods of controlling plants, reducing the expression of a plant's hppd gene, preparing a nucleotide, and identifying polynucleotides useful in modulating the expression of the hppd gene in the external treatment of a plant, compositions and cassette of microbial expression
|
US20140308705A1
(en)
|
2011-09-20 |
2014-10-16 |
Novozymes A/S |
Polypeptides Having Cellulolytic Enhancing Activity And Polynucleotides Encoding Same
|
US9352312B2
(en)
|
2011-09-23 |
2016-05-31 |
Alere Switzerland Gmbh |
System and apparatus for reactions
|
WO2013055530A1
(en)
|
2011-09-30 |
2013-04-18 |
Genentech, Inc. |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
|
EP3616690A1
(en)
|
2011-10-03 |
2020-03-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of th2 mediated diseases
|
UA115132C2
(en)
|
2011-10-04 |
2017-09-25 |
Байєр Інтелекчуал Проперті Гмбх |
RNAi FOR THE CONTROL OF FUNGI AND OOMYCETES BY INHIBITING SACCHAROPINE DEHYDROGENASE GENE
|
EP2766733A2
(en)
|
2011-10-14 |
2014-08-20 |
Inserm |
Biomarkers of renal disorders
|
ES2687951T3
(en)
|
2011-10-14 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Anti-HtrA1 antibodies and procedures for use
|
EP3597644B1
(en)
|
2011-10-18 |
2021-09-29 |
Dicerna Pharmaceuticals, Inc. |
Amine cationic lipids and uses thereof
|
EP2768971A1
(en)
|
2011-10-20 |
2014-08-27 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods for the detection and the treatment of cardiac remodeling
|
BR112014010546B1
(en)
|
2011-11-02 |
2021-04-13 |
Ceres, Inc |
METHOD OF INCREASING PLANT Yield IN SOIL CONTAINING HIGH LEVELS OF AL3 +, METHOD OF INCREASING TOLERANCE IN A PLANT
|
SG11201401648RA
(en)
|
2011-11-03 |
2014-05-29 |
Quark Pharmaceuticals Inc |
Methods and compositions for neuroprotection
|
EP2773183A4
(en)
|
2011-11-04 |
2015-04-15 |
Arista Cereal Technologies Pty Ltd |
High amylose wheat - ii
|
WO2013068836A1
(en)
|
2011-11-07 |
2013-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
|
EP2776565A1
(en)
|
2011-11-08 |
2014-09-17 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
EP3342860A1
(en)
|
2011-11-22 |
2018-07-04 |
Novozymes, Inc. |
Polypeptides having beta-xylosidase activity and polynucleotides encoding same
|
EP2782933A1
(en)
|
2011-11-22 |
2014-10-01 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical compositions for reducing airway hyperresponse
|
BR112014012417A2
(en)
|
2011-12-01 |
2017-06-06 |
Novozymes Inc |
isolated polypeptide and polynucleotide, recombinant host cell, methods for producing a polypeptide, a mutant of a source cell, and a protein, and for inhibiting expression of a polypeptide, transgenic plant, part of the plant or cell of plant, rna molecule, processes for degrading or converting a cellulosic or xylan-containing material, to produce a fermentation product, and fermentation of a cellulosic or xylan-containing material, and integral broth formulation or cell culture composition
|
WO2013079531A2
(en)
|
2011-12-02 |
2013-06-06 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
US9404093B2
(en)
|
2011-12-02 |
2016-08-02 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
BR112014013853A2
(en)
|
2011-12-09 |
2020-01-14 |
Ceres Inc |
use of an isolated nucleic acid, method of obtaining a transgenic plant cell, method of obtaining a transgenic plant, method of producing a plant, method of producing biomass, method of biomass processing, method of altering the composition of biomass , biomass composition modulation method, production method of a forage product
|
UA116097C2
(en)
|
2011-12-11 |
2018-02-12 |
Зе Стейт Оф Ізраел, Міністрі Оф Агрікалче Енд Руерал Девелопмент, Агрікалчерал Рісьоч Організейшн, (А.Р.О.), Волкані Сентре |
Methods of modulating stomata conductance and plant expression constructs for executing same
|
EP2791330B1
(en)
|
2011-12-16 |
2017-07-26 |
Novozymes, Inc. |
Polypeptides having laccase activity and polynucleotides encoding same
|
WO2013096992A1
(en)
|
2011-12-27 |
2013-07-04 |
Commonwealth Scientific And Industrial Reserach Organisation |
Simultaneous gene silencing and supressing gene silencing in the same cell
|
CA2860434C
(en)
|
2011-12-27 |
2023-08-08 |
Commonwealth Scientific And Industrial Research Organisation |
Processes for producing lipids
|
AU2012327162A1
(en)
|
2011-12-27 |
2013-07-11 |
Commonwealth Scientific And Industrial Research Organisation |
Production of dihydrosterculic acid and derivatives thereof
|
WO2013101783A2
(en)
|
2011-12-30 |
2013-07-04 |
Bio-Rad Laboratories, Inc. |
Methods and compositions for performing nucleic acid amplification reactions
|
US20130180008A1
(en)
|
2012-01-06 |
2013-07-11 |
Pioneer Hi Bred International Inc |
Ovule Specific Promoter and Methods of Use
|
US9006515B2
(en)
|
2012-01-06 |
2015-04-14 |
Pioneer Hi Bred International Inc |
Pollen preferred promoters and methods of use
|
CA2860611A1
(en)
|
2012-01-06 |
2013-07-11 |
Pioneer Hi-Bred International, Inc. |
Compositions and methods for the expression of a sequence in a reproductive tissue of a plant
|
CA2860676A1
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
EP2802215B1
(en)
|
2012-01-11 |
2021-09-15 |
The Australian National University |
Method for modulating plant root architecture
|
WO2013109738A1
(en)
|
2012-01-17 |
2013-07-25 |
The Trustees Of Columbia University In The City Of New York |
Novel phosphodiesterase inhibitors and uses thereof
|
WO2013113762A1
(en)
|
2012-01-31 |
2013-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
|
UY34607A
(en)
|
2012-02-01 |
2013-09-02 |
Dow Agrosciences Llc |
GLIFOSATO RESISTANT PLANTS AND ASSOCIATED METHODS.
|
WO2013121034A1
(en)
|
2012-02-17 |
2013-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing adipose tissue inflammation
|
BR112014018876A2
(en)
|
2012-02-20 |
2017-07-04 |
Novozymes As |
isolated polypeptide with endoglycanase activity, composition, isolated polynucleotide, nucleic acid construct or expression vector, recombinant host cell, and method of producing a polypeptide
|
US9663560B2
(en)
*
|
2012-02-28 |
2017-05-30 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Cotton PHYA1 RNAi improves fiber quality, root elongation, flowering, maturity and yield potential in Gossypium hirsutum L
|
MX2014010953A
(en)
|
2012-03-16 |
2014-10-13 |
Hoffmann La Roche |
Methods of treating melanoma with pak1 inhibitors.
|
EP3459565A1
(en)
|
2012-03-29 |
2019-03-27 |
The Trustees of Columbia University in the City of New York |
Methods for treating hair loss disorders
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP2650013A1
(en)
|
2012-04-10 |
2013-10-16 |
Deutsches Krebsforschungszentrum |
Inhibitors of Receptor for Advanced Glycation-End products (RAGE) for use in treating and/or preventing inflammation- and/or damage-induced cancer
|
WO2013158032A1
(en)
|
2012-04-19 |
2013-10-24 |
Temasek Life Sciences Laboratory Limited |
Methods for increasing cotton fiber length
|
US10155959B2
(en)
|
2012-04-20 |
2018-12-18 |
Futuragene Israel Ltd. |
Bronze bug control agents
|
CN104508134A
(en)
|
2012-04-23 |
2015-04-08 |
富优基尼以色列股份有限公司 |
Glycaspis brimblecombei control agents
|
EP2841570B1
(en)
|
2012-04-23 |
2017-12-20 |
Novozymes A/S |
Polypeptides having glucuronyl esterase activity and polynucleotides encoding same
|
EP2841569A2
(en)
|
2012-04-23 |
2015-03-04 |
Novozymes A/S |
Polypeptides having alpha-glucuronidase activity and polynucleotides encoding same
|
WO2013159149A1
(en)
|
2012-04-25 |
2013-10-31 |
Commonwealth Scientific And Industrial Research Organisation |
High oleic acid oils
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
EP2844668A1
(en)
|
2012-05-03 |
2015-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation
|
WO2013167582A1
(en)
|
2012-05-09 |
2013-11-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
|
WO2013171296A1
(en)
|
2012-05-16 |
2013-11-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Diagnostic and treatment of sarcoidosis
|
EP2852679A1
(en)
|
2012-05-22 |
2015-04-01 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for diagnosing and treating focal segmental glomerulosclerosis
|
DK2858647T3
(en)
|
2012-06-08 |
2018-08-20 |
Sensorion |
H4 RECEPTOR INHIBITORS FOR TINNITUS TREATMENT
|
WO2013187556A1
(en)
|
2012-06-14 |
2013-12-19 |
Scripps Korea Antibody Institute |
Novel antibody specific for clec14a and uses thereof
|
US10689660B2
(en)
|
2012-06-22 |
2020-06-23 |
The Regents Of The University Of California |
Compositions and methods for mediating plant stomatal development in response to carbon dioxide and applications for engineering drought tolerance in plants
|
WO2014001451A1
(en)
|
2012-06-27 |
2014-01-03 |
Metanomics Health Gmbh |
Methods for identifying diabetes drugs
|
WO2014006025A2
(en)
|
2012-07-02 |
2014-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Marker of pathogenicity in salmonella
|
US20150184155A1
(en)
|
2012-07-18 |
2015-07-02 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for preventing and treating chronic kidney disease (ckd)
|
ES2817897T3
(en)
|
2012-07-23 |
2021-04-08 |
La Jolla Inst Allergy & Immunology |
PTPRS and proteoglycans in autoimmune disease
|
AU2013308519A1
(en)
|
2012-08-31 |
2015-04-09 |
The General Hospital Corporation |
Biotin complexes for treatment and diagnosis of Alzheimer's disease
|
EP2897633B1
(en)
|
2012-09-18 |
2020-01-01 |
UTI Limited Partnership |
Treatment of pain by inhibition of usp5 de-ubiquitinase
|
AU2013318338B2
(en)
|
2012-09-21 |
2017-05-25 |
Intensity Therapeutics, Inc |
Method of treating cancer
|
US20150259701A1
(en)
*
|
2012-10-03 |
2015-09-17 |
Futuragene Israel Ltd. |
Gall wasp control agents
|
WO2014053871A1
(en)
|
2012-10-04 |
2014-04-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for screening a compound capable of inhibiting the notch1 transcriptional activity
|
WO2014055825A1
(en)
|
2012-10-04 |
2014-04-10 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
A formulation of mycobacterial components as an adjuvant for inducing th17 responses
|
CA2887069A1
(en)
|
2012-10-05 |
2014-04-10 |
Bioneer Corporation |
Amphiregulin-specific double-helical oligo-rna, double-helical oligo-rna structure comprising double-helical oligo-rna, and composition for preventing or treating respiratory diseases containing same
|
WO2014058896A1
(en)
|
2012-10-08 |
2014-04-17 |
Novozymes A/S |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
CA2886120A1
(en)
|
2012-10-08 |
2014-04-17 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
|
WO2014057045A1
(en)
|
2012-10-10 |
2014-04-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of gastrointestinal stromal tumors
|
CA2887571A1
(en)
|
2012-10-11 |
2014-04-17 |
Pioneer Hi-Bred International, Inc. |
Guard cell promoters and uses thereof
|
WO2014056919A2
(en)
|
2012-10-12 |
2014-04-17 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
US9499801B2
(en)
|
2012-10-12 |
2016-11-22 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
CN104704115B
(en)
|
2012-10-12 |
2018-11-02 |
诺维信公司 |
With the active polypeptide of peroxygenases
|
WO2014056927A2
(en)
|
2012-10-12 |
2014-04-17 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
US9458435B2
(en)
|
2012-10-12 |
2016-10-04 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
WO2014056921A2
(en)
|
2012-10-12 |
2014-04-17 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
US9453207B2
(en)
|
2012-10-12 |
2016-09-27 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
AU2013336237A1
(en)
|
2012-10-22 |
2015-06-11 |
Sabag-Rfa Ltd |
A system for delivering therapeutic agents into living cells and cells nuclei
|
CA2887711A1
(en)
|
2012-10-23 |
2014-05-01 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
IN2015DN03795A
(en)
|
2012-10-24 |
2015-10-02 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
|
US20150275194A1
(en)
|
2012-10-24 |
2015-10-01 |
Novozymes A/S |
Polypeptides Having Cellulolytic Enhancing Activity And Polynucleotides Encoding Same
|
WO2014064192A1
(en)
|
2012-10-26 |
2014-05-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction
|
EP2911681A1
(en)
|
2012-10-26 |
2015-09-02 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
|
EP2914260A1
(en)
|
2012-10-31 |
2015-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
EP2917347B1
(en)
|
2012-11-08 |
2019-01-02 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of bone metastases
|
EP2732815A1
(en)
|
2012-11-16 |
2014-05-21 |
Neurochlore |
Modulators of intracellular chloride concentration for treating fragile X syndrome
|
WO2014090765A1
(en)
|
2012-12-12 |
2014-06-19 |
Bayer Cropscience Ag |
Use of 1-[2-fluoro-4-methyl-5-(2,2,2-trifluoroethylsulfinyl)phenyl]-5-amino-3-trifluoromethyl)-1 h-1,2,4 tfia zole for controlling nematodes in nematode-resistant crops
|
US9486473B2
(en)
|
2012-12-13 |
2016-11-08 |
Ymir Genomics, Llc |
MicroRNAs and uses thereof
|
AU2013358981A1
(en)
|
2012-12-14 |
2015-06-04 |
Novozymes A/S |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
US10308954B2
(en)
|
2012-12-14 |
2019-06-04 |
Icar |
Method for the control of nematodes in plants
|
WO2014099798A1
(en)
|
2012-12-19 |
2014-06-26 |
Novozymes A/S |
Polypeptides having cellulolytic enhancinc activity and polynucleotides encoding same
|
EP2935333A1
(en)
|
2012-12-21 |
2015-10-28 |
Sykehuset Sorlandet HF |
Egfr targeted therapy of neurological disorders and pain
|
EP2938628A4
(en)
|
2012-12-24 |
2016-10-19 |
Novozymes As |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
WO2014113541A1
(en)
|
2013-01-16 |
2014-07-24 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Attenuated chlamydia vaccine
|
US20150377888A1
(en)
|
2013-02-01 |
2015-12-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for Predicting and Preventing Metastasis in Triple Negative Breast Cancers
|
AU2014212081A1
(en)
|
2013-02-04 |
2015-08-13 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a Wnt pathway inhibitor
|
WO2014122199A1
(en)
|
2013-02-06 |
2014-08-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of chronic intestinal pseudo-obstruction
|
WO2014128127A1
(en)
|
2013-02-19 |
2014-08-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of prostate cancer
|
EP2767594A1
(en)
|
2013-02-19 |
2014-08-20 |
Deutsches Krebsforschungszentrum |
The signature of Wnt/ß-catenin signaling in Cancer
|
EP2961412A4
(en)
|
2013-02-26 |
2016-11-09 |
Triact Therapeutics Inc |
Cancer therapy
|
US10398661B2
(en)
|
2013-02-28 |
2019-09-03 |
The Board Of Regents Of The University Of Texas System |
Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers
|
WO2014135655A1
(en)
|
2013-03-06 |
2014-09-12 |
Institut Curie |
Compositions and methods for treating muscle-invasive bladder cancer
|
EA030650B1
(en)
|
2013-03-08 |
2018-09-28 |
Новартис Аг |
Lipids and lipid compositions for the delivery of active agents
|
US9243258B2
(en)
|
2013-03-12 |
2016-01-26 |
Pioneer Hi Bred International Inc |
Root-preferred promoter and methods of use
|
US9273322B2
(en)
|
2013-03-12 |
2016-03-01 |
Pioneer Hi Bred International Inc |
Root-preferred promoter and methods of use
|
EP2968424B1
(en)
|
2013-03-13 |
2020-01-22 |
Geneweave Biosciences Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
WO2014140165A1
(en)
|
2013-03-14 |
2014-09-18 |
Dsm Ip Assets B.V. |
Cell wall deconstruction enzymes of paecilomyces byssochlamydoides and uses thereof
|
WO2014140167A1
(en)
|
2013-03-14 |
2014-09-18 |
Dsm Ip Assets B.V. |
Cell wall deconstruction enzymes of malbranchea cinnamomea and uses thereof
|
US9546364B2
(en)
|
2013-03-15 |
2017-01-17 |
Carnegie Mellon University |
Synthetic lariat RNA for RNA interference
|
CA2907152A1
(en)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Fusion proteins and methods thereof
|
JP6566933B2
(en)
|
2013-03-15 |
2019-08-28 |
サッター ベイ ホスピタルズ |
FALZ for use as a target for therapy to treat cancer
|
ES2731232T3
(en)
|
2013-03-15 |
2019-11-14 |
Inst Nat Sante Rech Med |
Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction
|
WO2014147246A1
(en)
|
2013-03-21 |
2014-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
WO2014170712A1
(en)
|
2013-04-15 |
2014-10-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Rac-1 inhibitors or pi3k inhibitors for preventing intestinal barrier dysfunction
|
CA2909434A1
(en)
|
2013-04-18 |
2014-10-23 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for inhibiting lymphocyte proliferation in a subject in need thereof
|
EP2989118A2
(en)
|
2013-04-26 |
2016-03-02 |
Oslo Universitetssykehus HF |
Compositions and methods for targeting antigen-presenting cells
|
EP2810952A1
(en)
|
2013-06-03 |
2014-12-10 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Novel pest control methods
|
EA035876B1
(en)
|
2013-06-13 |
2020-08-25 |
Коммонвелт Сайнтифик Энд Индастриэл Рисерч Организэйшн |
Barley with very low levels of hordeins
|
US10155001B2
(en)
|
2013-06-14 |
2018-12-18 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
RAC1 inhibitors for inducing bronchodilation
|
US20160145628A1
(en)
|
2013-06-18 |
2016-05-26 |
Ramot At Tel-Aviv University Ltd. |
Nanocarrier system for micrornas and uses thereof
|
EP3682873A1
(en)
|
2013-06-25 |
2020-07-22 |
The Walter and Eliza Hall Institute of Medical Research |
Smac mimetics for use in the treatment of persistent hiv infection
|
US9856472B2
(en)
|
2013-07-01 |
2018-01-02 |
California Institute Of Technology |
Small conditional RNAs
|
WO2015001053A1
(en)
|
2013-07-03 |
2015-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the screening of substances that may be useful for the prevention and treatment of infections by enterobacteriaceae family
|
AU2014284396A1
(en)
|
2013-07-03 |
2016-02-04 |
City Of Hope |
Anticancer combinations
|
WO2015006554A1
(en)
|
2013-07-10 |
2015-01-15 |
The Regents Of The University Of Michigan |
Therapeutic antibodies and uses thereof
|
WO2015009930A2
(en)
|
2013-07-17 |
2015-01-22 |
The Trustees Of Columbia University In The City Of New York |
Novel phosphodiesterase inhibitors and uses thereof
|
CN105452465B
(en)
|
2013-07-31 |
2019-06-21 |
奇比艾企业有限公司 |
Poly- alkylamine-the oligonucleotide compound of sphingolipid-
|
WO2015015498A1
(en)
|
2013-07-31 |
2015-02-05 |
Qbi Enterprises Ltd. |
Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
|
EP2835423A1
(en)
|
2013-08-09 |
2015-02-11 |
Commissariat à l'Énergie Atomique et aux Énergies Alternatives |
Ligase E3 RNF185 inhibitors and uses thereof
|
CA2923667A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutics, Inc. |
Cancer therapy
|
US20160201073A1
(en)
|
2013-09-11 |
2016-07-14 |
Pioneer Hi-Bred International, Inc. |
Plant regulatory elements and methods of use thereof
|
US10016424B2
(en)
|
2013-09-16 |
2018-07-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of epilepsy
|
WO2015049365A2
(en)
|
2013-10-03 |
2015-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
|
WO2015051044A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Novel formats for organic compounds for use in rna interference
|
EP3052107B1
(en)
|
2013-10-04 |
2018-05-02 |
Novartis AG |
Organic compounds to treat hepatitis b virus
|
US9988627B2
(en)
|
2013-10-04 |
2018-06-05 |
Novartis Ag |
Formats for organic compounds for use in RNA interference
|
EP3052464B1
(en)
|
2013-10-04 |
2020-04-15 |
Novartis AG |
3'end caps for rna-interferring agents for use in rna interference
|
WO2015054451A1
(en)
|
2013-10-09 |
2015-04-16 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
|
EP3055328A1
(en)
|
2013-10-11 |
2016-08-17 |
F. Hoffmann-La Roche AG |
Nsp4 inhibitors and methods of use
|
AR098055A1
(en)
|
2013-10-16 |
2016-04-27 |
The Australian Nat Univ |
METHOD TO MODULATE THE GROWTH OF PLANTS
|
EP2862928A1
(en)
|
2013-10-18 |
2015-04-22 |
Université de Strasbourg |
Dynamin 2 inhibitor for the treatment of centronuclear myopathies
|
JP6560205B2
(en)
|
2013-11-04 |
2019-08-14 |
ダウ アグロサイエンシィズ エルエルシー |
Optimal soybean locus
|
UA120503C2
(en)
|
2013-11-04 |
2019-12-26 |
Дау Агросайєнсиз Елелсі |
Optimal maize loci
|
BR102014027438B1
(en)
|
2013-11-04 |
2022-09-27 |
Dow Agrosciences Llc |
RECOMBINANT NUCLEIC ACID MOLECULE AND PRODUCTION METHOD OF A TRANSGENIC PLANT CELL
|
US10203327B2
(en)
|
2013-11-05 |
2019-02-12 |
Novartis Ag |
Organic compounds
|
US20170002064A1
(en)
|
2013-11-08 |
2017-01-05 |
The Board Of Regents Of The University Of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
WO2015070158A1
(en)
|
2013-11-11 |
2015-05-14 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety
|
EP3068440B1
(en)
|
2013-11-15 |
2020-01-08 |
Northwestern University |
Inhibition of oxidative stress in atrial fibrillation
|
US20170166939A1
(en)
|
2013-11-26 |
2017-06-15 |
Novozymes A/S |
Enzyme Compositions and Uses Thereof
|
JP6612246B2
(en)
|
2013-11-28 |
2019-11-27 |
シーエスエル、リミテッド |
How to treat nephropathy
|
US10934550B2
(en)
|
2013-12-02 |
2021-03-02 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer
|
EP3079475B1
(en)
|
2013-12-11 |
2020-10-07 |
Sloan-kettering Institute For Cancer Research |
Glucocorticoid inhibitors for treatment of prostate cancer
|
ES2851386T3
(en)
|
2013-12-18 |
2021-09-06 |
Csl Ltd |
Wound treatment method
|
EP4019506A1
(en)
|
2013-12-19 |
2022-06-29 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
ES2774968T3
(en)
|
2013-12-19 |
2020-07-23 |
Novartis Ag |
Lipids and lipid compositions for the administration of active agents
|
JP6490077B2
(en)
|
2013-12-20 |
2019-03-27 |
フォンダツィオーネ・イスティトゥート・イタリアーノ・ディ・テクノロジャFondazione Istituto Italiano Di Tecnologia |
Modulator of intracellular chloride concentration for treating Down's syndrome
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
US9274117B2
(en)
|
2013-12-21 |
2016-03-01 |
Catholic University Industry Academic |
Use of SIRT7 as novel cancer therapy target and method for treating cancer using the same
|
US10174111B2
(en)
|
2013-12-27 |
2019-01-08 |
National University Corporation Kochi University |
Therapeutic drug for malignant tumors
|
TW201527312A
(en)
|
2013-12-31 |
2015-07-16 |
Dow Agrosciences Llc |
Novel maize ubiquitin promoters
|
TW201527314A
(en)
|
2013-12-31 |
2015-07-16 |
Dow Agrosciences Llc |
Novel maize ubiquitin promoters
|
TW201527313A
(en)
|
2013-12-31 |
2015-07-16 |
Dow Agrosciences Llc |
Novel maize ubiquitin promoters
|
TW201527316A
(en)
|
2013-12-31 |
2015-07-16 |
Dow Agrosciences Llc |
Novel maize ubiquitin promoters
|
BR112016016098A2
(en)
|
2014-01-09 |
2017-08-08 |
Intracellular Therapies Inc |
ORGANIC COMPOUNDS
|
WO2015118167A1
(en)
|
2014-02-10 |
2015-08-13 |
Institut Curie |
Use of mcoln-1 modulators to regulate cell migration
|
TW201538518A
(en)
|
2014-02-28 |
2015-10-16 |
Dow Agrosciences Llc |
Root specific expression conferred by chimeric gene regulatory elements
|
RU2752933C2
(en)
|
2014-03-11 |
2021-08-11 |
Селлектис |
Method for creation of t-cells suitable for allogeneic transplantation
|
WO2015140351A1
(en)
|
2014-03-21 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing myelination
|
US9856475B2
(en)
|
2014-03-25 |
2018-01-02 |
Arcturus Therapeutics, Inc. |
Formulations for treating amyloidosis
|
WO2015148582A1
(en)
|
2014-03-25 |
2015-10-01 |
Arcturus Therapeutics, Inc. |
Transthyretin allele selective una oligomers for gene silencing
|
CN110846316B
(en)
|
2014-03-25 |
2023-10-31 |
阿克丘勒斯治疗公司 |
UNA oligomers with reduced off-target effects in gene silencing
|
JP6426268B2
(en)
|
2014-04-04 |
2018-11-21 |
バイオニア コーポレーションBioneer Corporation |
Novel double helix oligo RNA and pharmaceutical composition for preventing or treating fibrosis or respiratory disease comprising the same
|
WO2015158760A1
(en)
|
2014-04-16 |
2015-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ApoO FOR USE IN A METHOD FOR TREATING CANCER AND VARIOUS PATHOPHYSIOLOGICAL SITUATIONS
|
EP2932969A1
(en)
|
2014-04-17 |
2015-10-21 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Pancreatic cancer therapy and diagnosis
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
US9101100B1
(en)
|
2014-04-30 |
2015-08-11 |
Ceres, Inc. |
Methods and materials for high throughput testing of transgene combinations
|
US9545417B2
(en)
|
2014-05-01 |
2017-01-17 |
The Johns Hopkins University |
Methods of inhibiting cancer stem cells with HMGA1 inhibitors
|
WO2015171723A1
(en)
|
2014-05-06 |
2015-11-12 |
Research Development Foundation |
Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
|
KR101633876B1
(en)
|
2014-05-08 |
2016-06-28 |
고려대학교 산학협력단 |
REV-ERB Use of REV-ERB for treating affective and addictive disorders
|
KR101633881B1
(en)
|
2014-05-08 |
2016-06-28 |
고려대학교 산학협력단 |
REV-ERB Use of REV-ERB for treating dopamine-dependent disorders
|
US10273515B2
(en)
|
2014-06-06 |
2019-04-30 |
Novozymes A/S |
Enzyme compositions and uses thereof
|
WO2015200281A1
(en)
|
2014-06-24 |
2015-12-30 |
The Regents Of The University Of California |
Methods for production of xylosyl-xylitol oligomers
|
EP2966157B1
(en)
|
2014-07-07 |
2023-11-01 |
Nuseed Global Innovation Ltd |
Processes for producing industrial products from plant lipids
|
WO2016005422A1
(en)
|
2014-07-09 |
2016-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating neuropathic pain
|
AU2015289691B2
(en)
|
2014-07-15 |
2020-12-24 |
Ceres, Inc. |
Methods of increasing crop yield under abiotic stress
|
ES2949172T3
(en)
|
2014-07-16 |
2023-09-26 |
Novartis Ag |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
US20170209488A1
(en)
|
2014-07-17 |
2017-07-27 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for treating neuromuscular junction-related diseases
|
WO2016022947A1
(en)
|
2014-08-07 |
2016-02-11 |
The Johns Hopkins University |
Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases
|
CA2955828A1
(en)
|
2014-08-08 |
2016-02-11 |
Pioneer Hi-Bred International, Inc. |
Ubiquitin promoters and introns and methods of use
|
CN114796497A
(en)
|
2014-08-22 |
2022-07-29 |
广州英恩迈生物医药科技有限公司 |
Methods and compositions for treating and/or preventing diseases or disorders associated with abnormal levels and/or activity of the IFP35 protein family
|
EA201790434A1
(en)
|
2014-08-22 |
2017-07-31 |
Окленд Юнисервисиз Лимитед |
CHANNEL MODULATORS
|
EP3188746A4
(en)
|
2014-09-05 |
2018-05-02 |
The Johns Hopkins University |
Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
|
WO2016037053A1
(en)
|
2014-09-05 |
2016-03-10 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
KR102506169B1
(en)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
|
WO2016044271A2
(en)
|
2014-09-15 |
2016-03-24 |
Children's Medical Center Corporation |
Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
|
EP3193865B1
(en)
|
2014-09-19 |
2019-11-06 |
Memorial Sloan-Kettering Cancer Center |
Methods for treating brain metastasis
|
KR20170070068A
(en)
|
2014-09-25 |
2017-06-21 |
콜드스프링하버러보러토리 |
Treatment of rett syndrome
|
EP3197446A2
(en)
|
2014-09-26 |
2017-08-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cdc25a inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse
|
WO2016050680A1
(en)
|
2014-09-29 |
2016-04-07 |
Novozymes A/S |
Yoqm-inactivation in bacillus
|
US9705501B2
(en)
|
2014-10-01 |
2017-07-11 |
Maxim Integrated Products, Inc. |
Systems and methods for enhancing confidentiality via logic gate encryption
|
EP3009147A1
(en)
|
2014-10-16 |
2016-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating resistant glioblastoma
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
SG11201703132UA
(en)
|
2014-10-22 |
2017-05-30 |
Temasek Life Sciences Lab Ltd |
Terpene synthases from ylang ylang (cananga odorata var. fruticosa)
|
WO2016066608A1
(en)
|
2014-10-28 |
2016-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
|
WO2016066671A1
(en)
|
2014-10-29 |
2016-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating resistant cancers using progastrin inhibitors
|
CA2974716A1
(en)
|
2014-11-12 |
2016-05-19 |
Nmc, Inc. |
Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
EP3229842B1
(en)
|
2014-12-08 |
2022-07-06 |
The Board of Regents of The University of Texas System |
Lipocationic polymers and uses thereof
|
JP7105065B2
(en)
|
2014-12-15 |
2022-07-22 |
ダイセルナ ファーマシューティカルズ, インコーポレイテッド |
Ligand-modified double-stranded nucleic acid
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
EP3925979A3
(en)
|
2014-12-23 |
2022-03-23 |
The Trustees of Columbia University in the City of New York |
Fgfr-tacc fusion proteins and methods thereof
|
US10264976B2
(en)
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
KR102360028B1
(en)
*
|
2014-12-26 |
2022-02-08 |
삼성전자주식회사 |
Composition for reducing senescence of a cell or a subject comprising Smurf2 inhibitor and use thereof
|
US9434947B2
(en)
*
|
2015-01-20 |
2016-09-06 |
Oregon Health & Science University |
Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
|
US20180031579A1
(en)
|
2015-02-12 |
2018-02-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
|
WO2016131944A1
(en)
|
2015-02-20 |
2016-08-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cardiovascular diseases
|
US10500273B2
(en)
|
2015-03-02 |
2019-12-10 |
180 Therapeutics Lp |
Method of treating a localized fibrotic disorder using an IL-33 antagonist
|
MA41629A
(en)
|
2015-03-04 |
2018-01-09 |
Center For Human Reproduction |
COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
|
WO2016139331A1
(en)
|
2015-03-05 |
2016-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of melanoma
|
WO2016145008A2
(en)
|
2015-03-09 |
2016-09-15 |
University Of Kentucky Research Foundation |
Mirna for treatment of breast cancer
|
WO2016145003A1
(en)
|
2015-03-09 |
2016-09-15 |
University Of Kentucky Research Foundation |
Rna nanoparticle for treatment of gastric cancer
|
CN107531740B
(en)
|
2015-03-09 |
2021-03-19 |
肯塔基大学研究基金会 |
RNA nanoparticles for brain tumor treatment
|
WO2016142427A1
(en)
|
2015-03-10 |
2016-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method ank kit for reprogramming somatic cells
|
WO2016146587A1
(en)
|
2015-03-13 |
2016-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Hepcidin antagonists for use in the treatment of inflammation
|
KR101797569B1
(en)
|
2015-03-18 |
2017-11-22 |
한국교통대학교산학협력단 |
Liver Targeting Metal Nano-particle Based Nucleic Acid Delivery System And Manufacturing Method Thereof
|
US10519447B2
(en)
|
2015-04-01 |
2019-12-31 |
Arcturus Therapeutics, Inc. |
Therapeutic UNA oligomers and uses thereof
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
EP3078378B1
(en)
|
2015-04-08 |
2020-06-24 |
Vaiomer |
Use of factor xa inhibitors for regulating glycemia
|
US10851176B2
(en)
|
2015-04-13 |
2020-12-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of administering neutralizing anti-protease nexin-1 antibodies to treat hemophilia A
|
EP3085785A1
(en)
|
2015-04-22 |
2016-10-26 |
Université de Strasbourg |
Dynamin 2 inhibitor for the treatment of duchenne's muscular dystrophy
|
WO2016170027A1
(en)
|
2015-04-22 |
2016-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of th17 mediated diseases
|
WO2016170382A1
(en)
|
2015-04-23 |
2016-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions comprising a bradykinin 2 receptor antagonist for prevention or treatment of impaired skin wound healing
|
WO2016176617A2
(en)
|
2015-04-29 |
2016-11-03 |
New York University |
Method for treating high-grade gliomas
|
US10857237B2
(en)
|
2015-05-05 |
2020-12-08 |
University Of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents
|
US20180148793A1
(en)
|
2015-05-19 |
2018-05-31 |
Fred Hutchinson Cancer Research Center |
Biomarkers and uses thereof for selecting pancreas cancer intervention
|
EP3297615A1
(en)
|
2015-05-20 |
2018-03-28 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for modulation polarization and activation of macrophages
|
US20180134788A1
(en)
|
2015-05-26 |
2018-05-17 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas
|
WO2016191734A1
(en)
|
2015-05-28 |
2016-12-01 |
University Of California Berkeley |
Monofunctional aldehyde and alcohol dehydrogenases for production of fuels and commodity chemicals
|
BR112017025724A2
(en)
|
2015-05-29 |
2018-08-14 |
Arcadia Biosciences Inc. |
reduced gluten grains and compounds thereof
|
JP2018518491A
(en)
|
2015-06-12 |
2018-07-12 |
アレクトル エルエルシー |
Anti-CD33 antibody and method of use thereof
|
SG10201912085WA
(en)
|
2015-06-12 |
2020-02-27 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
WO2016205502A1
(en)
|
2015-06-17 |
2016-12-22 |
Pioneer Hi-Bred International, Inc. |
Plant regulatory elements and methods of use thereof
|
EP3313420B1
(en)
|
2015-06-25 |
2024-03-13 |
The Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
|
CA2991598A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
WO2017013270A1
(en)
|
2015-07-23 |
2017-01-26 |
Universite De Strasbourg |
Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
|
WO2017015671A1
(en)
|
2015-07-23 |
2017-01-26 |
Arcturus Therapeutics, Inc. |
Compositions for treating amyloidosis
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
AU2016312530A1
(en)
|
2015-08-24 |
2018-03-01 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
US10072065B2
(en)
|
2015-08-24 |
2018-09-11 |
Mayo Foundation For Medical Education And Research |
Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
|
US10590198B2
(en)
|
2015-08-28 |
2020-03-17 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
CN114525280A
(en)
|
2015-09-02 |
2022-05-24 |
阿尔尼拉姆医药品有限公司 |
iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof
|
AU2016318051B2
(en)
|
2015-09-04 |
2022-11-03 |
Keygene N.V. |
Diplospory gene
|
MA44908A
(en)
*
|
2015-09-08 |
2018-07-18 |
Sylentis Sau |
ARNSI MOLECULES AND THEIR USE IN PROCESSES AND COMPOSITIONS TO INHIBIT NRARP GENE EXPRESSION
|
AU2016321298A1
(en)
|
2015-09-09 |
2018-03-29 |
The Trustees Of Columbia University In The City Of New York |
Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
|
CN108271360B
(en)
|
2015-09-14 |
2023-01-24 |
得克萨斯州大学系统董事会 |
Lipophilic cationic dendritic polymer and use thereof
|
US10086063B2
(en)
|
2015-09-23 |
2018-10-02 |
Regents Of The University Of Minnesota |
Methods of making and using live attenuated viruses
|
US10383935B2
(en)
|
2015-09-23 |
2019-08-20 |
Regents Of The University Of Minnesota |
Methods of making and using live attenuated viruses
|
US10857145B2
(en)
|
2015-09-29 |
2020-12-08 |
Duke University |
Compositions and methods for identifying and treating dystonia disorders
|
EP3356415A1
(en)
|
2015-09-29 |
2018-08-08 |
Amgen Inc. |
Asgr inhibitors
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
JP2018531037A
(en)
|
2015-10-19 |
2018-10-25 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNAs
|
SG11201803567XA
(en)
|
2015-10-29 |
2018-05-30 |
Alector Llc |
Anti-siglec-9 antibodies and methods of use thereof
|
SI3368578T1
(en)
|
2015-10-30 |
2021-08-31 |
F. Hoffmann-La Roche Ag |
Anti-htra1 antibodies and methods of use thereof
|
US11452272B2
(en)
|
2015-11-18 |
2022-09-27 |
Commonwealth Scientific And Industrial Research Organisation |
Rice grain with reduced ROS1A activity
|
WO2017085566A1
(en)
|
2015-11-20 |
2017-05-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for increase/induction of immune responses
|
JP6975720B2
(en)
|
2015-11-30 |
2021-12-01 |
シェ、ヤンホイXie Yanhui |
Use of Akt2 in the diagnosis and treatment of tumors
|
CA3004913A1
(en)
|
2015-11-30 |
2017-06-08 |
Pioneer Hi-Bred International, Inc. |
Plant regulatory elements and methods of use thereof
|
EP3383429B1
(en)
|
2015-11-30 |
2020-10-14 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Nmdar antagonists for the treatment of tumor angiogenesis
|
US20180353486A1
(en)
|
2015-12-01 |
2018-12-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of darier disease
|
CN108601752A
(en)
|
2015-12-03 |
2018-09-28 |
安吉奥斯医药品有限公司 |
MAT2A inhibitor for treating MTAP deletion form cancers
|
BR112018008344A2
(en)
|
2015-12-13 |
2018-10-30 |
Nitto Denko Corp |
nucleic acid molecule, pharmaceutical composition, vector or cell, method for preventing, treating or ameliorating a disease, and use of a composition
|
GB201522186D0
(en)
|
2015-12-16 |
2016-01-27 |
Singapore Health Services Pte Ltd And Nat University Of Singapore The |
Treatment of fibrosis
|
EP4257694A3
(en)
|
2015-12-22 |
2023-12-06 |
Pioneer Hi-Bred International, Inc. |
Tissue-preferred promoters and methods of use
|
WO2017129558A1
(en)
|
2016-01-25 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
|
US20170360815A1
(en)
|
2016-02-25 |
2017-12-21 |
Applied Biological Laboratories, Inc. |
Compositions and methods for protecting against airborne pathogens and irritants
|
BR112018067914A2
(en)
|
2016-02-25 |
2019-01-29 |
Applied Biological Laboratories Inc |
compositions and methods for protection against airborne pathogens and irritants
|
WO2017152073A1
(en)
|
2016-03-04 |
2017-09-08 |
University Of Louisville Research Foundation, Inc. |
Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (vsels)
|
KR102402444B1
(en)
|
2016-03-15 |
2022-05-27 |
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) |
Early and non-invasive methods for assessing the risk of a subject suffering from pancreatic ductal adenocarcinoma and methods of treating such disease
|
EP3429603B1
(en)
|
2016-03-15 |
2021-12-29 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
EP3433615A1
(en)
|
2016-03-21 |
2019-01-30 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods for diagnosis and treatment of solar lentigo
|
EP3432911A1
(en)
|
2016-03-23 |
2019-01-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Targeting the neuronal calcium sensor 1 for treating wolfram syndrome
|
KR20190003504A
(en)
|
2016-03-24 |
2019-01-09 |
유니버시타이트 라이덴 |
How to Transform Plants and Reduce Random Integration Events
|
WO2017173327A1
(en)
|
2016-03-31 |
2017-10-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
MA45469A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
BETA-CATENIN NUCLEIC ACIDS AND THEIR USES
|
MA45328A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
MA45349A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
EGFR NUCLEIC ACIDS AND THEIR USES
|
MA45470A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
KRAS NUCLEIC ACIDS AND THEIR USES
|
CN108779155A
(en)
|
2016-04-19 |
2018-11-09 |
诺维信公司 |
The filamentous fungal host cell of RlmA inactivations
|
WO2017182834A1
(en)
|
2016-04-19 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating resistant glioblastoma
|
EP3448369A4
(en)
|
2016-04-29 |
2020-01-01 |
The Regents of The University of Colorado, A Body Corporate |
Compounds and compositions useful for treating metabolic syndrome, and methods using same
|
RU2725286C2
(en)
|
2016-05-13 |
2020-06-30 |
4Д Молекьюлар Терапьютикс Инк. |
Versions of adenoassociated virus capsids and methods of use thereof
|
CN109414408B
(en)
|
2016-05-16 |
2022-03-29 |
得克萨斯州大学系统董事会 |
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
|
EP3464357A1
(en)
|
2016-05-24 |
2019-04-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
|
PT109454A
(en)
|
2016-06-14 |
2017-12-14 |
Phyzat Biopharmaceuticals Lda |
NUCLEIC ACIDS OF INTERFERENCE AND COMPOSITIONS THAT UNDERSTAND THEM
|
US10829563B2
(en)
|
2016-06-16 |
2020-11-10 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Method of screening a candidate compound for activity as an elastase 2A (ELA2A) inhibitor
|
US20190194676A1
(en)
|
2016-06-24 |
2019-06-27 |
Pioneer Hi-Bred International, Inc. |
Plant regulatory elements and methods of use thereof
|
EP3481843B1
(en)
|
2016-07-05 |
2022-01-26 |
California Institute of Technology |
Fractional initiator hybridization chain reaction
|
US11292801B2
(en)
|
2016-07-05 |
2022-04-05 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
EP3483283A4
(en)
*
|
2016-07-08 |
2019-07-24 |
Tak-Circulator Co., Ltd. |
Method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5
|
US11312956B2
(en)
|
2016-07-08 |
2022-04-26 |
Tak-Circulator Co., Ltd |
Nucleic acid inhibiting expression of the MEX3B gene, MEX3B gene expression inhibitor, method for inhibiting MEX3B gene expression, and prophylactic or therapeutic agent for disease caused by MEX3B gene expression
|
KR20230074294A
(en)
|
2016-07-19 |
2023-05-26 |
유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
Oncolytic viruses targeting stat3
|
EP3490606B8
(en)
|
2016-07-26 |
2024-04-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
|
US20190271702A1
(en)
|
2016-07-28 |
2019-09-05 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of treatement of cancer disease by targetting tumor associated macrophage
|
WO2018020012A1
(en)
|
2016-07-29 |
2018-02-01 |
Danmarks Tekniske Universitet |
Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
|
US20190183114A1
(en)
|
2016-08-05 |
2019-06-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for the preservationof organs
|
IL264831B
(en)
|
2016-08-30 |
2022-09-01 |
California Inst Of Techn |
Immunohistochemistry via hybridization chain reaction
|
EP3510407A1
(en)
|
2016-09-08 |
2019-07-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating nephrotic syndrome
|
EP3516062A1
(en)
|
2016-09-21 |
2019-07-31 |
Alnylam Pharmaceuticals, Inc. |
Myostatin irna compositions and methods of use thereof
|
ES2873377T3
(en)
|
2016-09-22 |
2021-11-03 |
Inst Nat Sante Rech Med |
Methods and pharmaceutical compositions for the treatment of lung cancer
|
JP2020500207A
(en)
|
2016-09-28 |
2020-01-09 |
ブレード・セラピューティクス・インコーポレイテッド |
Calpain modulators and their therapeutic use
|
WO2018069232A1
(en)
|
2016-10-10 |
2018-04-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of having cardiac hypertrophy
|
WO2018078083A1
(en)
|
2016-10-28 |
2018-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating multiple myeloma
|
EP3318277A1
(en)
|
2016-11-04 |
2018-05-09 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
|
CA3043030A1
(en)
|
2016-11-10 |
2018-05-17 |
Jose Baselga BASELGA |
Inhibition of kmt2d for the treatment of cancer
|
US20190345500A1
(en)
|
2016-11-14 |
2019-11-14 |
|Nserm (Institut National De La Santé Et De La Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
US20190276833A1
(en)
|
2016-11-17 |
2019-09-12 |
Deutsches Krebsforschungszentrum |
Cancer treatment by glycerol-3-phosphate dehydrogenase 1 inhibition
|
US11147249B2
(en)
|
2016-12-08 |
2021-10-19 |
Alector Llc |
Siglec transgenic mice and methods of use thereof
|
US20200054660A1
(en)
|
2016-12-09 |
2020-02-20 |
St. Jude Children's Research Hospital |
Dna methylation profiling for t-cell immunotherapy
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
BR112019011689A2
(en)
|
2016-12-14 |
2019-10-22 |
Progenity Inc |
treating a gastrointestinal tract disease with a tnf inhibitor
|
EP3554539B9
(en)
|
2016-12-14 |
2023-10-04 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
CA3046093A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
JP2020502126A
(en)
|
2016-12-14 |
2020-01-23 |
プロジェニティ, インコーポレイテッド |
Treatment of gastrointestinal diseases with JAK inhibitors
|
CA3045472A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
CA3045475A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
|
EP3555138A1
(en)
|
2016-12-16 |
2019-10-23 |
Université de Bordeaux |
Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
|
WO2018115083A1
(en)
|
2016-12-21 |
2018-06-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of gut diseases such as irritable bowel syndrome (ibs)
|
WO2018115477A1
(en)
|
2016-12-23 |
2018-06-28 |
Universite De Strasbourg |
Dynamin 2 inhibitor for the treatment of myotonic dystrophy
|
US20230190958A1
(en)
|
2017-01-13 |
2023-06-22 |
Jichi Medical University |
AAV Vector for Disrupting Coagulation Factor-Related Gene on Liver Genome
|
WO2018134386A1
(en)
|
2017-01-23 |
2018-07-26 |
Novozymes A/S |
Host cells and methods for producing double-stranded rna
|
WO2018138106A1
(en)
|
2017-01-27 |
2018-08-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of heart failure
|
WO2018141753A1
(en)
|
2017-01-31 |
2018-08-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating squamous cell carcinomas
|
AU2018219895A1
(en)
|
2017-02-09 |
2019-08-29 |
Indapta Therapeutics, Inc. |
Engineered Natural Killer (NK) cells and compositions and methods thereof
|
WO2018162676A1
(en)
|
2017-03-08 |
2018-09-13 |
Université De Strasbourg |
DISINTEGRATABLE POROUS ORGANOSILICA OR ORGANOMETALOXIDE NANOPARTICLES AND USES THEREOF AS VEHICLE FOR CONTROLLED DELIVERY OF siRNA
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
WO2018172155A1
(en)
|
2017-03-23 |
2018-09-27 |
Novozymes A/S |
Improved filamentous fungal host cells
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
US20210138213A1
(en)
|
2017-03-30 |
2021-05-13 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
CA3054159A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
EP3610264A1
(en)
|
2017-04-13 |
2020-02-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
WO2018193393A1
(en)
|
2017-04-19 |
2018-10-25 |
St. Jude Children's Research Hospital |
Tumor suppression by modulation of non-canonical autophagy (lap) in myeloid cells
|
CN106942162A
(en)
*
|
2017-04-25 |
2017-07-14 |
遵义医学院 |
A kind of device and its application method suitable for white backed planthopper feeding method RNA interference experiments
|
EP3615662A1
(en)
|
2017-04-28 |
2020-03-04 |
Precision Biosciences, Inc. |
Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells
|
WO2018199777A1
(en)
|
2017-04-28 |
2018-11-01 |
Auckland Uniservices Limited |
Methods of treatment and novel constructs
|
CA3062698A1
(en)
|
2017-05-08 |
2018-11-15 |
Precision Biosciences, Inc. |
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
|
EP3625258A1
(en)
|
2017-05-16 |
2020-03-25 |
Alector LLC |
Anti-siglec-5 antibodies and methods of use thereof
|
EP3624780A1
(en)
|
2017-05-17 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 inhibitors for improving pain treatments by opioids
|
CA3064774A1
(en)
|
2017-05-25 |
2018-11-29 |
The Governors Of The University Of Alberta |
Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
|
EP3412288A1
(en)
|
2017-06-08 |
2018-12-12 |
Galderma Research & Development |
Vegf inhibitors for use for preventing and/or treating acne
|
SI3538645T1
(en)
|
2017-06-20 |
2021-08-31 |
Institut Curie |
Immune cells defective for suv39h1
|
EP3641739A1
(en)
|
2017-06-20 |
2020-04-29 |
Institut Curie |
Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
|
WO2018234538A1
(en)
|
2017-06-23 |
2018-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism
|
WO2019012030A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Dhodh inhibitor and chk1 inhibitor for treating cancer
|
JP7299160B2
(en)
|
2017-08-03 |
2023-06-27 |
アレクトル エルエルシー |
ANTI-CD33 ANTIBODY AND METHOD OF USE THEREOF
|
EP3444347A1
(en)
|
2017-08-18 |
2019-02-20 |
Universität Heidelberg |
Use of anti-crispr polypeptides for specific activation of cas nucleases
|
WO2019047914A1
(en)
|
2017-09-07 |
2019-03-14 |
北京泰德制药股份有限公司 |
Double-stranded rna molecule targeting ckip-1 and use thereof
|
PT3684423T
(en)
|
2017-09-20 |
2023-06-09 |
4D Molecular Therapeutics Inc |
Adeno-associated virus variant capsids and methods of use thereof
|
KR20200056434A
(en)
|
2017-09-25 |
2020-05-22 |
파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 |
Tissue-preferred promoters and methods of use
|
WO2019072832A1
(en)
|
2017-10-10 |
2019-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating fibrotic interstitial lung disease
|
WO2019072885A1
(en)
|
2017-10-11 |
2019-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Magnetic nanoparticles for the treatment of cancer
|
CA3079865C
(en)
|
2017-10-26 |
2023-09-12 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for treating tubulin carboxypeptidases associated diseases
|
US11873489B2
(en)
|
2017-11-13 |
2024-01-16 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
|
WO2019096787A1
(en)
|
2017-11-14 |
2019-05-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Regulatory t cells genetically modified for the lymphotoxin alpha gene and uses thereof
|
WO2019101882A1
(en)
|
2017-11-23 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating dengue virus infection
|
WO2019104279A1
(en)
|
2017-11-27 |
2019-05-31 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
WO2019108835A1
(en)
|
2017-11-29 |
2019-06-06 |
The Trustees Of Columbia University In The City Of New York |
Delta-2-tubulin as a biomarker and therapeutic target for peripheral neuropathy
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
KR102443358B1
(en)
|
2017-12-06 |
2022-09-14 |
어비디티 바이오사이언시스 인크. |
Compositions and methods for treating muscular dystrophy and myotonic dystrophy
|
US11470827B2
(en)
|
2017-12-12 |
2022-10-18 |
Alector Llc |
Transgenic mice expressing human TREM proteins and methods of use thereof
|
EP3502259A1
(en)
|
2017-12-19 |
2019-06-26 |
Universiteit Leiden |
A combinational strategy for reducing random integration events when transfecting plants
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
CN111819285A
(en)
|
2018-01-09 |
2020-10-23 |
希博斯美国有限公司 |
Breakage-proof genes and mutations
|
WO2019147824A1
(en)
|
2018-01-26 |
2019-08-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
US20210363587A1
(en)
|
2018-02-07 |
2021-11-25 |
St. Jude Children's Research Hospital |
EPIGENETIC HISTONE REGULATION MEDIATED BY CXorf67
|
WO2019158512A1
(en)
|
2018-02-13 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prognosis and the treatment of glioblastoma
|
CA3090620A1
(en)
|
2018-03-06 |
2019-09-12 |
Institut Curie |
Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy
|
WO2019185683A1
(en)
|
2018-03-28 |
2019-10-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
JP2021519587A
(en)
|
2018-03-30 |
2021-08-12 |
ユニバーシティ オブ ジュネーブ |
MicroRNA expression constructs and their use
|
US20210162007A1
(en)
|
2018-04-09 |
2021-06-03 |
President And Fellows Of Harvard College |
Modulating nuclear receptors and methods of using same
|
WO2019207066A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for the treatment of sjögren's syndrome
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
CA3096516A1
(en)
|
2018-05-22 |
2019-11-28 |
Pioneer Hi-Bred International, Inc. |
Plant regulatory elements and methods of use thereof
|
GB201808927D0
(en)
|
2018-05-31 |
2018-07-18 |
Institute Of Cancer Res Royal Cancer Hospital |
Materials and methods for monitoring the development of resistance of cancers to treatment
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
US20230009902A1
(en)
|
2018-06-20 |
2023-01-12 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue orginating from the endoderm
|
WO2019246313A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
US20220257600A1
(en)
|
2018-06-20 |
2022-08-18 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
|
WO2019246271A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
US20230033021A1
(en)
|
2018-06-20 |
2023-02-02 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
CA3097915A1
(en)
|
2018-06-28 |
2020-01-02 |
Pioneer Hi-Bred International, Inc. |
Methods for selecting transformed plants
|
WO2020016160A1
(en)
|
2018-07-16 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat neurological diseases
|
WO2020016377A1
(en)
|
2018-07-19 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination for treating cancer
|
WO2020023920A1
(en)
|
2018-07-27 |
2020-01-30 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
EP3831949A4
(en)
|
2018-07-30 |
2022-05-04 |
Gene Therapy Research Institution Co., Ltd. |
Method for enhancing gene expression by aav vector
|
EP3833757A4
(en)
*
|
2018-08-10 |
2022-05-18 |
City of Hope |
Programmable conditional sirnas and uses thereof
|
US20210278420A1
(en)
|
2018-09-05 |
2021-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating asthma and allergic diseases
|
US20210393740A1
(en)
|
2018-09-19 |
2021-12-23 |
La Jolla Institute For Immunology |
Ptprs and proteoglycans in rheumatoid arthritis
|
WO2020074502A1
(en)
|
2018-10-09 |
2020-04-16 |
Novozymes A/S |
Modified filamentous fungal host cell
|
CN112888440A
(en)
|
2018-10-16 |
2021-06-01 |
豪夫迈·罗氏有限公司 |
Use of Akt inhibitors in ophthalmology
|
CN112955462A
(en)
|
2018-10-18 |
2021-06-11 |
国家医疗保健研究所 |
Combination of a beta IG-H3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumors
|
WO2020089273A1
(en)
|
2018-10-31 |
2020-05-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating t-helper type 2 mediated disease
|
EP3874050A1
(en)
|
2018-10-31 |
2021-09-08 |
Pioneer Hi-Bred International, Inc. |
Compositions and methods for ochrobactrum-mediated plant transformation
|
EP3874273B1
(en)
|
2018-10-31 |
2024-03-27 |
Arizona Board of Regents on behalf of the University of Arizona |
Biomarkers and methods of use for radiation-induced lung injury
|
EP3650040A1
(en)
|
2018-11-07 |
2020-05-13 |
Galderma Research & Development |
Vegf inhibitors for use for preventing and/or treating atopic dermatitis
|
JP2022512077A
(en)
|
2018-11-16 |
2022-02-02 |
日東電工株式会社 |
RNA interference delivery products and methods for malignant tumors
|
JP2022513649A
(en)
|
2018-11-28 |
2022-02-09 |
ノボザイムス アクティーゼルスカブ |
Modified filamentous fungus host cell
|
US11883401B2
(en)
|
2019-01-08 |
2024-01-30 |
Duke University |
Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same
|
CN113316722A
(en)
|
2019-01-17 |
2021-08-27 |
豪夫迈·罗氏有限公司 |
E3 ubiquitin ligase (UBE3A) protein targets
|
JP2022518251A
(en)
|
2019-01-21 |
2022-03-14 |
シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド |
Treatment of hepatotoxicity
|
KR20210123338A
(en)
|
2019-02-01 |
2021-10-13 |
유니버시타트 바셀 |
Calcineurin Inhibitor Resistant Immune Cells for Use in Adoptive Cell Transfer Therapy
|
EP3921031A1
(en)
|
2019-02-04 |
2021-12-15 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for modulating blood-brain barrier
|
EP3920889A4
(en)
|
2019-02-08 |
2022-12-07 |
Board of Regents, The University of Texas System |
Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
|
WO2020169707A1
(en)
|
2019-02-21 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Foxo1 inhibitor for use in the treatment of latent virus infection
|
GB201902419D0
(en)
|
2019-02-22 |
2019-04-10 |
Singapore Health Serv Pte Ltd |
Treatment of kidney injury
|
WO2020178193A1
(en)
|
2019-03-01 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of sarcoidosis
|
CN113412333A
(en)
|
2019-03-11 |
2021-09-17 |
先锋国际良种公司 |
Method for clonal plant production
|
WO2020183011A1
(en)
|
2019-03-14 |
2020-09-17 |
Institut Curie |
Htr1d inhibitors and uses thereof in the treatment of cancer
|
CA3128376A1
(en)
|
2019-03-27 |
2020-10-01 |
Pioneer Hi-Bred International, Inc. |
Plant explant transformation
|
CA3127173A1
(en)
|
2019-03-28 |
2020-10-01 |
Pioneer Hi-Bred International, Inc. |
Modified agrobacterium strains and use thereof for plant transformation
|
WO2020193740A1
(en)
|
2019-03-28 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
WO2020208082A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating cmv related diseases
|
JP2022531841A
(en)
|
2019-04-19 |
2022-07-12 |
ソルボンヌ ウニベルシテ |
P16INK4a inhibitor for the prevention or treatment of Huntington's disease
|
CN114364693A
(en)
|
2019-05-03 |
2022-04-15 |
新加坡保健服务私人有限公司 |
Treatment and prevention of metabolic disorders
|
GB201906291D0
(en)
|
2019-05-03 |
2019-06-19 |
Singapore Health Serv Pte Ltd |
Treatment and prevention of metabolic diseases
|
WO2020229648A1
(en)
|
2019-05-16 |
2020-11-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat type 2 inflammation or mast-cell dependent disease
|
WO2020249769A1
(en)
|
2019-06-14 |
2020-12-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating ocular diseases related to mitochondrial dna maintenance
|
US11473086B2
(en)
|
2019-06-19 |
2022-10-18 |
Ut-Battelle, Llc |
Loss of function alleles of PtEPSP-TF and its regulatory targets in rice
|
WO2021001539A1
(en)
|
2019-07-04 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy to detect and treat eosinophilic fasciitis
|
EP3997225A1
(en)
|
2019-07-10 |
2022-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
JP7371954B2
(en)
|
2019-07-12 |
2023-10-31 |
株式会社遺伝子治療研究所 |
Adeno-associated virus virions for gene transfer into human liver
|
EP4004187A1
(en)
|
2019-07-26 |
2022-06-01 |
Novozymes A/S |
Modified filamentous fungal host cell
|
WO2021019536A1
(en)
|
2019-07-30 |
2021-02-04 |
The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) |
Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
|
CA3149691A1
(en)
|
2019-08-14 |
2021-02-18 |
Vanarix Sa |
Method for in vitro production of hyaline cartilage tissue
|
US20220290156A1
(en)
|
2019-08-27 |
2022-09-15 |
Sanofi |
Compositions and methods for inhibiting pcsk9
|
US20220340975A1
(en)
|
2019-09-05 |
2022-10-27 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Method of treatment and pronostic of acute myeloid leukemia
|
GB201913030D0
(en)
|
2019-09-10 |
2019-10-23 |
Francis Crick Institute Ltd |
Treatment of hr deficient cancer
|
KR102100163B1
(en)
|
2019-09-24 |
2020-04-13 |
테고사이언스 (주) |
Compositions of Prevention or Treatment of Keloid or Hypertrophic scar
|
EP4034151A1
(en)
|
2019-09-27 |
2022-08-03 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of müllerian inhibiting substance inhibitors for treating cancer
|
EP3825408A1
(en)
|
2019-11-19 |
2021-05-26 |
FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. |
Methods of multi-species insect pest control
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
WO2021105384A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Targeting the nls region of nupr1 protein to treat cancer
|
WO2021105391A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination comprising nupr1 inhibitors to treat cancer
|
CN115176005A
(en)
|
2019-12-18 |
2022-10-11 |
诺华股份有限公司 |
Compositions and methods for treating hemoglobinopathies
|
JOP20220152A1
(en)
|
2019-12-18 |
2023-01-30 |
Novartis Ag |
3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
AU2021205929A1
(en)
|
2020-01-08 |
2022-09-01 |
Regeneron Pharmaceuticals, Inc. |
Treatment of fibrodysplasia ossificans progressiva
|
WO2021150300A1
(en)
|
2020-01-22 |
2021-07-29 |
Massachusetts Institute Of Technology |
Inducible tissue constructs and uses thereof
|
WO2021156329A1
(en)
|
2020-02-05 |
2021-08-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of cancer disease by targeting an epigenetic factor
|
EP4103699A1
(en)
|
2020-02-10 |
2022-12-21 |
BioMarin Pharmaceutical Inc. |
Virus-free cell cultures
|
WO2021173965A1
(en)
|
2020-02-28 |
2021-09-02 |
Massachusetts Institute Of Technology |
Identification of variable influenza residues and uses thereof
|
KR20220156867A
(en)
|
2020-03-19 |
2022-11-28 |
어비디티 바이오사이언시스 인크. |
Compositions and methods for the treatment of facial scapular brachial muscular dystrophy
|
EP4138791A1
(en)
|
2020-04-20 |
2023-03-01 |
Board of Regents, The University of Texas System |
Biologically active dry powder compositions and method of their manufacture and use
|
US20210332364A1
(en)
|
2020-04-28 |
2021-10-28 |
Phyzat Biopharmaceuticals, Lda |
siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
WO2021228585A1
(en)
|
2020-05-09 |
2021-11-18 |
Phyzat Biopharmaceuticals, Lda |
Sina molecules, methods of production and uses thereof
|
EP4153192A1
(en)
|
2020-05-19 |
2023-03-29 |
Institut Curie |
Methods for the diagnosis and treatment of cytokine release syndrome
|
EP4157864A1
(en)
|
2020-05-27 |
2023-04-05 |
Antion Biosciences SA |
Adapter molecules to re-direct car t cells to an antigen of interest
|
EP3919062A1
(en)
|
2020-06-02 |
2021-12-08 |
Institut Gustave-Roussy |
Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
|
EP4157288A2
(en)
|
2020-06-02 |
2023-04-05 |
Institut Gustave-Roussy |
Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
|
AU2021283380A1
(en)
|
2020-06-03 |
2023-01-05 |
Alexis Bio, Inc. |
Selection and monitoring methods for xenotransplantation
|
WO2021245224A1
(en)
|
2020-06-05 |
2021-12-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating ocular diseases
|
EP4162048A1
(en)
|
2020-06-09 |
2023-04-12 |
Genethon |
Treatment of genetic dilated cardiomyopathies
|
WO2021250079A1
(en)
|
2020-06-09 |
2021-12-16 |
Genethon |
Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies
|
EP4168006A1
(en)
|
2020-06-18 |
2023-04-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
New strategy for treating pancreatic cancer
|
GB202009292D0
(en)
|
2020-06-18 |
2020-08-05 |
Singapore Health Serv Pte Ltd |
Treatment and prevention of disease caused by type IV collagen dysfunction
|
EP4171527A1
(en)
|
2020-06-25 |
2023-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment and diagnostic of pathological conditions associated with intense stress
|
WO2022006286A1
(en)
|
2020-06-30 |
2022-01-06 |
Lunglife Ai |
Methods for detecting lung cancer
|
JP2023540429A
(en)
|
2020-07-10 |
2023-09-25 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
Methods and compositions for treating epilepsy
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
CN116096864A
(en)
|
2020-07-30 |
2023-05-09 |
居里研究所 |
SOCS1 deficient immune cells
|
US20230340149A1
(en)
|
2020-09-07 |
2023-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of inflammatory bowel diseases
|
JP2023544016A
(en)
|
2020-09-30 |
2023-10-19 |
パイオニア ハイ-ブレッド インターナショナル, インコーポレイテッド |
Rapid transformation of monocot explants
|
GB202017244D0
(en)
|
2020-10-30 |
2020-12-16 |
Nat Univ Singapore |
Methods to extend health-span and treat age-related diseases
|
WO2022107106A2
(en)
|
2020-11-23 |
2022-05-27 |
Phyzat Biopharmaceuticals, Lda |
Sina molecules, methods of production and uses thereof
|
EP4263822A1
(en)
|
2020-12-15 |
2023-10-25 |
Novozymes A/S |
Mutated host cells with reduced cell motility
|
WO2022147481A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma Inc. |
Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
|
WO2022162015A1
(en)
|
2021-01-26 |
2022-08-04 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
US11873485B2
(en)
|
2021-01-26 |
2024-01-16 |
California Institute Of Technology |
Allosteric conditional guide RNAs for cell-selective regulation of CRISPR/Cas
|
WO2022165111A1
(en)
|
2021-01-28 |
2022-08-04 |
Precision Biosciences, Inc. |
Modulation of tgf beta signaling in genetically-modified eukaryotic cells
|
WO2022171777A1
(en)
|
2021-02-12 |
2022-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for prognosis and treating a patient suffering from cancer
|
WO2022218998A1
(en)
|
2021-04-13 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating hepatitis b and d virus infection
|
EP4322937A1
(en)
|
2021-04-14 |
2024-02-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
New method to improve the anti-tumoral activity of macrophages
|
EP4322938A1
(en)
|
2021-04-14 |
2024-02-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
New method to improve nk cells cytotoxicity
|
EP4328313A1
(en)
|
2021-04-21 |
2024-02-28 |
Jichi Medical University |
Adeno-associated virus virion for treating ornithine transcarbamylase deficiency
|
TW202313096A
(en)
|
2021-05-28 |
2023-04-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Recombinant adeno-associated virus with capsid variant and its application
|
WO2022253910A1
(en)
|
2021-06-02 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A new method to treat an inflammatory skin disease
|
WO2022269518A2
(en)
|
2021-06-23 |
2022-12-29 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
US11593428B2
(en)
|
2021-07-08 |
2023-02-28 |
Bank Of America Corporation |
System and method for detecting errors in a task workflow from a video stream
|
WO2023006765A1
(en)
|
2021-07-26 |
2023-02-02 |
Boehringer Ingelheim International Gmbh |
Treatment and prevention of alcoholic liver disease
|
WO2023012165A1
(en)
|
2021-08-02 |
2023-02-09 |
Universite De Montpellier |
Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
|
WO2023012343A1
(en)
|
2021-08-06 |
2023-02-09 |
Institut Du Cancer De Montpellier |
Methods for the treatment of cancer
|
WO2023020980A1
(en)
|
2021-08-16 |
2023-02-23 |
F. Hoffmann-La Roche Ag |
E3 ubiquitin ligase (ube3a) protein targets
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
WO2023041805A1
(en)
|
2021-09-20 |
2023-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
|
WO2023057484A1
(en)
|
2021-10-06 |
2023-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
|
WO2023073099A1
(en)
|
2021-10-28 |
2023-05-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to improve phagocytosis
|
WO2023078906A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating acute myeloid leukemia
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
WO2023081767A1
(en)
|
2021-11-05 |
2023-05-11 |
Precision Biosciences, Inc. |
Methods for immunotherapy
|
WO2023089032A1
(en)
|
2021-11-19 |
2023-05-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
WO2023089159A1
(en)
|
2021-11-22 |
2023-05-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy targeting stroma/tumor cell crosstalk to treat a cancer
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
WO2023111173A1
(en)
|
2021-12-16 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An ezh2 degrader or inhibitor for use in the treatment of resistant acute myeloid leukemia
|
WO2023111196A1
(en)
|
2021-12-16 |
2023-06-22 |
Singapore Health Services Pte. Ltd. |
Treatment and prevention of glomerular disease
|
WO2023122805A1
(en)
|
2021-12-20 |
2023-06-29 |
Vestaron Corporation |
Sorbitol driven selection pressure method
|
WO2023118546A2
(en)
|
2021-12-23 |
2023-06-29 |
Boehringer Ingelheim International Gmbh |
METHODS AND MOLECULES FOR RNA INTERFERENCE (RNAi)
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
GB202206507D0
(en)
|
2022-05-04 |
2022-06-15 |
Antion Biosciences Sa |
Expression construct
|
WO2023230531A1
(en)
|
2022-05-24 |
2023-11-30 |
Lunglife Ai, Inc. |
Methods for detecting circulating genetically abnormal cells
|
EP4299742A1
(en)
|
2022-06-30 |
2024-01-03 |
Université de Strasbourg |
Combination therapy for melanoma
|
WO2024003350A1
(en)
|
2022-06-30 |
2024-01-04 |
Universite De Strasbourg |
Combination therapy for melanoma
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
EP4311546A1
(en)
|
2022-07-26 |
2024-01-31 |
Dynacure |
Combination therapy for myopathies
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
WO2024028476A1
(en)
|
2022-08-05 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of th2-mediated diseases
|
WO2024037910A1
(en)
|
2022-08-17 |
2024-02-22 |
Institut National de la Santé et de la Recherche Médicale |
Syk inhibitors for use in the treatment of cancer
|
GB202212077D0
(en)
|
2022-08-18 |
2022-10-05 |
Tribune Therapeutics Ab |
Agents that inhibit ccn ligand-induced signalling for treating disease
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024059618A2
(en)
|
2022-09-13 |
2024-03-21 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed tgfbr shrnas
|
WO2024056659A1
(en)
|
2022-09-13 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
Method for treating prostate cancer and other epithelial cancers
|
WO2024059824A2
(en)
|
2022-09-16 |
2024-03-21 |
Arsenal Biosciences, Inc. |
Immune cells with combination gene perturbations
|